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Abstract
Inflammation involving eosinophilic and neutrophilic granulocytes,
which are closely related in ontogeny, has been associated with the
pathogenesis of a variety of diseases such as asthma and other allergic
conditions. It has been demonstrated in vivo that apoptosis is an
important mechanism for the clearance of extravasated granulocytes
from inflamed sites; leading to their phagocytosis by inflammatory
macrophages, without exacerbating the inflammatory response.
Eosinophils and neutrophils have been shown to undergo constitutive
apoptosis in vitro and their rate of apoptosis can be modulated by a
variety of growth factors and inflammatory mediators.
Glucocorticoids have long been successfully employed as potent anti¬
inflammatory agents, yet the means by which they exert their effects in
vivo are poorly understood. The purpose of these studies was to
determine the effects and mechanisms of action of glucocorticoids on
eosinophil and neutrophil apoptosis and to examine the effects of these
drugs on the phagocytosis of apoptotic granulocytes by macrophages.
We have demonstrated that dexamethasone exerts diametrically opposed
effects on these two cell types; promoting eosinophil apoptosis and
inhibiting neutrophil apoptosis. Similarly, elevation of [Ca2+]j also
differentially affects the rate of constitutive granulocyte apoptosis. In
contrast, elevation of cAMP inhibits the rate of apoptosis in both
granulocytes, whereas inhibition of PKC promotes the rate of granulocyte
apoptosis. Moreover, inhibition of protein phosphatases inhibits the rate
of granulocyte apoptosis at lower concentrations and promotes the rate of
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granulocyte apoptosis at higher concentrations. Inhibition of the
MAPK/ERK cascade inhibits the rate of constitutive eosinophil apoptosis,
while having no effect upon the rate of constitutive neutrophil apoptosis.
However, inhibition of this cascade selectively blocks the neutrophil
survival-promoting effects of LPS, but exerts no effect on glucocorticoid-
mediated inhibition of neutrophil apoptosis. Furthermore, we have
demonstrated that dexamethasone mediates inhibition of neutrophil
apoptosis by a PKA-dependent mechanism, whereas the pro-apoptotic
effect of dexamethasone upon eosinophil apoptosis appears to be PKA-
independent. Finally, we have shown that dexamethasone potentiates
macrophage recognition and phagocytosis of apoptotic eosinophils and
neutrophils, an event which may promote more efficient resolution of
the inflammatory response.
Demonstration of the marked apoptosis-promoting effects of
corticosteroids on eosinophil apoptosis together with the augmentation
of macrophage clearance of apoptotic eosinophils, may in part explain the
known beneficial therapeutic effects of corticosteroids on established
'eosinophilic' inflammatory diseases such as asthma. The opposite effect
on neutrophil apoptosis may underlie the lower efficacy of these drugs in
'neutrophilic' inflammatory diseases such as ARDS. Further dissection
of the intracellular mechanisms governing the divergent effects of
corticosteroids on eosinophil and neutrophil apoptosis may lead to new
therapeutic targets with which selective induction of apoptosis could be
achieved.
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1.1 The inflammatory response
In the aftermath of physical trauma, particularly in response to bacterial
or parasitic infection of tissues, there is a fairly stereotyped sequence of
events involving vasodilatation and increased vascular permeability,
leading to tissue oedema, which is often associated with a large leukocyte
influx (Haslett, 1995). Finally, when all the invading organisms are
phagocytosed by the recruited leukocytes, extravasated inflammatory cells
such as eosinophils and neutrophils are cleared, thereby restoring normal
tissue integrity and function in readiness for the next inflammatory
insult. Clinically, these processes are well characterised, comprising of
redness, heat, swelling, pain and loss or alteration of function. This
innate response, known as 'inflammation', comprises of a co-ordinated
network of mechanisms promoting wound repair (Baumann & Gauldie,
1994).
Paradoxically, when this same, normally beneficial, complex interplay of
events occurs in a persistent or uncontrolled manner, the result is
excessive tissue damage, often associated with the pathogenesis of a large
number of inflammatory diseases. These include asthma, emphysema,
chronic bronchitis, rheumatoid arthritis, and glomerulonephritis. Thus,
elucidation of the mechanisms underlying the induction and resolution
of the inflammatory response may help in developing an understanding
of, and therapeutic approach to inflammation.
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1.2 The eosinophil
The eosinophil plays a particularly important role in allergic
inflammation and parasitic infections. Eosinophilia, characterised by an
increased production of eosinophils in the bone marrow and the
accumulation of eosinophils in tissues and blood, is specifically associated
with a variety of diseases including asthma (Bousquet et al., 1990), chronic
urticaria (Peters et al., 1983, Spry et al., 1985), allograft rejection
(Lautenschlager et al., 1985), the hypereosinophilic syndrome (Fauci, 1982)
and the eosinophil-myalgia syndrome (Hertzman et al., 1990).
Eosinophils originate from pluripotential stem cells in the bone marrow;
the development and differentiation of which are specifically promoted
by cytokines, such as GM-CSF, IL-3 and IL-5 (Sanderson, 1992).
Eosinophils are mainly tissue-dwelling cells and are most abundant in
tissues with an epithelial surface, such as the respiratory tract (Weller,
1994). Eosinophil tissue longevity is unknown but it is assumed to be at
least several days, based on in vitro studies involving the induction of
human eosinophil survival in culture over a week, upon addition of
several peptide growth factors including GM-CSF, IL-3 and IL-5 (Tai et al.,
1991) and in light of findings demonstrating that large numbers of
eosinophils can be found in the tissues even when blood eosinophil
counts are low (Weller, 1991). Blood counts reflect an intricate
relationship between the number of cells leaving the bone marrow,
marginating and then leaving the blood, with no significant recirculation
of eosinophils back from the tissues to blood. The half-life of eosinophils
in normal human blood is 18 h and is prolonged in eosinophilia, a
finding that may be attributed to the limited number of sites through
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which eosinophils can migrate into the tissues, causing cells to
accumulate in the circulation.
1.2.1 Morphology
Eosinophils share some structural similarities with other granulocytes,
but have bilobed nuclei and distinctive cytoplasmic granules (see
Appendix). Eosinophilic granulocytes are slightly larger than
neutrophils, having a mean diameter of 8 |im. The distinctive feature of
mammalian eosinophils is the presence of characteristic secondary
granules, with crystalloid cores. Eosinophils also contain two other types
of granules: primary granules, which lack a crystalloid core and are
characteristically seen in eosinophilic promyelocytes (Bainton &
Farquhar, 1970), and the so-called small granules, which reportedly
contain aryl-sulphatase and other enzymes (Parmley & Spicer, 1974).
Prominent tubulovesicular structures are sometimes identified as a
fourth population of granules (microgranules) (Parmley & Spicer, 1974).
Other cytoplasmic structures of the eosinophil, include lipid bodies,
which are non-membrane-bound, lipid-rich inclusions found in many
cell types and are often misidentified as granules (Weller, 1991). The
functions of the lipid bodies have not been fully elucidated but they do
serve as intracellular sites of arachidonic acid storage and metabolism
(Bozza et al., 1996).
1.2.2 Intracellular constituents
Secondary granules contain lysosomal hydrolases as well as most of the
cationic proteins unique to eosinophils. The crystalloid core of the
granule is composed of major basic protein (MBP) and the matrix
surrounding the core contains three well-characterised cationic proteins,
namely eosinophil cationic protein (ECP), eosinophil-derived neurotoxin
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(EDN) and eosinophil peroxidase (EPO) (Peters et al., 1986, Egesten et al.,
1986). The functional properties of these cationic proteins have been well
studied and are summarised overleaf. MBP has no recognised enzymatic
activity, but is toxic to helminthic parasites, tumour cells and host cells
(Butterworth et al., 1979, Gleich & Adolphson, 1986). ECP is less abundant
than MBP in granules, with bactericidal and helminthotoxic activities.
EDN is a potent neurotoxin but is a relatively weak helminthotoxin.
Finally, EPO, which in the presence of hydrogen peroxide is able to
oxidise halides to form highly reactive hypohalous acids. Thus, under
these conditions EPO is toxic to helminthic and protozoan parasites,
bacteria, tumour cells and host cells (Venge, 1993). Another distinctive
protein found in the primary granules of human eosinophils, forms
Charcot-Leyden crystals, which constitutes a hydrophobic protein with
lysophospholipase activity.
1.2.3 Mediator release
In addition to the toxic cationic proteins, upon appropriate stimulation,
eosinophils synthesise and secrete a number of inflammatory mediators
including lipids, such as platelet-activating factor (PAF) and leukotriene
C4 (LTC4) and cytokines, including transforming growth factor alpha
(TNF-a), IL-1, IL-3, IL-5 and GM-CSF (Weller & Austen, 1983, Kita et al.,
1991a, Moqbel et al., 1994). Eosinophils are also capable of generating two
potentially toxic oxygen metabolites, the superoxide radical anion, O2"
and H2O2.
1.2.4 Mechanisms of eosinophil recruitment at sites of inflammation
Following tissue injury, eosinophils migrate and emigrate into tissues
through post-capillary venules where slow blood flow allows loose
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attachments to endothelial cells (Weller, 1991). Inflammatory mediators,
such as C5a, leukotriene B4 (LTB4), IL-8 and eotaxin, are generated in
response to an appropriate stimulus and result in cellular activation.
Eosinophils express on their surface either selectins (E-, L- and P-selectin),
or selectin ligands, which primarily mediate tethering of the circulating
eosinophil and allow rolling on the endothelial surface of post-capillary
venules. Locally released mediators bind to specific eosinophil receptors
leading to increased expression of eosinophil surface integrins, in
particular Pi and P2 integrins. These integrins bind to their ligands on
the endothelial cell for example, ICAM-1, VCAM-1, and strengthen the
eosinophil-endothelial cell adhesion, resulting in firm adhesion. The
eosinophils can then traverse the endothelial cell layer of the blood
vessel wall into the extravascular tissue space, travelling towards the
inflammatory focus along a chemotactic gradient and are finally
immobilised in the locality of the infection. This model describes the
generalised mechanisms underlying recruitment of both eosinophilic
and neutrophilic inflammatory cells, at post-capillary venules of the
systemic microcirculation (Carlos & Harlan, 1994, Springer, 1994).
However, selective recruitment of the different inflammatory cell types is
achieved by the existence of multiple steps that are specific for each
granulocyte type. For example, generation of specific inflammatory
mediators determines which type of inflammatory cell is recruited. In
this regard, the C-C chemokines RANTES, monocyte chemotactic protein
(MCP)-3 and eotaxin stimulate eosinophils in vitro (but not neutrophils)
(Baggiolini & Dahinden, 1994, Schall & Bacon, 1994, Kita & Gleich, 1996)
and eotaxin (Griffiths-Johnson et al., 1993, Jose et al., 1994) appears to
cause a specific eosinophil accumulation in vivo. Thus, these
chemokines appear to be key mediators in the induction of a tissue
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eosinophilia. In contrast, the C-X-C chemokine IL-8 is a potent
neutrophil chemoattractant (Teran et al., 1993). The expression of
different adhesion molecules may also allow the specific accumulation of
one cell in relation to another. Expression of the Pi integrin VLA-4 and
the P7 integrin 0C4P7 by eosinophils but not neutrophils, suggests that
through binding to VCAM-1 these adhesion pathways allow selective
migration of eosinophils (Wardlaw et al., 1994, Walsh, 1997). The
recruitment of granulocytes therefore depends upon the complex
interaction between the nature of the injurious stimulus, the
inflammatory mediators generated, the adhesion molecules expressed
and the physiology of the vasculature.
1.2.5 Functions
Over the years, there has been considerable debate regarding the role of
eosinophils in inflammatory diseases such as asthma. It is now known
that eosinophils can have roles that are both beneficial and detrimental to
the host. These granulocytes have a specialised role in host defence
against large organisms that are not able to be phagocytosed, most notably
the multicellular helminthic parasites (Butterworth, 1984). Interestingly,
although eosinophils are capable of phagocytosing and destroying small
microbes and bacteria in vitro, this does not form part of their major role
in host defence in vivo. Moreover, eosinophils cannot effectively defend
against bacterial infections when neutrophil function is deficient, as is
apparent in leukocyte adhesion deficiency syndrome (Anderson et al.,
1985). The eosinophil's armamentarium of noxious substances makes
these granulocytes particularly toxic to helminths, in particular since
MBP and ECP, which are the first cationic proteins to be deposited after
binding to the surface of the parasite, are potent helminthotoxins and
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moreover, since EPO generates hypohalous acids that also kills parasites
such as Schistoma mansoni (Jong et al., 1981). Finally, eosinophil
oxidative products also mediate helminthotoxicity (Butterworth, 1984).
Uncontrolled release of the eosinophil-derived superoxide anions and
cationic proteins active in host defence, can prove detrimental to the
host. Thus, the eosinophil by virtue of its cytotoxic capabilities can cause
many of the adverse effects associated with an allergic reaction, such as
epithelial injury in the lungs of asthmatics (Gleich et al., 1988).
1.3 The neutrophil
The neutrophil is specifically associated with diseases such as rheumatoid
arthritis (Brown, 1988), however this granulocyte has also been
implicated in a variety of pulmonary inflammatory diseases, such as
adult respiratory distress syndrome (ARDS) and neonate (Weiland et al.,
1986). The size of its contribution in human asthma and other allergies
remains uncertain. The eosinophilic granulocyte is thought to be more
critically involved in the pathogenesis of asthma however, the
prominent role of the neutrophil is becoming more apparent with the
abundance of neutrophilic granulocytes reported in some cases of fatal
human asthma (Sur et al., 1993).
Neutrophils are the most abundant leukocytes in the blood, constituting
approximately half of the white cell population and originate from
myeloid precursors in the bone marrow. Constitutive granulocytopoesis
is under the control of general growth factors such as IL-3, GM-CSF and
G-CSF. Neutrophils are short-lived cells, with a circulating half-life of
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only 6 h and therefore need to be continuously replaced in order to
maintain a stable circulating neutrophil population.
1.3.1 Morphology
Neutrophils have a mean diameter of 7 |im, a multilobed nucleus and a
large number of intracellular granules (see Appendix). The traditional
classification of neutrophil granules as peroxidase-positive (azurophil or
primary) and peroxidase-negative (specific or secondary) has now been
revised, describing four essentially different types of intracellular
granules and vesicles (Borregaard et al., 1993), which are summarised
below. Secretory vesicles, have been identified as a highly mobilisable
light membrane structure, containing alkaline phosphatase (Borregaard
et al., 1990). It has now been established that the secretory vesicle
membrane also contains the adhesion protein CDllb/CD18 (Mac-1),
which is essential for integrin-mediated neutrophil adhesion (Calafat et
al., 1993), the receptor for the chemotactic tripeptide, FMLP (Jesaitis et al.,
1982) and the membrane component of NADPH oxidase, cytochrome bsss
(Calafat et al., 1993). Specific (or secondary) granules, are spherical in
shape and are defined by their lactoferrin content. They are also an
important source of cytochrome bsss (Borregaard & Tauber, 1984),
adhesion receptors (Bainton et al., 1987) and FMLP receptors (Fletcher &
Gallin, 1983). Gelatinase (or tertiary) granules, are smaller than specific
granules and constitute approximately 25% of all peroxidase-negative
granules. They are principally composed of the protease gelatinase,
which may be involved in digesting the vascular basement membrane to
allow neutrophil extravasation (Peppin & Weiss, 1986). Finally,
azurophil (peroxidase-positive) granules, generally contain agents that
are released into the phagocytic vacuole at the end of the phagocytic
process. These agents include digestive proteinases and microbicidal
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proteins, including defensins. Moreover, the membrane of azurophil
granules has not been shown to contain any receptors or adhesion
molecules of importance for interaction of the neutrophil with its
environment. Of particular significance, is the presence of
myeloperoxidase in azurophil granules, which is required for full
function of the oxygen-dependent bactericidal system in neutrophils.
Thus, azurophil granules, in particular, contain many noxious agents
effective in bacterial killing, which if inappropriately released would be
highly detrimental to host tissue.
1.3.2 Mediator release
As well as a variety of cytoplasmic and granule associated enzymes,
neutrophils are also able to synthesize and release a number of
inflammatory mediators including lipids, such as PAF, LTB4 and 5-HETE
and cytokines, including IL-la and p, TNF-a, IL-6, IFNa, GM-CSF and IL-
8 (McColl & Showell, 1994).
1.3.3 Functions
Neutrophils play important roles in host defence against all classes of
infectious agents and constitute the first line of defence against nonself
substances. Their major role is to phagocytose and destroy pathogens,
such as bacteria, fungi and protozoa. With many microbes, however,
neutrophil defences are ineffective in the absence of opsonins and
various agents that amplify the cytotoxic response. Thus, bacteria and
other foreign particles are phagocytosed most effectively when coated
with opsonizing IgG, promoting recognition by the Fc receptors (FcR) of
the neutrophil.
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Although neutrophils are essential to host defence, it is now clear that
neutrophils are involved in several aspects of the inflammatory response
and have been implicated in the pathology of many chronic
inflammatory conditions (Weiss, 1989). Host tissue damage may occur by
a variety of mechanisms including release of microbicidal products into
the extracellular milieu during the killing of microbes and/or failure to
terminate acute inflammatory responses. However, under physiological
conditions, a number of mechanisms exist to limit the destructive
capacity of inflammatory cells and allow resolution to occur. These
include a reduction in the effective concentration of pro-inflammatory
stimuli; an increase in anti-inflammatory mediators; decreased cellular
responsiveness and ultimately death by apoptosis and removal of the cell
itself.
1.4 Apoptosis
Before the seminal work of Wyllie and colleagues (Kerr et alv 1972,
Wyllie et al., 1980), who described a physiological mode of cell death
termed apoptosis, it was widely believed that the usual fate of cells was to
die by necrosis. This 'accidental' form of cell death refers to the
morphology most often seen when cells die from severe and sudden
injury, such as ischaemia or physical or chemical trauma. The distinctive
morphology and biochemical characteristics associated with necrosis
(Schwartzman & Cidlowski, 1993), ultimately lead to organelle
dissolution and rupture of the plasma membrane, allowing release of the
cytotoxic cellular contents into the surrounding milieu. Thus, in contrast
to apoptosis, necrosis usually provokes an inflammatory response.
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Apoptosis is a widespread phenomenon that plays a crucial role in a
myriad of physiological and pathological processes (Ellis et al., 1991). It is,
for example, essential in many aspects of normal development and is
required for homeostasis, maintaining correct numbers of cells in the
body by balancing cell production with cell death. Moreover, apoptosis
represents a natural form of cell death that is now associated with the
resolution of the inflammatory response (Haslett et al., 1994). In addition,
to the beneficial effects of apoptosis, the inappropriate activation of
apoptosis may cause or contribute to a variety of diseases including
acquired immunodeficiency syndrome (AIDS) and neurodegenerative
diseases (Savill, 1994).
Apoptosis has been associated with specific and characteristic
morphological and biochemical changes, which may be indicative of a
common underlying series of molecular mechanisms. Importantly,
apoptotic cells remain functionally intact, retaining their cytoplasmic
granules and maintaining plasma membrane integrity, as assessed by
vital dye exclusion (e.g., trypan blue). Moreover, apoptosis leads to swift
recognition, uptake and degradation of intact cells by phagocytes, without
release of noxious contents, thus protecting host tissue against potentially
inflammatory stimuli (figure 1.1). The distinctive morphology of
apoptosis has been described in detail from observations using light and
electron microscopy (Wyllie et al., 1980). Briefly, characteristic
morphological changes include, a reduction in cellular volume,
condensation of chromatin around the periphery of the nucleus and
eventual dissolution of the entire cell into small membrane-bound,
smooth-surfaced, spherical structures known as apoptotic-bodies,
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This is accompanied by the fragmentation of DNA, which forms a ladder
pattern of regular subunits when subjected to agarose gel electrophoresis.
Because of its near universality, internucleosomal DNA degradation is
considered a diagnostic hallmark of cells undergoing apoptosis.
Apoptosis can also be assessed by various other methods, including
propidium iodide (PI) staining, which involves changes in dye binding to
nuclear material (Nicoletti et al., 1991) and by measuring cell surface
changes. With regard to this latter method of evaluating apoptosis, most
apoptotic cells express phosphatidylserine molecules on the external
surface of their plasma membranes. This provides the acquired property
of binding annexin V, which is a calcium-dependent phospholipid-
binding protein with a high affinity for phosphatidylserine. Thus, the
almost universal exposure of phosphatidylserine on apoptotic cells has
now been shown to serve as a reliable diagnostic for the occurrence of
apoptosis per se (Koopman et al., 1994, Homburg et al., 1995). Moreover,
in specific cells such as the neutrophil, shedding of cell surface FcyRIII
(CD16) has been associated with the appearance of apoptotic morphology
and hence levels of CD16 expression can be used to define non-apoptotic
and apoptotic neutrophils (Dransfield et al., 1994). It has also been shown
that during apoptosis, there is a marked loss of a number of neutrophil
functions, including chemotaxis, phagocytosis and secretion of granule
enzymes after deliberate external neutrophil stimulation (Whyte et al.,
1993a), thereby rendering this cell functionally isolated from the
surrounding environment.
1.4.1 Clearance of apoptotic cells
It has now been demonstrated both in vitro (Haslett et al., 1987, Stern et
al., 1992) and in vivo (Savill et al., 1989a, Woolley et al., 1996) that
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apoptotic granulocytes can be cleared by macrophages without release of
pro-inflammatory mediators, such as thromboxane B2 and cytokines,
which are normally released during phagocytosis, exemplifying the
tissue-injury limiting properties of this clearance mechanism (Meagher et
al., 1992, Stern et al., 1992).
Macrophages originate from pluripotential stem cells in the bone marrow
and circulate in the bloodstream as mature monocytes which, under
normal steady-state conditions, migrate into tissues and body cavities
where they differentiate into macrophages. They have a central role in
host defence, by nature of their noxious secretory substances and are
particularly important for phagocytosing invading organisms prior to
leukocyte recruitment.
1.4.2 Regulation of apoptosis
The highly organised removal of 'unwanted' cells by apoptosis strongly
suggests that the apoptotic process is subject to careful regulation.
However, the study of apoptosis and its control, is complicated by the fact
that diverse stimuli may be responsible for initiating the onset of the
apoptotic programme in different cell types. Hence, signals producing
apoptosis in one cell type may have differing effects on other cell types;
many examples of which will be discussed in this thesis.
The onset of apoptosis in both eosinophils and neutrophils can be
delayed by haematopoietins and inflammatory mediators (Stern et al.,
1992, Lee et al., 1993); the specific details of which are discussed in Chapter
3. However, comparatively speaking, very little is known about the
precise controls and triggers of granulocyte apoptosis, particularly in
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contrast to, for example, apoptosis in thymocytes, which can be induced
by a variety of different mechanisms. Glucocorticoid treatment,
irradiation, Fas ligand and TNF-a are all pro-apoptotic signals in the
thymocyte (Schwartz & Osborne, 1993, Suda & Nagata, 1994). It has
recently been demonstrated that anti-Fas activating antibodies or Fas
ligand promote eosinophil and neutrophil apoptosis, an effect prevented
by anti-Fas blocking antibodies (Matsumoto et al., 1995, Liles et al., 1996).
Moreover, hypoxic conditions, which are found in chronically inflamed
sites, inhibit neutrophil apoptosis, whereas in some cell lines, apoptosis is
induced (Hannah et al., 1995). Mixed genetic control of apoptosis by
individual genes has also been demonstrated by various cells. Some cells
expressing the c-myc proto-oncogene product, have been shown to
undergo apoptosis readily, whereas other cells expressing the oncogene
product bcl-2 are protected from undergoing apoptosis (Schwartz &
Osborne, 1993). However, the significance of such molecular control on
eosinophil and neutrophil apoptosis is unknown.
1.5 Glucocorticoids
Glucocorticoids are highly effective in the control of many inflammatory
and immune diseases and have been employed therapeutically for many
years. Inhaled steroids have now become first-line therapy for the
treatment of chronic asthma, yet the mechanisms by which they exert
their effects in vivo are still poorly understood (Goulding & Guyre, 1993).
Further studies elucidating the underlying anti-inflammatory
mechanisms employed by these agents may offer attractive therapeutic
alternatives, with fewer clinical side-effects.
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1.5.1 Glucocorticoid receptors
Glucocorticoids diffuse passively through the cell membrane into the
cytoplasm, where they bind reversibly with high affinity and specificity, to
soluble receptor proteins known as glucocorticoid receptors (GRs). The
GR is a member of the steroid hormone receptor supergene family, which
includes cytosolic receptors for other steroid hormones such as
progesterone. Moreover, it has been established that there are two
receptor isoforms of the human GR, namely hGRa and hGR[3, which
originate from the same gene by alternative splicing (Hollenberg et al.,
1985, Encio & Detera-Wadleigh, 1991). These isoforms have been detected
in a variety of tissues, including cells from the lungs (Ballard & Ballard,
1974) and in inflammatory cells such as eosinophils and neutrophils
(Peterson et al., 1981) and macrophages (Werb et al., 1978). Moreover, it
has been demonstrated that saturable glucocorticoid binding in human
eosinophils is similar to that observed in neutrophils and the affinity of
the GR (Kd = 15.3 ± 0.6 nM in the eosinophil and 17.7 ± 0.8 nM in the
neutrophil) indicates that it is capable of mediating effects at physiological
hormonal concentrations (Peterson et al., 1981).
The structural organisation of the GR is characterised by a short and
highly conserved cysteine-rich central region, constituting the DNA-
binding domain; a relatively well-conserved carboxy-terminal domain,
important for both hormone binding and transactivation and a variable
amino-terminal region containing the transactivation domains
responsible for gene activation. The GR is a phosphoprotein (Housley &
Pratt, 1983), being phosphorylated predominantly on serine residues at
the N-terminal, but the definitive role of phosphorylation in steroid
actions is unknown (Muller & Renkawitz, 1991).
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In the absence of ligand, the GR is part of a heteromeric complex
consisting of one receptor molecule, two molecules of 90 kDa heat shock
protein (hsp 90) and one molecule each of hsp 70, hsp 57 and hsp 23
(Hutchison et al., 1993, Czar et al., 1994). The hsp molecules act as a
'molecular chaperone', preventing the unoccupied GR from localising to
the nuclear compartment. As depicted in figure 1.2, hormone-binding
leads to a conformational change in the GR molecule, allowing it to
dissociate from the hsp complex, homodimerize with another hormone-
activated receptor molecule and translocate to the nucleus, where it
exhibits DNA binding ability arid interacts with a wide range of nuclear
targets. Activated GRs have been shown to bind to DNA at consensus
sites termed glucocorticoid response elements (GREs) and negative GREs
(nGREs), in the regulatory regions of glucocorticoid target genes, resulting
in transcriptional activation and repression, respectively (Yamamoto,
1985). Thus, glucocorticoids are known to both up- and down-regulate
the expression of specific proteins (Maroder et al., 1993) and it is this
protein regulation which is ultimately thought to bring about altered cell
function and expression of glucocorticoid activity. The GR is therefore a
signal transduction protein that transduces the hormone signal to a
transcriptional response at the level of specific target genes, which are
expressed in a cell-specific manner.
1.5.2 Receptor interaction with transcription factors
GRs have the ability to interact with other transcription factors and this
may be an important determinant of steroid responsiveness underlying
the anti-inflammatory actions of glucocorticoids (Schule & Evans, 1991,
Ponta et al., 1992, Cato & Wade, 1996). Studies show that direct protein-
protein interactions between the components of AP-1 or NF-kB and GRs
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Figure 1.2 Simplified general mechanism of steroid action.
Circulating steroids are complexed to binding proteins such as transcortin
and albumin. However, a small percentage of exogenous synthetic
corticosteroids circulate in an unbound and active state. These free steroid
molecules (S) enter cells, combine with specific receptors (R), and move to
the nucleus where new mRNA is synthesised. The mRNA initiates new
cytosolic protein synthesis, which may alter cellular function.
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may prevent DNA binding and/or transactivation by these pro¬
inflammatory transcription factors, thereby partly accounting for the
inflammation suppressive properties of glucocorticoids (Adcock et al.,
1994a, Mukaida et al., 1994, Ray & Prefontaine, 1994). For example, in
human lung TNF-a and phorbol esters reportedly increase AP-1 and NF-
kB binding to DNA, and this is inhibited by glucocorticoids (Adcock et al.,
1994a; 1994b). Moreover, an additional mechanism of repression by
glucocorticoids on NF-A:B-mediated transcription has been demonstrated,
involving a rapid induction of IkBa mRNA and protein synthesis,
following steroid treatment (Auphan et al., 1995). Newly synthesised
IkBa interacts with mRNA heterodimers thereby inhibiting NF-/cB DNA
binding and transcriptional activation by cytokines. However, Adcock
and colleagues have recently shown that IL-1 (3 induces GM-CSF release in
human lung epithelial-like (A549) cells via a NF-fcB-dependent
mechanism and repression occurred at concentrations of dexamethasone
that were shown not to induce IkB (Adcock et al., 1997). Collectively,
these findings suggest that the induction of IkB does not represent a
universal anti-inflammatory mechanism underlying glucocorticoid
action.
GRs may interact with other transcription factors, such as CREB. There is
evidence that (3-adrenoceptors, via formation of cyclic AMP and
activation of PKA, result in the activation of the transcription factor
CREB, that binds to a cyclic AMP response element (CRE) on genes
(Yamamoto et al., 1988). ^-Adrenoceptor agonists increase CRE binding
in human lung in vitro and at the same time reduce GRE binding,
suggesting that there may be a protein-protein interaction between CREB
and GRs within the nucleus (Peters et al., 1993). Similar interactions
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have been demonstrated in a hepatoma cell line (Imai et al., 1993) and in
human pulmonary epithelial cells (Stevens et al., 1995).
1.5.3 Anti-inflammatory mechanisms of glucocorticoids
The anti-inflammatory mechanisms employed by glucocorticoids in
controlling inflammation may be effective by regulating several aspects of
the inflammatory process through increasing or decreasing gene
transcription. Possible mechanisms particularly germane to the results
presented in this thesis are introduced below.
1.5.3.1 Cytokines
Cytokines play an important role in chronic inflammation and it has
been reported that steroids have potent inhibitory effects on cytokine-
mediated inflammation. Steroids inhibit the transcription of several pro¬
inflammatory cytokines, including TNF-a, GM-CSF, IL-1, IL-3, IL-4, IL-5,
IL-6 and IL-8 (Guyre et al., 1988, Rolfe et al., 1992). These effects may be
mediated directly via interaction of GRs with nGREs in the upstream
promoter sequence of the cytokine gene, resulting in reduced gene
transcription. However, since there is no apparent nGRE consensus
sequence in the upstream promoter region of many cytokines, such as IL-
2, IL-8 and RANTES, it has been suggested that glucocorticoids also
inhibit transcription indirectly via interference with other transcription
factors. Thus, glucocorticoid-mediated inhibition of IL-2 gene
transcription in T lymphocytes is predominantly regulated by a cell-
specific transcription factor, nuclear factor of activated T cells (NF-AT),
which is activated in the cytoplasm on T cell receptor stimulation via
calcineurin (Thomson & Starzl, 1993). The nuclear factor AP-1 also
appears to be necessary for increased activation, forming a transcriptional
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complex with NF-AT by direct binding (Northrop et al., 1993).
Glucocorticoids inhibit IL-2 gene transcription indirectly by binding to
AP-1, thereby preventing increased transcription due to NF-AT
(Paliogianni et al., 1993). Transcription of IL-8 and RANTES is inhibited
by glucocorticoids in a similar manner. Negative regulation of IL-8 is
mediated by the interaction of glucocorticoids with NF-fcB (Mukaida et
al., 1994), while the transcription of RANTES is inhibited by the
interaction of glucocorticoids with both NF-A:B and AP-1 (Nelson et al.,
1993).
In addition to blocking the synthesis of cytokines, steroids may also
inhibit the synthesis of certain cytokine receptors, as has been
demonstrated with the IL-2 receptor (Grabstein et al., 1986). Interestingly
in neutrophils, it has been reported that dexamethasone can induce
synthesis of the type II receptor (a decoy molecule for IL-1); an effect
which has been suggested to contribute to the anti-inflammatory
activities of dexamethasone (Muzio et al., 1994). Moreover, steroids have
also been reported to counteract cytokine-induced activation of certain
transcription factors, such as TNF-oc-mediated activation of AP-1 and NF-
kB (Adcock et al., 1994a).
1.5.3.2 Inhibitory proteins
Glucocorticoids may have an inhibitory effect on inflammation by
increasing the synthesis of anti-inflammatory proteins, such as
lipocortin-1 (Flower & Rothwell, 1994). This 37 kDa protein inhibits the
action of phospholipase A2 and may therefore inhibit the production of
arachidonic metabolites, such as leukotrienes, prostaglandins and PAF.
Thus, production of lipocortin-1 would act to limit the pro-inflammatory
potential of the above lipid mediators. Steroids induce the formation of
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lipocortin-1 in several cells, including rat and human leukocytes
(Goulding et al., 1990, Peers et al., 1993). Moreover, it has been reported
that recombinant lipocortin-1 has acute anti-inflammatory properties and
inhibits the release of pro-inflammatory mediators such as thromboxane
from guinea-pig isolated perfused lung (Cirino et al., 1987).
Steroid-induced production of lipocortin-1 was one of the first proposed
anti-inflammatory mechanisms of action of the glucocorticoids (Flower &
Rothwell, 1994). However, it is now apparent that lipocortin-1 has rather
non-specific effects (Davidson & Dennis, 1989) and moreover,
glucocorticoids do not induce expression of lipocortin-1 in all cell types
(Bronnegard et al., 1988). Thus, while production of lipocortin-1 may
account for several of the pharmacological actions of glucocorticoids, it
does not underlie a universal anti-inflammatory mechanism of steroid
action.
1.5.3.3 Effect on cell function
Steroids may have direct inhibitory actions on several inflammatory cells
implicated in inflammatory diseases such as asthma (Barnes et al., 1995).
Inhibition of inflammatory mediator release from eosinophils,
macrophages and T lymphocytes has been a reported cellular effect of
glucocorticoids. One of the best described actions attributed to steroids in
asthma is a reduction in the number of circulating eosinophils after
administration of corticosteroids, an observation which has been
suggested may reflect an action on eosinophil production in the bone
marrow (Barnes, 1995a). Although corticosteroids are known to reduce
the neutrophil influx to an inflammatory site, the direct effect of these
agents on neutrophil function remains ill defined.
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1.5.3.4 Effect on cell survival
The survival of certain inflammatory cells, such as eosinophils and
thymocytes is markedly reduced after exposure to steroids. It is now well
documented that eosinophil survival is dependent on the presence of
such cytokines as IL-5 and GM-CSF and that exposure to steroids inhibits
the survival-promoting effects of these cytokines, leading to apoptosis
(Lamas et al., 1991, Owens et al., 1991, Wallen et al., 1991, Hallsworth et
al., 1992). The mechanisms by which the inhibition of eosinophil
survival may occur have not been fully defined but increased expression
of specific endonucleases has been suggested as being relevant to the
action of steroids on inflammatory cell survival (Compton & Cidlowski,
1987, Owens et al., 1991). Thus, the main focus of my thesis has been to
investigate the mechanisms underlying the effect of corticosteroids on
granulocyte apoptosis.
1.6 Signal transduction
Between the signal that initiates the process of apoptosis and the genes
encoding the machinery that kills the cell, are signal transduction
pathways. Several different signal transduction systems have been
associated with the regulation of apoptosis and the final response varies
with cell type. The details appertaining to the modulation of apoptosis by
specific signal transduction pathways will be discussed in the chapters
following, however the classical pathways are introduced below.
1.6.1 Calcium (Ca2+) and Protein kinase C (PKC)
Elucidation of the role of Ca2+ as an intracellular messenger, began over
one hundred years ago with the observation by Ringer (1881) that the
contraction of cardiac muscle requires the presence of extracellular Ca2+.
Changes in the concentration of free Ca2+ in the cytoplasmic space












Figure 1.3 Schematic diagram illustrating Ca2+ and PKC signal
transduction pathways.
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messenger in most cells, ranging from bacteria to specialised neurones
(Clapham, 1995). As illustrated in figure 1.3, stimulation by a hormone or
neurotransmitter increases the [Ca2+] in the cytosol as calcium channels
open in the plasma membrane or as Ca2+ is released from intracellular
stores, such as the endoplasmic or sarcoplasmic reticulum and
mitochondria. When the concentration rises, Ca2+ binding proteins in
the cytosol, such as the specific receptor, calmodulin, attach to Ca2+ and
the Ca2+-protein complexes then interact with other proteins in the cell to
alter their functions.
Metabolism of inositol phospholipids represents another mechanism by
which the [Ca2+]i is elevated. The initial signal is transduced via a GTP-
binding protein, which in turn activates phospholipase C (PLC). This
leads to the hydrolysis of phosphatidylinositol (4,5)-bisphosphate [Ptdlns
(4,5)P2l to form the second messengers diacylglycerol (DAG) and inositol
(l,4,5)-trisphosphate [Ins (1,4,5)P3], which constitute an interacting pair of
signals that activate the Ca2+- and phospholipid-dependent enzyme PKC
(Takai et al., 1979, Nishizuka, 1984) and liberate intracellular sequestered
Ca2+, respectively. The effects of Ins (1,4,5)P3 can be mimicked in vitro by
pharmacological agents such as (1) thapsigargin, which increases cytosolic
Ca2+ by inhibiting the ATP-dependent endoplasmic reticulum Ca2 +
pump, thereby promoting Ca2+ release from intracellular stores and
influx of extracellular Ca2+ by a capacitative mechanism (Thastrup et al.,
1989) and (2) Ca2+ ionophores such as A23187, which increase
intracellular Ca2+ by facilitating Ca2+ influx across the plasma membrane
(Reed & Lardy, 1972). In neutrophils, for example, combined treatment of
cells with Ca2+ ionophores and PKC activators, such as phorbol esters, can
reproduce all the downstream biological responses normally promoted by
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PLC stimulation, including exocytosis of secretory granules and NADPH-
oxidase activation (Di Virgilio et al., 1984, Robinson et al., 1984).
PKC activation, via DAG, elicits a variety of cellular responses by
phosphorylating target proteins on serine or threonine residues. With
the advent of PKC activators, such as PMA and PKC inhibitors, such as
staurosporine (Nakadate et al., 1988) and Ro-31-8220 (Keller & Niggli,
1993), studies investigating the role of PKC in the regulation of apoptosis
are now possible. Although some physiological substrates of this enzyme
have been identified, the functions of many of these proteins in the cell
and the role phosphorylation plays in their activity is unknown.
1.6.2 Protein tyrosine kinases
Protein tyrosine kinase receptors, which mediate the biological functions
of many peptide growth factors and cytokines have now been
characterised (Ullrich & Schlessinger, 1990). All tyrosine kinase receptors
are composed of three major domains; an extracellular domain connected
via a single membrane-spanning domain to a cytoplasmic domain. Upon
ligand binding, the extracellular domain transmits the biological signal to
the cytoplasmic domain, whose role is to convey the biological signal to
intracellular target proteins. In addition to the catalytic protein tyrosine
kinase, the cytoplasmic domain also contains distinct regulatory
sequences with tyrosine, serine and threonine phosphorylation sites.
Ligand binding to the extracellular domain of receptor tyrosine kinases is
followed by receptor dimerization, stimulation of protein tyrosine kinase
activity and autophosphorylation. Autophosphorylation provides an
important regulatory step which determines the selectivity of signalling
pathways recruited by growth factor receptors.
42
Receptor tyrosine phosphorylation promotes interaction of the receptor
with a number of target proteins, including phospholipase C-y (PLC-y)
(Ronnstrand et al., 1992), growth-factor-receptor binding protein 2 (Grb2)
(Arvidsson et al., 1994) and has been shown to activate several
serine/threonine kinases such as the MAP kinases (Chao, 1992).
1.6.2.1 SH2-containing proteins
The tyrosine-phosphorylated regions in growth factor receptors function
as high affinity binding sites for cellular proteins such as PLC (Burgess et
al., 1990), and the association between these receptors and proteins is
mediated by a conserved region known as src homology 2 domains (SH2)
(Koch et al., 1991, Parsons & Parsons, 1997). SH2 domains represent
recognition motifs for specific tyrosine-phosphorylated peptide sequences,
and are usually accompanied by a SH3 domain, the function of which is
still poorly understood.
Proteins containing SH2 and SH3 domains can be divided into two
groups (Mayer & Baltimore, 1993). Type I defines proteins that contain, in
addition to the SH2 (and usually also SH3) domains, various catalytic
activities, while type II contains only SH2 and SH3 domains. Thus, PLC-y
represents an example of a type I protein (Kim et al., 1991) and Grb2
represents an example of a type II protein (Lowenstein et al., 1992, Ren et
al., 1993). Type II SH2-containing proteins therefore merely serve as
adapter molecules to couple the activated receptor to other intermediates.
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1.6.2.2 Cytokine-mediated receptor signalling with no intrinsic kinase
activity
The IL-3, IL-5 and GM-CSF receptors share a common signal transducer
that possesses no intrinsic kinase domain. These cytokine receptors are
heterodimers of a- and P-subunits (Lopez et al., 1992), with the a-subunit
being specific to each and the p-subunit common to all three receptors.
Despite the absence of kinase domains in their receptors, these cytokines
induce tyrosine phosphorylation of cellular substrate proteins and of their
receptors, which has led to the assumption that a protein tyrosine kinase
physically associates with their receptors and becomes activated following
ligand binding (Ihle et al., 1994). It has now been reported that upon
ligand binding these cytokines activate JAK2, which is a member of the
JAK family of protein kinases (Silvennoinen et al., 1993, Briscoe et al.,
1994, Karnitz & Abraham, 1995). Activation of JAKs by cytokines leads to
JAK tyrosine phosphorylation, increased catalytic activity and the ability
to associate with cytokine receptors. Structurally, JAKs possess two kinase
domains, however they are unique among other cytoplasmic tyrosine
kinases as they lack SH2 and SH3 domains (Pawson & Gish, 1992).
JAKs phosphorylate a group of nuclear proteins called signal transducers
and activators of transcription (STAT proteins) and as their name
suggests, couple ligand binding and activation of gene expression (Briscoe
et al., 1994, Ihle et al., 1994, Karnitz & Abraham, 1995). The STAT family
of proteins is characterised by the presence of a carboxy-terminal SH3
domain followed by a SH2 domain, and have been shown to be activated
in association with JAKs, by for example, IL-5 in eosinophils (Pazdrak et
al., 1995, Van der Bruggen et al., 1995).
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1.6.3 Mitogen-activated protein kinases
The MAP kinase (mitogen-activated protein kinase) pathway represents a
signal transduction cascade that is highly conserved in evolutionary
distinct organisms and has been demonstrated in a variety of cells of
mammalian, amphibian and yeast ancestries (Pelech, 1993). As illustrated
in figure 1.4, the 'MAP kinases' constitute a superfamily of proteins that









Figure 1.4. A schematic diagram illustrating the organisation of the three
known mammalian MAP kinase cascades, leading to activation of ERK,
JNK and p38. Abbreviations: MEK, MAP kinase kinase; MEKK-1, MEK
kinase; MEKK-X, MEKK-like enzyme. (Modified diagram taken from Lin
et al., 1995.)
terminal kinases) and p38 MAP kinases. Growth factors and mitogens
preferentially activate ERK1 and ERK2, whereas inflammatory cytokines
and various forms of stress preferentially activate JNK and/or p38 (Lin et
al., 1995). With the advent of selective MAPK pathway inhibitors such as
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PD 098059, which inhibits the MAPK/ERK cascade (Alessi et al., 1995,
Dudley et al., 1995) and SB 203580, which inhibits the p38 MAPK cascade
(Lee et al., 1994, Cuenda et al., 1995), it has become possible to investigate
the influences of MAPKs on the regulation of apoptosis; discussed further
in Chapter 5.
Several cytoplasmic signal transduction pathways involving sequential
protein kinase reactions use the MAPK/ERK cascade. It is activated by
phosphorylation on both tyrosine and threonine, a reaction which is in
turn catalysed by a specific threonine/tyrosine directed kinase, MEK
(MAPK/ERK kinase). MEK (MEK1/2) is phosphorylated and activated by
the serine/threonine protein kinase, Raf. Recent evidence suggests the
existence of several pathways to activation of MEK, including MEK kinase
(MEKK) (Kyriakis et al., 1992, Lange-Carter et al., 1993) and Mos (Posada et
al., 1993). However, the best delineated pathway indicates the
involvement of Ras and Raf which phosphorylate MEK in response to
tyrosine-linked receptors, such as FMLP receptors on neutrophils
(Worthen et al., 1994). Regulation of MAPK/ERK involves an array of
signals that ultimately converge on Raf.
Historically, this type of pathway has been associated with growth factor
receptors which display intrinsic tyrosine kinase activity (Fantl et al.,
1993), however a number of G-protein-coupled receptors have now also
been shown to activate the MAP kinase cascade (Kahan et al., 1992).
Receptors such as those for (3-adrenergic agonists can activate the MAP
kinase pathway and are coupled to the G proteins, Gi and Gq. Subsequent
activation of ai, aq and Py-complexes can regulate effectors that
ultimately stimulate Raf activity, as illustrated in figure 1.5. The GTP-
46
bound aq subunit and the fty-complexes can regulate phospholipase C-{3
(PLC-(3) activity, leading to the activation of PKC. PKC directly
phosphorylates Raf, however there are conflicting reports as to whether
this results in Raf activation (Kolch et al., 1993, Macdonald et al., 1993).
Interestingly, PKC-independent mechanisms are also able to stimulate the
MAPK/ERK cascade, through the activation of Ras by heterotrimeric G
proteins. Gi can activate the MAPK pathway by regulating GTP loading of
Ras, however the precise steps involved are unknown. Such agents as
thrombin and the mitogenic phospholipid lysophosphatidic acid (LPA)
have been shown to activate the MAPK/ERK pathway (Kahan et al., 1992,
Hordijk et al., 1994) by a mechanism independent of changes in PKC
activation. Tyrosine kinases also activate Raf and the MAPK/ERK
pathway. One such example is the epidermal growth factor (EGF)-
receptor pathway, which involves the SH2 and SH3 domains of an
adapter protein, Grb2, and the Ras guanine-nucleotide exchange factor,
Sos. Growth factor binding results in receptor autophosphorylation and
subsequent association between the Grb2 SH2 domain and a specific
phosphotyrosine-containing sequence in the EGF-receptor (Egan et al.,
1993, Buday & Downward, 1993). Sos, interacts with this receptor at the
cytoplasmic surface of the plasma membrane, via the Grb2 SH3 domain
and through formation of the Grb2-Sos complex, catalyses dissociation of
GDP from Ras, allowing GTP loading and activation. The active Ras-GTP
complex interacts directly with Raf (Van Aelst et al., 1993, Vojtek et al.,
1993, Warne et al., 1993, Zhang et al., 1993) thereby recruiting Raf to the
plasma membrane where it is activated by currently unidentified signals
and by an as yet unidentified mechanism (Cai et al., 1993, Leevers et al.,
1994, Stokoe et al., 1994). The presence of Raf as a major convergence
point for different signals allows the integration of G protein and tyrosine
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Figure 1.5. A simplified schematic diagram illustrating the MAP kinase
(p42/p44) signalling cascade.
Autophosphorylation of tyrosine kinase encoded growth factor receptors
and activation of STMR (receptors with seven transmembrane helices)
coupled to heterotrimeric G proteins leads to the activation of Ras, and
the ultimate translocation of ERK1/2 to the nucleus. Nucleus localised
ERK phosphorylates and activates SRF/Elk-1 transcription complex.
These cascades are inhibited by phosphatases PP2A and MKP-1. (Modified
diagram from Blumer & Johnson, 1994.)
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kinase activation of the MAPK/ERK cascade. Raf then phosphorylates
and activates MEK (Dent et al., 1992, Howe et al., 1992, Kyriakis et al.,
1992), which in turn phosphorylates and activates p42MAPK (ERK2) and
p44MAPK (ERK1). The MAPKs/ERKs then phosphorylate and regulate a
diverse group of proteins including cytoplasmic protein kinases (such as
p90 ribosomal S6 kinase [Rsk]), phospholipases (such as cytosolic
phospholipase A2) and nuclear transcription factors (such as Elk-1)
(Blenis, 1993). ERKs translocate to the nucleus and phosphorylate Elk-1 (a
TCF, or ternary complex factor) on five residues near its carboxyl
terminus (Gille et al., 1995). Elk-1 then associates with SRF (serum
response factor), forming a ternary complex which binds the serum
response element in the c-Fos promoter. Phosphorylation of Elk-1 leads
to increased transcription of c-Fos mRNA, which is thought to result
from increased transcriptional activation strength of the TCF/SRF
complex (Treisman, 1994). In this way, MAPK/ERK transmits
information to the nucleus, resulting in the regulation of genes involved
in growth control.
As illustrated in figure 1.5, several of the components of the MAPK/ERK
pathway are subject to regulation by protein phosphatases. The protein
phosphatases, PP1 and PP2A, have been shown to dephosphorylate Raf in
vitro, although the physiological protein phosphatase for Raf is
unknown. Moreover, the activating phosphoserines in MEK and the
activating phosphothreonines in ERK1/2 can be dephosphorylated in
vitro by PP2A (Hunter, 1995). Furthermore, ERK1/2 can also be
inactivated in vivo by the dual specificity protein phosphatases, MKP-1
(CL 100, 3CH 134) and PAC-1 (Ward et al., 1994), which have been reported
to dephosphorylate both phosphothreonine and phosphotyrosine
49
residues. Interestingly these protein phosphatases have been reported to
exhibit considerable specificity for individual MAPKs (Keyse, 1995).
1.6.4 Protein phosphatases
Protein phosphatases are a diverse group of proteins that have been
classified based on various biochemical parameters. The
serine/threonine-specific protein phosphatases were initially divided into
two classes: type-1 phosphatases (PP1) are inhibited by nanomolar
concentrations of the thermostable proteins, termed inhibitor-1 (1-1) and
inhibitor-2 (1-2) and preferentially dephosphorylate the fi-subunit of
phosphorylase kinase, whereas type-2 phosphatases are insensitive to the
inhibitors and preferentially dephosphorylate the a-subunit of
phosphorylase kinase (Wera & Hemmings, 1995). The type-2
phosphatases comprise three enzymes (PP2A, PP2B and PP2C) that can be
distinguished by their requirement for cations. PP2A, like PP1, does not
have an absolute requirement for bivalent cations, whereas PP2B (or
calcineurin) and PP2C are Ca2+/calmodulin- and Mg2+-dependent,
respectively (Ingebritsen & Cohen, 1983, Cohen, 1989).
The precise regulation of protein phosphatases indicates their central role
in cellular regulation, and abnormal inhibition of these enzymes leads to
disorders of cellular functions. The discovery of many cell permeable
phosphatase inhibitors, such as okadaic acid and calyculin A, has
revolutionised the study of the function of protein phosphatases in
cellular regulation (Holmes & Boland, 1993). Okadaic acid is a complex
fatty acid produced by marine dinoflagellates which accumulates in the
digestive glands of shellfish and marine sponges such as Halichondria
okadii. It is the major cause of diarrhetic shellfish poisoning (Haystead et
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al., 1989) and a potent tumour promoter (Suganuma et al., 1988). It is a
potent inhibitor of PP2A and PP1; preferentially inhibiting PP2A at lower
concentrations and also, at higher concentrations, PP1. Calyculin A,
which is also isolated from sea sponges although is structurally unrelated
to okadaic acid, inhibits both PP1 and PP2A at nanomolar concentrations
with equal potency (Ishihara et al., 1989).
The native structure of PP1 is a 1:1 complex between the catalytic and a
number of different regulatory subunits (Hubbard & Cohen, 1993). These
regulatory subunits have an important role in targeting the catalytic
subunit towards specific subcellular locations and increasing activity
towards particular substrates (Hubbard & Cohen, 1993). PP2A, however,
exists as several trimeric holoenzyme forms. The core of these structures
consists of a 36 kDa catalytic subunit (PP2AC), homologous to that of PP1
(Berndt et al., 1987), complexed with a regulatory subunit of 65 kDa (PR65
or A subunit). This core dimer associates with variable regulatory
subunits of 55 kDa (PR55 or B subunit), 54 kDa (B' subunit), 72 kDa (PR72),
74 kDa (B" subunit) or 130 kDa (PR 130) (Mumby & Walter, 1993, Mayer-
Jaekel & Hemmings, 1994) and several isoforms of each subunit exist
(Axton et al., 1990). Again, as for PP1, the regulatory subunits have an
important role influencing the substrate specificity of the catalytic subunit
(Agostinis et al., 1992, Cegielska et al., 1994).
1.6.5 Protein kinase A (PKA)
Formation of cAMP results from a complex cascade of interactions,
initiated by the actions of agonists at a variety of receptors, such as (3-
adrenoceptors and certain PG receptors. The receptors are coupled via
intermediary GTP-binding regulatory proteins to the membrane-
associated enzyme, adenylyl cyclase, which exists as a family of
isoenzymes (Tang & Gilman, 1992). Agonist-stimulated activation of Gs
(a stimulatory guanine nucleotide-binding regulatory protein) leads to
subsequent activation of adenylyl cyclase which catalyses the conversion
of ATP to cAMP (Levitzki, 1988). The major effector system of cAMP is
PKA (or cAMP-dependent protein kinase), which is a multisubstrate
enzyme existing as two major types, I and II and is composed of regulatory
(RI, RII) and catalytic (C) subunits. A schematic diagram of the
cAMP/PKA signalling cascade is featured in Chapter 6. RI, RH and C exist
in subforms and several groups have now highlighted the diversity of
PKA and its subunit composition (McKnight, 1991, Doskeland et al., 1993).
The inactive PKA holoenzyme consists of two regulatory (R) and two
catalytic (C) subunits. Dissociation of this tetrameric complex occurs upon
binding of two cAMP molecules to each of the two regulatory subunits,
allowing the free activated catalytic subunits to phosphorylate specific
substrate proteins and thereby alter their activities (Whitehouse &
Abayasekara, 1994). As explained in Chapter 6, the downstream effects of
cAMP on gene transcription are thought to be predominantly mediated
through PKA phosphorylation of the transcription factor CREB (Gonzalez
& Montminy, 1989). Studies featured in this thesis, investigating the role
of PKA in the regulation of granulocyte apoptosis, have in part relied
upon the use of H-89, for which it has previously been demonstrated is a
selective inhibitor of PKA in vitro (Chijiwa et al., 1990).
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1.7 Aims/Scope of thesis
The aim of this thesis is to determine the effects and mechanisms of
action of glucocorticoids on eosinophil and neutrophil apoptosis and to
examine the effects of these agents on macrophage-mediated phagocytosis
of apoptotic granulocytes. The results section of this thesis is divided into
five chapters. The first results chapter (Chapter 3) describes the effect of
glucocorticoids on eosinophilic and neutrophilic apoptosis. The second
results chapter (Chapter 4) describes the role of calcium and protein
kinase C in basal and glucocorticoid-mediated granulocyte apoptosis. The
third results chapter (Chapter 5) details the role of MAPK/ERK and
protein phosphatases in basal and glucocorticoid-mediated granulocyte
apoptosis. The involvement of PKA (cAMP-dependent protein kinase)
in basal and glucocorticoid-mediated myeloid cell apoptosis is detailed in
the fourth results chapter (Chapter 6). The final results chapter (Chapter






The following reagents were obtained from Gibco Life Technologies
(Paisley, Scotland, UK): Hanks balanced salt solutions (HBSS), pH 7.4 and
HBSS with 1.2 mM Ca2+ and 0.8 mM Mg2+, pH 7.4 (HBSS with divalent
cations) and Iscove's Dulbecco's modified Eagles medium, without
supplement with L-glutamine (Iscove's DMEM) and culture supplements
Penicillin (50 U/ml)/Streptomycin (50 U/ml).
The following reagents were obtained from the Sigma Chemical
Company (Poole, Dorset, UK): bacitracin (dissolved in dH20 as required),
benzamidine (dissolved in dH20 as required), 8-bromoadenosine 5'-
monophosphate (dissolved in Iscove's DMEM at 20 mM and stored at
-20°C), A23187 (dissolved in DMSO at 10 mM and stored at 4°C),
cycloheximide (dissolved in DMSO at 10 mM and stored at -20°C),
dextran-500 (dissolved in sterile 0.9% saline (6% w/v) and stored at 4°C),
dimethoxybenzidine (o-DMB) (dissolved in sterile H2O at 10 mg/ml and
stored at -20°C), dimethyl sulfoxide (DMSO), (dl) dithiothreitol (DTT)
(dissolved in dH20 at 2 mM as required), N6, 2'-0-dibutyryladenosine
3':5'-cyclic monophosphate (dibutyryl-cAMP) (dissolved in Iscove's
DMEM at 20 mM and stored at -20°C), forskolin (dissolved in DMSO at 0.2
mM and stored at room temperature), fura-2 acetoxymethyl ester (fura-
2/AM) (dissolved in DMSO at 1 mM and stored at -20°C), hydrocortisone
(Cortisol) (dissolved in Iscove's DMEM at 10 mM and stored at -20°C), 3-
isobutyl-l-methylxanthine (IBMX) (dissolved in DMSO at 10 mM and
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stored at -20°C), kemptide (dissolved in dH20 at 2 mM and stored at
-20°C), lipopolysaccharide (LPS; E coli 0127:B8) (dissolved in Iscove's
DMEM at 10 mg/ml and stored at -20°C), phenylmethylsulfonylfluoride
(PMSF) (dissolved in methanol as required), progesterone (dissolved in
Iscove's DMEM at 10 mM and stored at -20°C), protein kinase inhibitor
(IP20) (dissolved in dH20 at 10 pM and stored at -20°C), soybean trypsin
inhibitor (dissolved in dH^O as required), staurosporine (dissolved in
DMSO at 1 mM and stored at 4°C) and thapsigargin (dissolved in DMSO
at 10 mM and stored at -20°C).
The following reagents were obtained from Baxter Healthcare Ltd.,
(Baillieston, Glasgow, Scotland, UK): Diff-Quick stain [Solution I (Eosin G
in phosphate buffer, pH 6.0); Solution II (Thiazine blue in phosphate
buffer, pH 6.0)].
The following reagents were obtained from Calbiochem-Novabiochem
Ltd., (Beeston, Nottingham, UK): l,2-bis-(o-Aminophenoxy)ethane-
N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA/AM)
(dissolved in DMSO at 10 mM and stored at -20°C), calyculin A (dissolved
in ethanol at 1 mM and stored at -20° C), N-[2-
bromocinnamyl(amino)ethyl]-5-isoquinoline sulfonamide, HC1 (H-89,
dihydrochloride) (dissolved in ethanol at 5 mM and stored at -20°C),
okadaic acid (dissolved in ethanol at 1 mM and stored at -20°C) and PD
098059 (dissolved in DMSO at 20 mM and stored at -20°C).
The following reagents were obtained from Cascade Biochem Ltd.,
(Reading, Berkshire, UK): prostaglandin D2 (PGD2) (dissolved in ethanol
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at 2.84 mM and stored at -20°C) and 11-deoxy prostaglandin Ei (PGEi)
(dissolved in ethanol at 2.95 mM and stored at -20°C).
The following reagents were obtained from Genzyme Diagnostics (Kent,
UK): recombinant human granulocyte-macrophage colony-stimulating
factor (GM-CSF) (dissolved in PBS without divalent cations at 1000
Units/ml and stored at -70°C) and monoclonal mouse anti-human GM-
CSF (dissolved in Iscove's DMEM at a stock protein concentration of 1
mg/ml and stored at 4°C).
The following reagents were gifts from Glaxo-Welcome Group Research
(UK): budesonide (dissolved in ethanol at 22 mM and stored at 4°C) and
BW A868C (dissolved in ethanol at 2.18 mM and stored at -20°C).
The following reagents were obtained from Schering Health Care (West
Sussex, UK): rolipram (dissolved in DMSO at 10 mM and stored at -20°C)
and ZK 118.182 (dissolved in Iscove's DMEM as required and stored at
-20°).
Dexamethasone was obtained from David Bull Laboratories (Warwick,
UK) and stored at 4°C at a stock concentration of 8.3 mM. Dynabeads M-
450 sheep anti-mouse IgG were obtained from Dynal (UK) Ltd., (Wirral,
UK) and are supplied as a suspension containing 4x108 beads/ml in
phosphate buffered saline (PBS) pH 7.4 with 0.1% human serum albumin
(HSA) and 0.2% sodium azide (NaN3). Fluorescein isothiocyanate (FITC)-
conjugated F(ab')2 fragments of rabbit anti-mouse immunoglobulin (Ig)
were obtained from Dako Corporation (Buckinghamshire, UK), [y-
32P]ATP was obtained from Amersham (Buckinghamshire, UK).
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Interleukin 5 (IL-5) was obtained from R&D Systems Europe Ltd
(Abingdon, UK) and was dissolved in PBS without divalent cations,
containing 0.1% HSA at 2 pg/ml and stored at -70°C. Percoll and Q-
sepharose were obtained from Pharmacia Fine Chemicals (Uppsala,
Sweden). Ro-31-8220 was obtained from Roche products Ltd (Welwyn
Garden City, Herts, UK) and was dissolved in DMSO at 30 mM and stored
at 4°C. RU38486 was kindly supplied by Roussel-UCLAF Center for
Research (Romainville, France) and was dissolved, by extensive
sonication, in PBS without divalent cations, containing 0.01% HSA at 10
mM and stored at -20°C . Sterile 3.8% sodium citrate was from Phoenix
■.» )' i.-i
Pharmaceuticals (Gloucestershire, UK). The hybridoma clone 3G8 (CD16)
was a generous gift from Dr. J. Unkeless, Mount Sinai Medical School,
N.Y.
All other chemicals were of molecular, reagent or cell culture grade and




Human neutrophils and eosinophils were purified according to the
methods previously described by Savill et al., (1989a) and Stern et al.,
(1992) respectively. Any donors with a history of atopy were
asymptomatic at the time of the study and none of the donors were on
glucocorticoid treatment. Cell isolation was performed under sterile
conditions using LPS-free reagents and plastic ware (Falcon, Oxford, UK).
Freshly drawn venous blood was collected and anticoagulated by addition
to 50 ml polypropylene tubes, each containing 4 ml of sterile 3.8% sodium
citrate solution (36 ml of blood was added to 4 ml citrate to make a total
volume of 40 ml). The citrate and blood were mixed gently by inverting
the tubes several times (in order to maintain the cells in a state of low
activation) and then centrifuged (370g, 20 min). The upper layer, platelet-
rich plasma (PRP), was aspirated taking care not to disturb the lower
leukocyte/erythrocyte pellet and centrifuged (2400g, 20 min) to obtain
platelet-poor plasma (PPP) or used to prepare autologous serum. The
erythrocyte/leukocyte layer was then sedimented by adding 5 ml of 6%
dextran (T500) [2.5 ml dextran per 10 ml cell pellet], and the volume made
up to 50 ml with sterile 0.9% saline. The efficiency of dextran
sedimentation is dependent upon temperature, thus 30 min prior to
sedimentation the dextran and saline were warmed up to 37°C in a water
bath. The cells were then allowed to sediment at room temperature for
30 min.
Autologous serum preparation. To a 15 ml glass tube, 10 ml of PRP was
added followed by 220 |il of CaCl2 at a final concentration of 22 mM
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(containing 10 mmoles Ca2+ ions and 20 mmoles CI" ions in each 10 ml
ampoule). This was left for 45 min, allowing recalcification, at 37°C to
form a clot.
Platelet poor plasma (PPP) preparation. The remaining aspirated PRP was
placed in a tube and centrifuged at 2400g for 20 min. The PPP was
decanted off and the pelleted platelets were discarded.
2.2.1.1 Neutrophil preparation
The leukocyte-rich layer was aspirated from the sedimented red cells,
centrifuged (235g, 6 min) and resuspended in 2.5 ml of 55% isotonic
Percoll (9:1 vol./vol. PercollrlO x PBS) in 1 x PBS without Ca2+/Mg2+. The
cell fraction was then overlayed in 15 ml Falcon tubes onto 2.5 ml of 70%
isotonic Percoll, previously overlayed on 2.5 ml of 81% isotonic Percoll.
The gradients were centrifuged (720g, 20 min) and polymorphonuclear
cells harvested from the 70%/81% Percoll interface. Mononuclear cells
sedimented at the 55%/70% interface. Purified neutrophils were
sequentially washed in PPP, HBSS without divalent cations and HBSS
with divalent cations (235g, 6 min) and finally resuspended in Iscove's
DMEM containing 5% (v/v) autologous serum. Density gradient
centrifugation does not separate neutrophils from eosinophils or
basophils, however harvested polymorphonuclear cells were generally
>98% pure, with basophils rarely seen and preparations containing >5%
eosinophils discarded.
2.2.1.2 Eosinophil preparation
Eosinophils (>98% pure on Diff-Quick stained cytopreparations) were
isolated using a two stage procedure based on a modification of a
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previously described method involving a combination of dextran
sedimentation and centrifugation through six isotonic discontinuous
plasma-Percoll gradients to produce cell fractions containing neutrophils
and eosinophils (Haslett et al., 1985). This was followed by
immunomagnetic separation of eosinophils from contaminating
neutrophils using the murine anti-neutrophil Ab 3G8 (anti-CD16)-coated
sheep anti-mouse IgG-Dynabeads, by a process known as 'negative
selection' (Bach et al., 1990). Cells were prepared from peripheral blood,
as described in section 2.2.1. The leukocyte-rich layer was aspirated from
the sedimented red cells, centrifuged (530g, 6 min) and finally re-
suspended in 2 ml autologous PPP. Percoll-plasma gradients (60-77%
Percoll) were prepared by diluting stock Percoll (9:1 vol./vol. Percoll:10 x
PBS) in 1 x PBS without divalent cations and overlaying 2 ml of each
gradient in a 15 ml Falcon tube. The leukocyte suspension was finally
overlayed and the gradients centrifuged (570g, 40 min) at 22°C, with the
brake and accelerator off. Eosinophilic and neutrophilic granulocytes
were harvested from the 74%/77% interface and washed sequentially in
PPP (370g, 5 min), followed by HBSS without divalent cations (260g, 5
min), before suspension in HBSS without divalent cations containing
0.1% gelatin. The cells were then counted and the percentage of
neutrophil contamination in each fraction was assessed either by flow
cytometry analysis involving antibody detection of cells expressing
surface CD16 or morphologically by examination of cytocentrifuge
preparations.
The CD16-Dynabeads were prepared under sterile conditions by
combining 3G8 cell supernatants with dynal M450 sheep anti-mouse
dynabeads (10 ml supt:700 |il dynabeads), in a 15 ml falcon tube and the
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mixture was then left to rotate (to ensure maximal coating of beads with
antibody) at 4°C overnight. Coated beads were washed three times in
HBSS without divalent cations containing 0.1% gelatin and the beads
retrieved by stationary contact (5 min) using a magnet (Dynal Magnetic
Particle Concentrator, MPC-1). Cells were mixed with washed 3G8-
Dynabeads at a bead:neutrophil ratio of 3:2 on a rotary mixer at 4°C for 20
min, and the beads with attached neutrophils were removed
magnetically by stationary contact (3 min) with a magnet. This procedure
was repeated once. Purified eosinophils (>99% pure with neutrophils as
the major contaminant) were washed twice in 8 ml of HBSS without
divalent cations containing 0.1% gelatin by centrifugation (235g, 5 min)
and finally resuspended in Iscove's DMEM containing 5% (v/v)
autologous serum.
Alternatively, eosinophils were isolated using a two step procedure
involving separation of dextran buoyant leukocytes into fractions and
centrifugation through three plasma-Percoll gradients (as described in
section 2.2.1.1), followed by extraction of the contaminating neutrophils
using the murine anti-neutrophil Ab 3G8 (anti-CD16)-coated sheep anti-
mouse IgG-Dynabeads (as described in section 2.2.1.2). Purified
eosinophils (>99% pure with neutrophils as the major contaminant)
were washed twice in 8 ml of HBSS without divalent cations containing
0.1% gelatin by centrifugation (235g, 5 min) and finally resuspended in
Iscove's DMEM containing 5% (v/v) autologous serum.
2.2.1.3 Mononuclear cell preparation
Mononuclear cells (MNC) were isolated from peripheral blood and
aspirated from the 55%/70% interface, which was prepared as described in
61
section 2.2.1.1. MNCs were sequentially washed in HBSS without
divalent cations, followed by HBSS with divalent cations (235g, 6 min)
and finally resuspended in Iscove's DMEM alone for production of
monocyte-derived macrophages (see section 2.2.2.3).
2.2.2 Cell culture
2.2.2.1 Neutrophils
Purified neutrophils were routinely suspended at a density of 2x106/ml in
Iscove's DMEM supplemented with 5% autologous serum and 50 U/ml
penicillin and 50 U/ml streptomycin. Neutrophils (3x105) were cultured
in flat-bottomed 96 well Falcon flexiwell plates, in a final volume of 150
pi, at 37°C in a humidified 5% CO2 atmosphere, for the time periods
indicated. Reagents to be examined in this assay system were diluted to
lOx the final concentration required in Iscove's DMEM.
2.2.2.2 Eosinophils
Purified eosinophils were routinely suspended at a density of 2x106/ml in
Iscove's DMEM supplemented with 5% autologous serum and 50 U/ml
penicillin and 50 U/ml streptomycin. Eosinophils (3xl05) were
maintained in flat-bottom flexible wells, in a final volume of 150 pi, at
37°C in a 5% CO2 atmosphere for the time periods indicated. Reagents to
be examined in this assay system were diluted to lOx the final
concentration required in Iscove's DMEM.
2.2.2.3 Macrophages
Mononuclear cells (MNC) were resuspended at 4xl06/ml in Iscove's
DMEM and at a volume of 1 ml per well, were allowed to adhere to 24
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well tissue culture plates for one hour at 37°C. The non-adherent cells
(lymphocytes) were removed by washing each well three times, in warm
HBSS with divalent cations. Monocytes were then cultured for six days
in Iscove's DMEM containing 5% autologous serum, with fresh medium
added on day 3, as previously described by Newman et al., (1982).
2.2.3 Assessment of apoptosis
Four different methods were employed to enable the assessment of
apoptosis.
2.2.3.1 Assessment of apoptosis bymorphological criteria
Cells were removed from culture at various times, as indicated in the
Results, for assessment of morphology according to the method of Savill
et al., (1989a). Cytocentrifuge preparations of cell samples in each
experiment were prepared in a Shandon Cytospin II (Shandon, UK), fixed
in methanol, and stained with Diff-Quick. Cells were examined under oil
immersion light microscopy (xl250 magnification), and apoptotic cells
were defined as those containing one or more darkly stained pyknotic
nuclei (see Chapter 3; figures 3.2 and 3.3). For each condition examined,
slides were prepared from duplicate or triplicate incubations and a total of
at least 500 neutrophils were counted over five fields of view, with the
observer blinded to the assay conditions.
2.2.3.1.1 Cell viability and recovery
Cell viability was determined as the ability to exclude trypan blue dye (10
pi of cells:40 pi of trypan blue). Cell recovery was determined by counting
the number of granulocytes occupying 25 squares of the haemocytometer.
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From this value the percentage of cells retrieved after the experiment,
compared with the number of cells added to each well initially was
estimated. Thus, at an initial cell concentration of 2x106/ml, cell recovery
was calculated using the following formula:
Recovery = No. of cells in 25 squares
200
2.2.3.2 Propidium iodide staining
Apoptosis in both neutrophils and eosinophils was also assessed by
analysis of the staining characteristics of fixed/permeabilised cells exposed
to the DNA-binding dye propidium iodide, using a modification of the
method previously described by Nicoletti et al., (1991). Neutrophils
(2x106/ml) were added to 96-well flexible assay plates, washed in cold PBS
(235g, 1 min) and fixed for 10 min in ice-cold 70% ethanol. Fixed cells
were then washed twice in 200 jil of cold PBS (235g, 6 min) and
resuspended finally in 150 (il of PBS containing 1.3 mg/ml RNase (Sigma
Chemical Co.) and 33 |ig/ml of propidium iodide (Sigma Chemical Co.).
The suspension was incubated in the dark at room temperature for 15
min before analysis on an EPICS Profile II (Coulter Electronics, Luton,
UK). The proportion of cells that display a "hypodiploid" peak has been
shown to correlate with apoptosis (Dransfield et al., 1994).
2.2.3.3 Assessment of neutrophil CD16 expression
Neutrophil apoptosis was assessed by antibody detection of cells with low
levels of surface CD16 (FcyRUI). Antibody labelling of intact cells was
performed as described previously by Dransfield et al., (1994). Neutrophil
cell surface CD16 was labelled with mAb 3G8 and compared with a
control mAb MOPC 21C (European Animal Cell Culture Collection,
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Porton Down, UK). The detecting Ab was FITC-conjugated F(ab')2 rabbit
anti-mouse Ig (Dako Corp., High Wycombe, UK). Neutrophils (2xl06/ml)
were added to 96-well flexible assay plates and washed in Tris-buffered
saline containing 0.2% BSA, 0.1% sodium azide (TBN). Cells were then
incubated in 50 |il of saturating concentrations (20 |ig/ml) of primary Ab
(3G8 supernatant) for 30 min on ice, washed twice in TBN (235g, 1 min)
and incubated in 30 |il of 1 /25 dilution of secondary Ab, FITC-conjugated
F(ab')2 rabbit Ab to mouse Igs for 30 min on ice. Cells were washed twuce
in TBN (235g, 1 min) and analysed by flow cytometry on an EPICS Profile
II (Coulter Electronics, Luton, UK).
2.2.4 Determination of cytosolic free calcium ion levels ([Ca2+]i)
! ,
2.2.4.1 Fluorometric measurements
[Ca2+]i was assayed using a modification of the method described by
Whyte et al., (1993b). Neutrophils were removed from culture, washed
three times in HBSS without phenol red and divalent cations, before
being resuspended at 107/ml in HBSS without divalent cations, for
incubation with fura-2/AM (final concentration 2 |iM) for 30 mins at
37°C. The cells were then washed twice to remove fura-2/AM and left in
HBSS without divalent cations for a further 10 mins for optimal
deesterification, before finally resuspending the neutrophils at 2x106/ml
• i
in HBSS without phenol red but with divalent cations. The changes in
fluorescence upon agonist addition were determined using a 'SPEX
Fluoromax' fluorimeter, with dual wavelength excitation (340 and 380
nm), emission at 510 nm, fitted with a thermostated cuvette
compartment and stirring attachment, to ensure complete mixing of
reagents.
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2.2.4.2 Calibration of the fluorescence
This was carried out prior to the experiment by measuring the maximal
fluorescence (Rmax) and the minimum fluorescence (Rmin)- Rmax is
therefore the ratio obtained in the presence of saturating [Ca2+]i (after
treatment with 50 pM digitonin). Rmin is the ratio obtained in the
absence of Ca2+ (addition of 25 mM EGTA).
[Ca2+]i was calculated from the relationship [Ca2+]i = Kd.(R-Rmin)/(Rmax"
R).(3: where [Ca2+]j is the cytosolic calcium concentration, R is the ratio of
fluorescence obtained at 340 and 380 nm in the cuvette before calibration,
Rmax is the fluorescence ratio under saturating [Ca2+]i, Rmin is the
fluorescence ratio in the absence of Ca2+, Kd is the dissociation constant
for fura-2/AM, taken as 224 nm at 37°C and (3 is the fluorescence ratio at
340 nm of cells in the absence and presence of Ca2+.
2.2.5 Macrophage recognition assay
2.2.5.1 Monocyte-derived macrophage culture
Mononuclear cells (MNC) were cultured as described in section 2.2.2.3.
2.2.5.2 Phagocytic assay for apoptotic granulocytes
Recognition of aged neutrophils and eosinophils by macrophages
matured from monocytes over 7 days, was assayed by a method
previously described by Newman et al., (1982). Aged granulocytes were
washed in Iscove's DMEM, suspended at 4x106/ml in Iscove's, and 1 ml
of suspension was added to each well of adherent macrophages cultured
in 24-well plates. After 30 min incubation at 37°C in a 5% CO2
atmosphere, the wells were vigorously washed with cold HBSS without
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divalent cations, fixed with 2.5% glutaraldehyde in PBS without divalent
cations, and then stained for peroxidase activity using hydrogen peroxide
and dimethoxybenzidine as substrate. The interaction was quantified by
counting, under light microscopy, the proportion of macrophages
containing peroxidase positive cells in five randomly selected fields, with
at least 500 macrophages being assayed per well.
2.2.5.3 Phagocytic assay for IgG-opsonised erythrocytes
Erythrocytes were obtained from the red blood cell pellet following
dextran sedimentation, described in section 2.2.1, and washed in PBS
without divalent cations (530g, 5 min). The cells were then re-suspended
in 50 ml PBS without divalent cations and stored at 4°C overnight, for
use on the day of the macrophage interaction assay.
Erythrocytes were centrifuged (530g, 5 min) and 200 pi of the pellet was re-
suspended in 10 ml PBS without, in a 15 ml Falcon tube, and incubated at
37°C with rabbit IgG to human erythrocyte membrane (1:4000) for 1 hr.
Opsonised erythrocytes were then washed twice in PBS without divalent
cations (528g, 5 min), re-suspended in Iscove's DMEM at a final
concentration of 4x106/ml and incubated with macrophages on 24 well
tissue culture plates, as described for apoptotic granulocytes in section
2.2.5.2. After 30 min, the wells were washed once in ice cold HBSS with
divalent cations and non-phagocytosed erythrocytes were lysed by
addition of one drop of dH20 per well for approximately 10 s, after which
time PBS without divalent Cations was added to the wells. The cells were
then fixed with glutaraldehyde and stained for peroxidase activity as
i
described in section 2.2.5.2.
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2.2.5.4 Discrimination between ingestion and binding of apoptotic
neutrophils
The macrophage interaction was carried out as described in section 2.2.5.2,
however instead of fixing, 150 pi of 0.25% trypsin, 0.02% EDTA was added
to each well and incubated at 37°C for 10 min. The cells were then mixed
with 20 pi of FCS and examined cytologically. The cytospins were
allowed to dry before addition of 50 pi of 2% formaldehyde for 10 min,
peroxidase activity staining for 30 min with hydrogen peroxide and
dimethoxybenzidine and finally counter-staining with Diff-Quick for 5 s,
for microscopic examination to confirm the presence of neutrophilic
granulocytes within the macrophages.
2.2.6 Protein kinase A (PKA) studies
2.2.6.1 Chromatographic separation of A-kinase isoenzymes
Unless otherwise stated all chromatographic procedures were performed
at 4 °C. For the separation, 200xl06 neutrophils were lysed for 15 min, by
addition of 5 ml of ice-cold buffer A (10 mM HEPES, pH 7.2, 1 mM EDTA,
2 mM DTT, 1% (v/v) Triton X-100) containing 100 pM PMSF, 10 pg/ml
soybean trypsin inhibitor, 20 pg/ml benzamidine and 100 pg/ml
bacitracin. Cells were then centrifuged (31,000 g, 30 min) at 4 °C. The
soluble enzyme (supernatant) was diluted in 5 ml of buffer B (buffer A
minus triton) and then applied to a column (Pharmacia; 1x6 cm) of Q-
sepharose, pre-equilibrated with buffer B. The column was then washed
with a further 40 ml of the same buffer to remove unbound protein and
A-kinase enzymes were eluted with a linear NaCl gradient running from
0 to 320 mM in a total volume of 60 ml. The flow rate was adjusted to 0.5
ml/min and 40x1 ml fractions were collected. Aliquots of each fraction
were then assayed for A-kinase activity as described overleaf.
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2.2.6.2 Measurement of PKA activity
Neutrophils (2xl06/ml) were cultured in the absence and presence of
various reagents illustrated in Chapter 6, results and at the appropriate
time period were washed and lysed (10xl06/ml), for 15 min, in buffer A.
The resulting lysed solution of cells was used as the source of soluble
enzyme.
Soluble A-kinase activity was measured using a modification of methods
previously described by Witt & Roskoski, (1975) and Giembycz &
Diamond, (1990). Assays were performed in triplicate at 30°C and
initiated by the addition of 25 pi of the soluble extract to 75 pi of a reaction
medium (pH 7.2) containing (final concentration): 20 mM HEPES, 10 mM
magnesium acetate, 2 mg/ml BSA, 100 pM IBMX, 100 pM ATP
supplemented with ~ 100 cpm/pmol [y-32P]ATP and 100 pM kemptide in
the absence and presence of 10 pM cAMP. In the chromatographic
separation of A-kinase isoenzymes, phosphotransferase activity was
defined with IP20 (I pM), a synthetic icosapeptide inhibitor of PKA
(Cheng et al., 1986). Reactions were terminated after 30 min by pipetting
50 pi aliquots of the mixture onto 2x2 cm phosphocellulose paper squares
(Whatman P81), which were left for 30 s before being immersed in 150
mM phosphoric acid. The paper squares were extensively washed in 4
litres of fresh phosphoric acid, immersed in industrial methylated spirits
and allowed to dry. Bound radioactivity (representing phosphokemptide)
was subsequently quantified by liquid scintillation counting. One unit of
phosphotransferase activity was defined as the amount of PKA that
catalysed the incorporation of 1 pmol of phosphate from ATP into
kemptide/min/106 cells at 30°C.
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2.2.7 Statistical analysis
All data are presented as mean ± SEM of the indicated number of
experiments. Data were analysed by the students t-test and where
appropriate by one way analysis of variance followed by Newman-Keuls
procedure. P values less than 0.05 were considered significant.
Data are presented as the percentage of apoptotic cells from raw data
counts, involving the proportion of cells exhibiting apoptotic




Effect of glucocorticoids on the rate of eosinophil and neutrophil
apoptosis
3.1 Introduction
Eosinophilic and neutrophilic granulocytes are key effector cells
mediating host defence against inciting bacteria and parasites by a variety
of mechanisms such as phagocytosis and secretion of cytotoxic and
degradative enzymes. Inflammatory infiltrates of these granulocytes has
been associated with the pathogenesis of many diseases, with allergic and
asthmatic reations being characterised by a predominantly eosinophilic
infiltrate (Wardlaw, 1996, Azzawi et al., 1992, Sur et al., 1993) and diseases
such as rheumatoid arthritis having a prominent neutrophil
involvement (Brown, 1988). Efficient resolution of inflammation
therefore relies upon the existence of a fine balance between proficient
tissue protective mechanisms and potentially detrimental effects of
inflammation to the host.
Clinically, glucocorticoids have been used as potent anti-inflammatory
agents, for the treatment of hypereosinophilia in a range of diseases.
However, the mechanisms underlying the anti-inflammatory advantage
conferred by glucocorticoids in vivo are poorly understood (Barnes, 1995b,
Goulding & Guyre, 1993). Glucocorticoids readily penetrate the cell
membrane and bind directly to cytosolic glucocorticoid receptors, which,
when activated, exhibit DNA-binding ability and thereby interact with a
wide range of nuclear targets, regulating both the positive and negative
expression of specific proteins (Maroder et al., 1993). The removal of
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eosinophils and neutrophils from an inflamed site is a pre-requisite for
the resolution of inflammation to occur. Apoptosis provides an efficient
mechanism for the clearance of unwanted cells, representing a tissue
injury-limiting mechanism, promoting the resolution of inflammation.
Granulocytes undergoing apoptosis are ingested, while still intact, by
macrophages, (Stern et al., 1992, Savill et al., 1989a), which are involved
in the specific recognition of apoptotic cells without inciting
inflammatory sequelae (Meagher et al., 1992, Stern et al., 1996). Clearance
of apoptotic granulocytes by macrophages may therefore be a central
component of the resolution or limitation of inflammation, removing
these cells before the onset of necrosis and thereby preventing
disgorgement of their potentially histotoxic contents (Haslett et al., 1989).
Despite their close haemopoietic origins, tissue longevity of eosinophils
and neutrophils, like granulocytopoeisis, is controlled by different
external factors. It has now been ascertained that these observations may
be explained by inhibition of the process of apoptosis, which precedes
necrosis in cultured eosinophils and neutrophils (Brach et al., 1992, Lee et
al., 1993). Thus, granulocyte apoptosis is an immutable process, being
delayed in the presence of inflammatory mediators such as GM-CSF,
complement factor C5a and LPS (Lee et al., 1993, Begley et al., 1986, Lopez
et al., 1986, Brach et al., 1992, Takanaski et al., 1994, Cox et al., 1992).
Eosinophils also respond specifically to IL-3 and IL-5 (which have no
effect on neutrophils), and inclusion of IL-5 and IL-3 in eosinophil culture
medium prolongs eosinophil lifespan by inhibiting apoptosis (Stern et al.,
1992, Her et al., 1991, Yamaguchi et al., 1991, Rothenberg et al., 1988, Tai et
al., 1991, Matsumoto et al., 1995). Thus, certain cytokine environments
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favour the survival of eosinophils while neutrophil survival is
unaffected, by virtue of cell-selective activation.
Many of the mechanisms that initiate and amplify inflammation are
susceptible to inhibition by corticosteroids. Thus macrophage production
of cytokines such as IL-1, is suppressed by corticosteroids (Kern et al.,
1988), as are the eosinophil life-prolonging effects of GM-CSF (Her et al.,
1991, Lamas et al., 1991) and IL-5 (Hallsworth et al., 1992). Dexamethasone
is known to induce apoptosis in a variety of different cell types, yet direct
effects of glucocorticoids upon the apoptotic programme of myeloid cells
have remained obscure. The purpose of these studies was to investigate
the direct effects of dexamethasone on the rate of eosinophil and
neutrophil apoptosis in the absence of exogenous cytokines.
73
3.2 Results
3.2.1 Effect of dexamethasone on the rate of eosinophil and neutrophil
apoptosis in vitro
Eosinophils (2xl06/ml) cultured in serum-supplemented Iscove's DMEM
showed increased apoptosis in the presence of 1 pM dexamethasone
(Figure 3.1A). Assessment of cell viability and recovery demonstrated
that dexamethasone did not significantly alter either of these parameters
(data not shown), excluding the possibility that the increased rates of
apoptosis observed reflected either dexamethasone-induced adhesion of
non-apoptotic cells, or a dexamethasone-induced switch between necrosis
and apoptosis seen in a number of distinct cell lines, including HL-60
cells, treated with high concentrations of a variety of death-inducing
agents (Lennon et al., 1991). The time point of 40 h was chosen to take
advantage of the temporal separation of apoptosis from necrosis as
described previously (Stern et al., 1992), allowing analysis of apoptotic
cultures before the onset of necrosis some hours later. These results
demonstrate a direct positive effect of dexamethasone on eosinophil
apoptosis.
In contrast to the effects observed on eosinophils, neutrophils (2xl06/ml)
cultured in serum-supplemented Iscove's DMEM showed decreased
apoptosis in the presence of 1 pM dexamethasone (Figure 3.1B), without
adversely affecting cell viability or recovery. The time period of 20 h was
chosen because it preceded the onset of significant necrosis (Savill et al.,


























Figure 3.1 Effect of dexamethasone on the rate of eosinophil (A) and
neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or in the presence of dexamethasone (1 pM).
Eosinophils were harvested following 40 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 12
separate experiments, each performed in duplicate (* p<0.05 compared
with control values). B, Neutrophils (2xl06/ml) were cultured in serum-
supplemented Iscove's DMEM either alone (control) or in the presence of
dexamethasone (1 pM). Neutrophils were harvested following 20 h in
culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 55 separate experiments, each performed in
triplicate (* p<0.05 compared with control values).
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Figure 3.2 Effect of dexamethasone on eosinophil morphology.
Photomicrographs (xl250 magnification) of cytocentrifuge preparations of
cultured human eosinophils isolated from the peripheral blood of a single
donor and harvested following 40 h in culture. Cells were cultured alone
(A) or in the presence of 1 pM dexamethasone (B).
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Figure 3.3 Effect of dexamethasone on neutrophil morphology.
Photomicrographs (xl250 magnification) of cytocentrifuge preparations of
cultured human neutrophils isolated from the peripheral blood of a single
donor and harvested following 20 h in culture. Cells were cultured alone (A)
or in the presence of 1 gM dexamethasone (B).
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3.2.2 Assessment of dexamethasone-mediated eosinophil and neutrophil
apoptosis
Eosinophils cultured for 40 h in the presence of dexamethasone (1 (iM)
showed light microscopic features characteristic of apoptosis (Wyllie et al.,
1980), as shown in figure 3.2. Morphological changes included nuclear
pyknosis or chromatin condensation, together with decreased cell size
and cytoplasmic vacuolation. Numerous anucleate eosinophils or
"ghosts" habitually appeared on the cytocentrifuge preparations,
indicative of nuclear extrusion, which is another morphological feature
associated with apoptosis. On light microscopy of 20 h aged neutrophils, a
reduction in the number of apoptotic cells was seen in dexamethasone-
treated cultures, by comparison with untreated controls (figure 3.3).
Furthermore, parallel analysis of aged cell cultures by morphologic
examination and staining with the DNA-binding dye propidium iodide
showed the predicted reduction in the proportion of cells generating the
hypodiploid peak, which corresponds with the apoptotic subpopulation
(Nicoletti et al., 1991) in dexamethasone-treated cultures, by comparison
with untreated controls (figure 3.4, A and B). Similarly, dexamethasone-
treated eosinophil cultures showed increased proportions of apoptotic
cells by analysis of propidium iodide staining characteristics (figure 3.4, C
and D), in agreement with morphologic data. Figure 3.4 illustrates that
the percentage of cells within the hypodiploid or apoptotic gate (gate B)
was reduced by dexamethasone treatment of neutrophils from 69.1% (A;
control) to 57.0% (B) and increased in eosinophils from 18.5% (C; control)
to 29.8%(D). The percentages of apoptosis in parallel cultures were
assessed morphologically as: A, 81.2%; B, 44.1%; C, 16.9%; and D, 27.9%.
These data confirm the close correlation that exists between these
assessment methods.
78






L„„,i n mi i rrrnr i i 11 hi
1000
LOG FLUORESENCE LOG FLUORESENCE
Figure 3.4 Effect of dexamethasone on neutrophils and eosinophils as
assessed by propidium iodide staining.
Neutrophils (A and B) and eosinophils (C and D) that had been cultured
under control conditions (A and C) or in the presence of 1 pM
dexamethasone (B and D) for 20 h were stained with propidium iodide
and analysed by flow cytometry. The results presented are from a
representative experiment.
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A reduction in cell surface expression of CD16 has been shown to be
associated with apoptosis in neutrophils (Dransfield et al., 1994). In
agreement with this, figure 3.5 shows that dexamethasone induced a
reduction in the number of cells expressing low levels of CD16. The CD16
"low" peak in the control 20 h cells (figure 3.5A) represents apoptotic cells
that have shed their surface CD16; the percentage of cells with "low" CD16
was markedly reduced when compared to cells that had been treated with
dexamethasone (figure 3.5B), whereas the corresponding CD16 "high"
peak was increased. Significantly, the percentage of apoptosis was reduced
from 58.9% (A; control) to 13.7% (B; dexamethasone).
i
3.2.3 Time-course for the effect of dexamethasone on eosinophil and
neutrophil apoptosis
Figure 3.6 examines the time-course of the effect of dexamethasone on the
rate of eosinophil (A) and neutrophil (B) apoptosis. With longer
• :i j
incubation periods, there is a progressive increase in the constitutive rate
of eosinophil apoptosis in vitro (Stern et al., 1992) and this time-
dependent observation is further accelerated in the presence of
dexamethasone (1 pM). Similarly, the constitutive rate of neutrophil
apoptosis was shown to increase over time (Savill et al., 1989a), however
in contrast to the eosinophil, in the presence of dexamethasone (1 pM)
the rate of neutrophil apoptosis was delayed. Figure 3.6 also illustrates





Figure 3.5 Effect of dexamethasone on neutrophil apoptosis as assessed by
the levels of expression of surface CD16.
The results are representative flow cytometric traces of control cells (A)



































Figure 3.6 Time-course for the effect of dexamethasone on eosinophil (A)
and neutrophil (B) apoptosis.
A, Eosinophils (2x106/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or in the presence of dexamethasone (1 pM).
At the time periods indicated, the cells were harvested and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 10
independent experiments, each performed in duplicate (* p<0.05
compared with control values). B, Neutrophils (2xl06/ml) were cultured
in serum-supplemented Iscove's DMEM either alone (control) or in the
presence of dexamethasone (1 pM). At the time periods indicated, the
cells were harvested and assessed for morphological features of apoptosis.
Data represent mean ± SEM of 19 separate experiments, each performed
in triplicate (* p<0.05 compared with control values).
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3.2.4 Concentration-dependency of the effect of dexamethasone on
eosinophil and neutrophil apoptosis
The differential effect of dexamethasone on eosinophil and neutrophil
apoptosis was concentration-dependent. Figure 3.7A illustrates an
increase in the proportion of eosinophils exhibiting classical
morphological features of apoptosis with increasing concentrations of
dexamethasone at 0.01 to 1 pM. Figure 3.7B shows decreasing levels of
neutrophil apoptosis in the presence of increasing concentrations of
dexamethasone (0.01-1 pM).
3.2.5 Requirement for protein synthesis in glucocorticoid-mediated
inhibition of neutrophil apoptosis
Treatment of neutrophils with cycloheximide, a protein synthesis
inhibitor, rapidly induces apoptosis (Flaslett et al., 1990), as shown in
figure 3.8. To explore the possible involvement of protein synthesis in
glucocorticoid-mediated inhibition of neutrophil apoptosis,
cycloheximide was co-incubated with dexamethasone (figure 3.8A) and
the alternative glucocorticoid, budesonide (figure 3.8B). These data show
that cycloheximide (50 pM) abrogated glucocorticoid-mediated inhibition
of neutrophil apoptosis. However, since the concentration of
cycloheximide (50 pM) employed promoted the rate of neutrophil
apoptosis when used alone, it is difficult to dissect the effect of protein
synthesis inhibition from the glucocorticoid effect. To compare the
efficacy of the two synthetic glucocorticoids used, the IC50 values of
dexamethasone and budesonide were obtained from standard steroid
binding assays and appropriate concentrations for use calculated based on


































Figure 3.7 Concentration-response for the effect of dexamethasone on
eosinophil (A) and neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or in the presence of dexamethasone (0.01-1
pM). Eosinophils were harvested following 40 h in culture and assessed
for morphological features of apoptosis. Data represent mean ± SEM of 3
separate experiments, each performed in duplicate (* p<0.05 compared
with control values). B, Neutrophils (2xl06/ml) were cultured in serum-
supplemented Iscove's DMEM either alone (control) or in the presence of
dexamethasone (0.01-1 pM). Neutrophils were harvested following 20 h
in culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3 separate experiments, each performed in


































0 Cycloheximide (50jJ.M)+Budesonide (60nM)
Figure 3.8 Effect of cycloheximide on basal, dexamethasone- and
budesonide-mediated inhibition of neutrophil apoptosis.
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with cycloheximide (50 pM), in the
presence and absence of either (A) dexamethasone (1 pM) or (B)
budesonide (60 nM). Neutrophils were harvested following 20 h in
culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3 separate experiments, each performed in
duplicate (* p<0.05 compared with control values).
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3.2.6 Effect of GM-CSF neutralising antibody on dexamethasone-mediated
eosinophil and neutrophil apoptosis
Both eosinophils and neutrophils can produce GM-CSF (Kita et al., 1991a),
a potent modulator of myeloid cell apoptosis. To investigate whether
dexamethasone regulated apoptosis by modulating endogenous
production of GM-CSF, a specific anti-GM-CSF mAb was used at a
concentration sufficient to completely block the effect of 5 U/ml of GM-
CSF. As illustrated in figure 3.9, GM-CSF neutralising Ab (25 fig/ml)
abrogated GM-CSF (5 U/ml)-mediated inhibition of neutrophil apoptosis.
This concentration of anti-GM-CSF mAb failed to block either the
apoptosis-promoting effect of dexamethasone on eosinophils (figure
3.10A) or its apoptosis-inhibiting effect upon neutrophils (figure 3.10B).











E3 Anti-GM-CSF (25|ig/ml)+GM-CSF (5U/ml)
Figure 3.9 Effect of GM-CSF neutralising antibody on basal and GM-CSF-
mediated inhibition of neutrophil apoptosis.
Neutrophils (2xl06/ml) were cultured for 20 h either in serum-
supplemented Iscove's DMEM alone (control), GM-CSF (5 U/ml), mouse
anti-human GM-CSF neutralising mAb (25 pg/ml) or an identical
concentration of GM-CSF pre-incubated for 30 min at 37°C with the
neutralising mAb (25 pg/ml). Neutrophils were harvested and assessed
for morphological features of apoptosis. Data represent mean ± SEM of 3



































Figure 3.10 Effect of GM-CSF neutralising antibody on basal and
dexamethasone-mediated eosinophil (A) and neutrophil (B) apoptosis.
A, Eosinophils (2x106/ml) were incubated either in serum-supplemented
Iscove's DMEM alone (control), dexamethasone (1 |iM), mouse anti-
human GM-CSF neutralising mAb (25 |ig/ml) or an identical
concentration of dexamethasone pre-incubated for 30 min at 37°C with
the neutralising mAb (25 pg/ml). Eosinophils were harvested following
20 h in culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3-6 separate experiments, each performed in
duplicate (* p<0.05 compared with control values). B, Neutrophils
(2x106/ml) were incubated either in serum-supplemented Iscove's DMEM
alone (control), dexamethasone (1 pM), mouse anti-human GM-CSF
neutralising mAb (25 pg/ml) or an identical concentration of
dexamethasone pre-incubated for 30 min at 37°C with the neutralising
mAb (25 pg/ml). Neutrophils were harvested following 20 h in culture
and assessed for morphological features of apoptosis. Data represent
mean ± SEM of 3-6 separate experiments, each performed in triplicate (*
p<0.05 compared with control values).
88
3.3 Discussion <3 k. ^^ ^
We have demonstrated thai 3^') $/* 7 ametrically opposed
effects upon the rate of « vitro; promoting
eosinophil apoptosis and inhibiting neutrophil apoptosis.
Administration of glucocorticoids has been reported to induce
fluctuations in the numbers of peripheral leukocytes in vivo,
observations which have long indicated divergent responses among
granulocyte types (Schleimer, 1990). The rapid and dramatic peripheral
blood eosinopenia following glucocorticoid treatment (Saunders &
Adams, 1950) is not mirrored in neutrophil counts, which, in fact, show
an increase (Athens et al., 1961, Dale et al., 1975). However, the
mechanisms underlying these phenomena have not been fully
elucidated. We propose that the direct influence of glucocorticoids on
apoptosis that we have described may be a major factor in the production
of this effect.
Dexamethasone-induced alterations in the rate of granulocyte apoptosis
have been shown to be mediated by the glucocorticoid receptor (GR)
(Meagher et al., 1996, Cox, 1995). These experiments involved the GR
antagonist, RU38486, which is a synthetic glucocorticoid that binds to the
GR without producing agonist activity (Bourgeois et al., 1984). The
presence of RU38486 alone was shown to have no effect on the rate of
apoptosis in either eosinophils (Meagher et al., 1996) or neutrophils
(Meagher et al., 1996, Cox, 1995), arguing against the possibility of toxicity
by RU38486 and suggesting that endogenous glucocorticoids (present in
serum) are not involved in determining the constitutive rate of apoptosis
of these cells in culture. Co-culture of eosinophils or neutrophils with 1
(iM dexamethasone and 10 pM RU38486 restored the rate of apoptosis in
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each culture to control levels (Meagher et al., 1996). We have also shown
that other glucocorticoid effects are also mediated by the GR, and these
data are discussed in Chapters 6 and 7. Similarly, Cox and colleagues have
demonstrated a concentration-dependent attenuation of dexamethasone-
mediated inhibition of neutrophil apoptosis in the presence of RU38486,
with concentrations of RU38486 as low as 0.1 pM being shown to
significantly abrogate the dexamethasone effect (Cox, 1995). Moreover,
the inhibitory effect of RU38486 was shown to be specific and did not alter
either GM-CSF-induced inhibition of apoptosis or cycloheximide-induced
promotion of apoptosis (Meagher et al., 1996). Furthermore, in
agreement, Cox and colleagues have also demonstrated that RU38486 at a
concentration (1 pM) sufficient to attenuate dexamethasone-mediated
inhibition of neutrophil apoptosis, did not alter LPS-stimulated survival
(Cox, 1995). Collectively, these data illustrate that RU38486 effectively and
specifically inhibits dexamethasone-induced alterations in the rate of
granulocyte apoptosis, which are directly mediated by the GR.
We have also shown that the alternative synthetic glucocorticoid
budesonide, which is available for clinical use in an inhaled form in
Canada and Europe, mirrors the effect of dexamethasone on neutrophil
apoptosis (figure 3.8B). Furthermore, endogenous glucocorticoids, such as
Cortisol, have been shown to promote eosinophil apoptosis and inhibit
neutrophil apoptosis, in contrast to progesterone, which has little
glucocorticoid activity and does not modulate granulocyte apoptosis
(Meagher et al., 1996). Similarly, several other laboratories have also
demonstrated that the ability of dexamethasone to inhibit neutrophil
apoptosis is confined to glucocorticoids, with the relative survival-
promoting effects been shown to correlate with their relative clinical
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potencies (Cox, 1995, Liles et al., 1995). Collectively, these observations
illustrate that dexamethasone-mediated up-regulation of apoptosis in
eosinophils and down-regulation of apoptosis in neutrophils is mirrored
by the physiologic glucocorticoid, Cortisol, and indicate that this
modulation of granulocyte apoptosis is limited to glucocorticoids and is
not simply a nonspecific response to high concentrations of any steroid.
Pharmacological inhibitors of protein synthesis have been widely used to
examine how apoptosis is regulated. It has been reported that many
glucocorticoid effects are protein synthesis dependent. For example,
apoptosis that is induced in thymocytes by dexamethasone is attenuated
by co-treatment with cycloheximide, a translation inhibitor, indicating
that this dexamethasone-mediated promotion of apoptosis is dependent
on the synthesis of new proteins (Wyllie et al., 1984). In contrast,
treatment of both neutrophils (figure 3.8, Haslett et al., 1990) and
eosinophils (Meagher and Haslett, unpublished observations) with
cycloheximide rapidly induces apoptosis, indicating that granulocyte
apoptosis does not depend on new protein synthesis. These observations
suggest that eosinophil and neutrophil apoptosis may be normally held
in check by the constant production of an inhibitor protein, the
production of which may be differentially affected by treatment with
dexamethasone in the two cell types. Studies investigating the
dependence on protein synthesis of dexamethasone in differentially
regulating granulocyte apoptosis have been hampered by the fact that the
effects of glucocorticoids on eosinophil and neutrophil apoptosis are not
readily apparent within 8 h of treatment, by which time, 50 |iM
cycloheximide has induced apoptosis in typically 80% of both eosinophils
and neutrophils. It has therefore been difficult to dissect the effect of
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protein synthesis inhibition from the glucocorticoid effect at this time.
However, Cox and colleagues have now reported that much lower
concentrations of cycloheximide (1 pg/ml =. 28 nM) are sufficient to
interfere with, but not abolish, protein synthesis in neutrophils (Cox et
al., 1994). Thus, several more recent reports have now investigated
whether dexamethasone-mediated inhibition of neutrophil apoptosis is
protein synthesis dependent. Kato and colleagues have demonstrated
that cycloheximide, at a concentration that did not affect neutrophil
apoptosis when used alone (0.1 |ig/ml = 2.8 nM), completely abrogated
dexamethasone-mediated inhibition of neutrophil apoptosis (Kato et al.,
1995). Similarly, identical data has also been presented using a 1 Jig/ml
concentration of cycloheximide (Cox & Austin, 1997). These findings lend
further support to the hypothesis that glucocorticoid hormones enhance
the production of apoptosis inhibitory proteins in neutrophils.
Glucocorticoids have been reported to modulate cytokine production
from various cell types, including monocytes (Lew et al., 1988, Waage &
Bakke, 1988) and murine T lymphocytes (Culpepper & Lee, 1985; 1987).
There have been a number of examples of a stimulation of inflammatory
cell survival inducing production of a survival factor that is released into
the supernatant, where it acts on adjacent cells in an autocrine or
paracrine fashion. For example, Lamas et al., (1989) have demonstrated
that dexamethasone treatment of endothelial cell cultures markedly
inhibited eosinophil survival induced by supernatant generated by those
cells. Moreover, Cox and colleagues have illustrated that conditioned
medium generated from human bronchial epithelial cells (HBEC) can
support eosinophil survival via the elaboration of GM-CSF. In addition,
it was shown that the glucocorticoid, budesonide, inhibited both
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unstimulated and IL-l-stimulated GM-CSF production by HBEC and had
a direct effect on eosinophils, since it prevented the ability of these cells to
respond to GM-CSF (Cox et al., 1991). Thus it has been suggested that
steroids may modulate this process by inhibiting cytokine production
from HBEC and by a direct effect on eosinophils preventing their
response to cytokines. Furthermore, several groups have reported that
glucocorticoids inhibit the effects of IL-5 and GM-CSF in prolonging
eosinophil survival in vitro (Her et al., 1991, Lamas et al., 1991, Wallen et
ah, 1991, Hallsworth et ah, 1992). Interestingly, glucocorticoids potentiate
GM-CSF-mediated inhibition of neutrophil apoptosis in vitro (Meagher
et al., 1996, Cox, 1995). However, although these findings are of interest
since glucocorticoids are used therapeutically at times when stimuli such
as GM-CSF might also be present, it is difficult to draw any mechanistic
conclusions from such experiments.
Upon appropriate activation, both eosinophils and neutrophils are
capable of producing and releasing GM-CSF (Kita et al., 1991a) which is a
potent inhibitor of apoptosis in both cell types (Stern et al., 1992, Lee et al.,
1993). We were interested to investigate whether glucocorticoids exerted
diametrically opposed effects upon myeloid cell apoptosis through
differential regulation of the elaboration of GM-CSF. Eosinophils and
neutrophils were routinely isolated according to methods designed to
minimise cell activation (Stern et al., 1992, Savill et al., 1989a). We have
reported that GM-CSF was undetectable in aging cultures and remained
undetectable following glucocorticoid treatment (Meagher et al., 1996).
Further studies demonstrated that an excess of blocking anti-GM-CSF Ab
failed to affect the modulation of apoptosis caused by glucocorticoids
(figure 3.10). In agreement with our findings, Kato and colleagues have
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reported that addition of supernatants obtained from neutrophils
pretreated with dexamethasone did not inhibit neutrophil apoptosis
(Kato et al., 1995). Contradicting these findings, Cox & Austin (1997) have
recently reported that dexamethasone-conditioned medium induced
neutrophil survival comparable to that found with dexamethasone.
However, this study also demonstrated that addition of RU38486
completely inhibited the effects of dexamethasone-conditioned medium
so that survival was reduced to levels similar to those found in control
conditions, suggesting that dexamethasone does not induce the release of
stable factors that modulate neutrophil apoptosis in an autocrine or
1 i • , |
paracrine fashion. We, therefore, propose that the differential regulation
of granulocyte apoptosis by glucocorticoids is not mediated by GM-CSF,
and the exact mechanism of action remains to be elucidated.
5
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The unique nature appertaining to the effect of glucocorticoids on
neutrophil apoptosis has been illustrated by Cox (1995), who has
\ \ i: v". . i
demonstrated that the effect on cell survival is distinct from priming or
activation of the cell. This report shows that cells induced to survive by
dexamethasone retain the capacity to generate superoxide without
significant enhancement of this response either in the basal state or
following FMLP stimulation. Moreover, untreated cells produced
detectable levels of IL-8, which is an index of new protein synthesis by
activated cells, whereas dexamethasone treatment significantly inhibited
this cytokine production. These results are particularly intriguing since
all other stimuli including GM-CSF, LPS and C5a, known to inhibit
neutrophil apoptosis also cause cell activation to some degree (Brach et
al., 1992, Colotta et al., 1992, Balazovich et al., 1991). The ability of
. j.
dexamethasone to prolong neutrophil survival without induction of cell
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activation would enhance the neutrophils host defence capabilities but
limit their potential to exacerbate the inflammatory response through
production of chemotactic and activating signals (Lloyd & Oppenheim,
1992).
Demonstration of the marked apoptosis-promoting effects of
dexamethasone on eosinophil apoptosis in vitro may underlie the
known beneficial effects of glucocorticoids on established 'eosinophilic'
inflammatory diseases such as allergy and asthma. In agreement with
our findings, Woolley and colleagues have recently provided the first
report of eosinophil apoptosis in vivo, in human asthma and have
highlighted the promotion of apoptosis after corticosteroid treatment,
concurrent with improved lung function (Woolley et al., 1996). These
findings provide direct human in vivo support for the dexamethasone-
mediated up-regulation of eosinophil apoptosis observed in vitro and
indicate that apoptosis-induction is clinically relevant to asthma.
However, experience in the clinical situation has not demonstrated the
same beneficial effects of glucocorticoids in neutrophil-mediated
inflammatory diseases, such as chronic obstructive airways disease
(Stoller et al., 1987). The opposite effect of glucocorticoids on neutrophil
apoptosis in vitro may therefore explain the lower efficacy of these drugs
in 'neutrophilic' inflammatory diseases. The differential effect of
glucocorticoids on granulocyte apoptosis provides the ability to selectively
induce apoptosis in discrete populations of inflammatory cells and may




The role of Ca2+ and PKC in basal and glucocorticoid-mediated
granulocyte apoptosis
4.1 Introduction
There has been intense interest in the underlying intracellular regulatory
signalling mechanisms mediating apoptosis. Several familiar signal
transduction pathways have now been implicated in the positive and
negative control of apoptosis in cells of diverse tissue origin. In
particular, considerable attention has focussed on the role of Ca2+ and
PKC since it is well known that various physiological responses can result
from synergistic interactions between this network of intracellular
signalling systems.
Several lines of evidence indicate that alterations in the cytosolic Ca2+
concentration are involved in the regulation of apoptosis. Early work by
Kaiser & Edelman (1977; 1978) demonstrated that glucocorticoid-
stimulated apoptosis is associated with Ca2+ influx and that the cytolytic
effects of glucocorticoids on lymphoid cells can be mimicked by treating
the cells with Ca2+ ionophores. It has since been well documented that
glucocorticoids induce cytosolic Ca2+ elevation in thymocytes and that the
Ca2+ increase is responsible for the initiation of apoptosis (Cohen & Duke,
1984, McConkey et al., 1989a). Treatment with thapsigargin and Ca2+
ionophores has been shown to induce apoptosis in thymocytes (Cohen &
Duke, 1984, McConkey et al., 1989b, Jiang et al., 1994) and in other cell
types including human hepatoma cells (Kaneko & Tsukamoto, 1994),
cerebellar granule neurones (Levick et al., 1995), rat prostatic glandular
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cells (Martikainen & Isaacs, 1990) and androgen-independent prostatic
cancer cells (Martikainen et al., 1991, Furuya et al., 1994). Moreover,
certain chemical toxins may also promote apoptosis by disrupting
intracellular Ca2+ homeostasis, leading to nonphysiological Ca2+ increases
that promote endonuclease activation and apoptotic cell death
(McConkey et al., 1988, Aw et al., 1990). Furthermore, Ca2+ increases have
been observed in many other examples of apoptosis (Perotti et al., 1990,
McConkey et al., 1991, Zheng et al., 1991, Bellomo et al., 1992). Direct
evidence that Ca2+ increases can mediate apoptosis has been obtained
from experiments with intracellular Ca2+ buffering agents and
extracellular Ca2+ chelators, which have been shown to inhibit both DNA
fragmentation and death in apoptotic cells (McConkey et al., 1989a,
McConkey et al., 1989c, Aw et al., 1990, McConkey et al., 1990a, Perotti et
al., 1990, McConkey et al., 1991, Bellomo et al., 1992, Story et al., 1992,
Robertson et al., 1993). Furthermore, calmodulin antagonists have been
shown to interfere with apoptosis in some of these systems (McConkey et
al., 1989a, Dowd et al., 1991) and increases in calmodulin expression are
linked to apoptosis in glucocorticoid-treated WEH17.2 lymphocytes
(Dowd et al., 1991) and in the prostate following withdrawal of androgen
(Furuya & Isaacs, 1993). Independent evidence for the involvement of
Ca2+ influx in the triggering of apoptosis has come from studies with
specific Ca2+ channel blockers, which abrogate apoptosis in the regressing
prostate following testosterone withdrawal (Martikainen & Isaacs, 1990)
and in pancreatic [3 cells treated with serum from patients with type I
diabetes (Juntti-Berrgren et al., 1993). Finally, recent work on the
biochemical mechanisms of apoptosis suppression by the bcl-2
oncoprotein have pointed to a central role for Ca2+ in regulating
apoptosis, in particular in the regulation of intracellular Ca2 +
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compartmentalisation (Baffy et al., 1993, Lam et al., 1994, Marin et al.,
1996). Thus, elevation of [Ca2+]i appears to represent a relatively common
trigger for apoptosis in cells of diverse tissue origins.
In other cellular systems, however, increases in cytosolic Ca2+ inhibit
apoptotic cell death. For example, Ca2+ ionophores block apoptosis in
aged neutrophils (Whyte et al., 1993b). In addition, treatment of IL-3-
dependent BAF-3 cells (a murine bone marrow progenitor cell line) with
Ca2+ ionophores prevents endogenous endonuclease activation and cell
death following withdrawal of IL-3 (Rodriguez-Tarduchy et al., 1990).
Similarly, PKC has also been implicated in both the positive and negative
regulation of apoptosis. PKC activation has been shown to stimulate
apoptosis in thymocytes (Kizaki et al., 1989a), U937 cells (De Vente et al.,
1995a) and in MCF-7 breast cancer cells (De Vente et al., 1995b).
Furthermore, it has been reported that glucocorticoid-induced apoptosis
in thymocytes appears to be dependent on PKC, since it is inhibited by
PKC inhibitors (Ojeda et al., 1990).
Other work suggests that PKC activation can also inhibit apoptosis.
Phorbol esters and other activators of PKC have been shown to inhibit
apoptosis in a variety of cell types including thymocytes (McConkey et al.,
1989d, Tomei et al., 1988, Kizaki et al., 1989b), a human mammary
adenocarcinoma cell line (BT-20) (Bellomo et al., 1992), normal (Illera et
al., 1993) and leukemic (McConkey et al., 1991, Forbes et al., 1992) B cells,
human synovial cells (Perotti et al., 1990), IL-3 dependent haematopoietic
cells (Rajotte et al., 1992) and kidney epithelial cells (Koseki et al., 1992).
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In light of the current literature, we investigated the direct effects of
agents that increase intracellular Ca2+ levels and inhibit PKC on the




4.2.1 Concentration-dependency of the effect of A23187 on neutrophil
apoptosis
Exposure of neutrophils to the calcium ionophore, A23187 (0.01-0.1 pM),
produced a concentration-dependent inhibition in the rate of apoptosis
(Figure 4.1). Assessment of cell viability and recovery demonstrated that
A23187 did not significantly alter either of these parameters, at the
concentrations shown in figure 4.1. However, higher concentrations of
A23187 (1-10 pM) rendered the cells necrotic, as assessed by trypan blue
exclusion. From these data, a maximal concentration of A23187 (0.1 pM)
was selected for use in further studies.
4.2.2 Divergent effects of agents that increase intracellular Ca2+ on
eosinophil and neutrophil apoptosis
Eosinophils (2xl06/ml) cultured in serum-supplemented Iscove's DMEM,
in the presence of A23187 (0.1 pM) and thapsigargin (2 pM), showed an
increase in the light microscopic features of apoptosis at 20 h, compared
with the control population (figure 4.2A). In contrast to the effects
observed on eosinophils, neutrophils (2xl06/ml) cultured in serum-
supplemented Iscove's DMEM showed decreased apoptosis in the
presence of both A23187 (0.1 pM) and thapsigargin (2 pM), as illustrated in
figure 4.2B. At the concentrations used these intracellular Ca2+ elevating
agents did not affect cell viability or recovery in either granulocyte type.
Interestingly, the pro-apoptotic effect seen in eosinophils and the anti-
apoptotic effect seen in neutrophils was more pronounced upon
treatment with thapsigargin compared with the effects seen in the
presence of A23187.
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Figure 4.1 Concentration response for the effect of A23187 on neutrophil
apoptosis.
Neutrophils (2xl06/ml) were incubated in serum-supplemented Iscove's
DMEM either alone (control) or in the presence of A23187 (0.01-0.1 pM).
Neutrophils were harvested following 20 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 3



































Figure 4.2 Effect of A23187 and thapsigargin on the rate of eosinophil (A)
and neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were cultured for 20 h in serum-supplemented
Iscove's DMEM either alone (control) or in the presence of A23187 (0.1
pM) and thapsigargin (2 pM). Eosinophils were harvested and assessed
for morphological features of apoptosis. Data represent mean ± SEM of 4-
7 separate experiments, each performed in duplicate (*p<0.05 compared
with control values). B, Neutrophils (2xl06/ml) were cultured for 20 h in
serum-supplemented Iscove's DMEM either alone (control) or in the
presence of A23187 (0.1 pM) and thapsigargin (2 pM). Neutrophils were
harvested and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3-7 separate experiments, each performed in
triplicate (*p<0.05 compared with control values).
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4.2.3 Role of Ca2+ in dexamethasone-mediated eosinophil and neutrophil
apoptosis
The differing effects of A23187 and thapsigargin on granulocyte apoptosis
mirror the effect of dexamethasone on these cell types (Chapter 3);
promoting eosinophil, but inhibiting neutrophil apoptosis. To
investigate whether dexamethasone modulated apoptosis by inducing an
elevation in intracellular Ca2+, A23187 (0.1 pM) and thapsigargin (2 pM)
were co-cultured in the presence of dexamethasone (1 pM). Figure 4.3
illustrates that A23187 and thapsigargin further enhance the eosinophil
apoptosis-promoting and neutrophil apoptosis-inhibiting ability of
dexamethasone. However, it is difficult to draw precise mechanistic
conclusions from such experiments, given that all of these agents
individually modulate the rate of basal granulocyte apoptosis in culture.
An alternative strategy was therefore adopted involving BAPTA/AM, an
intracellular Ca2+ chelator. Figure 4.4 illustrates that BAPTA/AM (2.5
pM) promotes neutrophil apoptosis after 8 h in culture. The assessment
of apoptosis was carried out at an earlier time period (8 h) to enable easy
detection, in comparison with the usual later time of 20 h, where a greater
proportion of cells would have undergone the apoptotic process.
BAPTA/AM (2.5 pM) and dexamethasone (1 pM) were co-cultured, to
determine whether chelation of intracellular Ca2+ abrogated the anti-
apoptotic effect of dexamethasone, as observed after co-incubation of
BAPTA/AM (2.5 pM) and A23187 (0.1 pM). Figure 4.4 illustrates that
chelation of intracellular Ca2+ does not affect dexamethasone-mediated
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Figure 4.3 Effect of A23187 and thapsigargin on dexamethasone-mediated
eosinophil (A) and neutrophil (B) apoptosis.
A, Eosinophils (2x106/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with A23187 (0.1 pM) and thapsigargin (2
pM), in the presence and absence of dexamethasone (1 uM). Eosinophils
were harvested following 20 h in culture and assessed for morphological
features of apoptosis. Data represent mean ± SEM of 2-7 separate
experiments, each performed in duplicate (*p<0.05 compared with control
values). B, Neutrophils (2xl06/ml) were cultured in serum-
supplemented Iscove's DMEM either alone (control) or with A23187 (0.1
pM) and thapsigargin (2 pM), in the presence and absence of
dexamethasone (1 pM). Neutrophils were harvested following 20 h in
culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3-7 separate experiments, each performed in


















Figure 4.4 Effect of BAPTA/AM on basal, A23187- and dexamethasone-
mediated inhibition of neutrophil apoptosis.
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with BAPTA/AM (2.5 (J.M), in the
presence and absence of A23187 (0.1 (iM) or dexamethasone (1 pM).
Neutrophils were harvested following 20 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 4
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Figure 4.5 Measurement of cytosolic calcium levels in freshly isolated
neutrophils in response to different stimuli.
Cytosolic calcium measurements (nM) in fura-2-loaded, freshly isolated
neutrophils (2xl06/ml) over 250 s. Dexamethasone (1 pM) was added to
the cell suspension after 40 s, followed by the sequential addition of PAF
(100 nM), after 225 s. The results presented are from a representative
experiment.
Cytosolic calcium levels, [Ca2+]j, were measured using the Ca2+-sensitive
fluorescent dye fura-2/AM in freshly isolated neutrophils, with the
subsequent addition of dexamethasone (1 pM) and PAF (100 nM), as
indicated in figure 4.5. Dexamethasone (1 pM) did not induce an
elevation in [Ca2+]i above resting [Ca2+]j values of 100 nM or below,
which are consistent with basal [Ca2+]i levels found in other studies
(Whyte et al., 1993b). In contrast, addition of PAF (100 nM) to the cuvette,
induced a rapid and dramatic rise in [Ca2+]i to a peak of 700 nM, before
returning to control levels. Thus, figure 4.5 illustrates that
dexamethasone does not induce a rapid transient rise in [Ca2+]j in freshly
isolated neutrophils.
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4.2.4 Effect of PKC inhibitors on eosinophil and neutrophil apoptosis
Eosinophils (2x106/ml) cultured in serum-supplemented Iscove's DMEM,
in the presence of the PKC inhibitor staurosporine (1 pM), showed an
increase in the light microscopic features of apoptosis at 20 h, compared
with the control population (figure 4.6), without significantly affecting
either cell viability or recovery. Figure 4.7 illustrates the effect of
staurosporine (A) and a more specific PKC inhibitor, Ro-31-8220 (B) on
the rate of neutrophil apoptosis, after 4, 8 and 20 h in culture. The highest
concentration of staurosporine used (10 pM), promoted neutrophil
apoptosis to a value comparable with that seen in the presence of Ro-31-
8220 (10 pM). The results observed in the presence of lower
concentrations of staurosporine (0.1-1 pM), were inconsistent between the
various time periods of apoptosis assessment and did not show any
consistent trend (figure 4.7A). However, in the presence of Ro-31-8220
(0.1-10 pM), the proportion of neutrophils exhibiting classical
morphological features of apoptosis increased in a concentration-
dependent manner, with a consistent increasing trend observed at all
time periods investigated (figure 4.7B). These results indicate that
inhibition of PKC, promotes the rate of both eosinophil and neutrophil
apoptosis.
4.2.5 Involvement of PKC in modulating dexamethasone-mediated
inhibition of neutrophil apoptosis
At a concentration of 0.1 pM staurosporine and Ro-31-8220 were shown to
have no significant effect upon the control rate of neutrophil apoptosis
(figure 4.7). To investigate whether dexamethasone-mediated inhibition
of neutrophil apoptosis involved PKC activation, neutrophils were co-
cultured with dexamethasone in the presence of staurosporine (figure
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4.8A) and Ro-31-8220 (figure 4.8B) at a concentration of 0.1 (iM for 20 h.
Interestingly, we observed a partial abrogation of dexamethasone-
mediated inhibition of neutrophil apoptosis, indicating that activation of




Figure 4.6 Effect of staurosporine on eosinophil apoptosis.
Eosinophils (2x106/ml) were incubated in serum-supplemented Iscove's
DMEM either alone (control) or in the presence of staurosporine (1 jiM).
Eosinophils were harvested following 20 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 3
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Figure 4.7 Effect of staurosporine and Ro-31-8220 on neutrophil
apoptosis.
Neutrophils (2xl06/ml) were incubated in serum-supplemented Iscove's
DMEM either alone (control) or in the presence of (A) staurosporine (0.1-
10 JJ.M) or (B) Ro-31-8220 (0.1-10 pM). Neutrophils were harvested
following 4, 8 and 20 h in culture and assessed for morphological features
of apoptosis. Data represent mean ± SEM of 3 separate experiments, each
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Figure 4.8 Effect of staurosporine and Ro-31-8220 on dexamethasone-
mediated inhibition of neutrophil apoptosis.
Neutrophils (2xl06/ml) were incubated in serum-supplemented Iscove's
DMEM either alone (control) or with dexamethasone (1 pM), in the
presence or absence of (A) staurosporine (0.1 pM) or (B) Ro-31-8220 (0.1
pM). Neutrophils were harvested following 20 h in culture and assessed
for morphological features of apoptosis. Data represent mean ± SEM of 3




We have demonstrated that elevation of [Ca2+]i, by either the calcium
ionophore A23187 or thapsigargin, differentially affects that rate of
granulocyte apoptosis; promoting eosinophil and inhibiting neutrophil
apoptosis (figure 4.2). Whyte and colleagues have previously reported
that elevation of [Ca2+]i exerts an inhibitory effect upon the rate of
neutrophil apoptosis (Whyte et al., 1993b), however the promotion of
eosinophil apoptosis observed after culture of eosinophils in the presence
of either Ca2+ elevating agent, has, to our knowledge, not been previously
reported. Moreover, we have illustrated that elevation of [Ca2+]i, through
independent mechanisms, elicits consistent trends in the modulation of
granulocyte apoptosis. However, the pro-apoptotic effect observed in
eosinophils and the anti-apoptotic effect observed in neutrophils was
more pronounced in the presence of thapsigargin as compared to A23187.
These results may suggest that the mechanism of calcium elevation is an
important factor in the regulation of granulocyte apoptosis. A23187 is a
compound which has been shown to elevate [Ca2+]j due to its Ca2 +
ionophore ability (Reed & Lardy, 1972). However, the mechanism of
thapsigargin-mediated [Ca2+]i elevation involves the initial release of
Ca2+ from intracellular stores, by a selective inhibition of the endoplasmic
reticulum Ca2+-ATPase and entry of Ca2+ from the extracellular space
(Takemura et al., 1989, Thastrup et al., 1989). This capacitative Ca2+ entry
pathway is now known to exist in most cell types (Putney, 1990).
Thapsigargin-induced [Ca2+]j elevation in cells is pharmacologically
indistinguishable from that observed during agonist stimulation and
mimics physiological [Ca2 + ]j increases. This avoids the possible
nonspecific effects associated with Ca2+ ionophores used in previous
studies (Wyllie et al., 1984) and provides a specific approach to examine
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the role of Ca2+ in the regulation of apoptosis. The more pronounced
effects of [Ca2+]j elevation upon granulocyte apoptosis in the presence of
thapsigargin, as compared to A23187, may therefore indicate that the
depletion of thapsigargin-sensitive endoplasmic reticulum Ca2+ pools is
important in the mechanism of [Ca2+]i elevation regulating granulocyte
apoptosis. Alternatively, these observations may result from the ability of
thapsigargin to elevate [Ca2+]j via two independent mechanisms, namely
mobilisation of Ca2+ from intracellular stores and an increase in the
influx of extracellular Ca2+. The resulting levels of Ca2+ within the
granulocytes may therefore be greater than the level achieved by
treatment of granulocytes with A23187. Direct measurements of the
extent to which Ca2+ is elevated by thapsigargin and A23187 in
eosinophils and neutrophils would need to be undertaken to make any
firm conclusions regarding this hypothesis. Particularly germane to our
findings, Zhu & Loh (1995) have demonstrated that mobilisation of Ca2+
from intracellular pools, rather than an increase in [Ca2+]i alone, provides
the signal for the initiation of apoptosis in HL-60 cells. This study
demonstrates that a solitary increase in [Ca2+]j did not result in apoptosis,
while the depletion of thapsigargin-sensitive Ca2+ pools in the
endoplasmic reticulum was closely associated with the induction of
apoptosis in HL-60 cells. Moreover, they reported that the extracellular
and intracellular Ca2+ chelators, EGTA and BAPTA, promoted apoptosis,
in contrast to the calmodulin antagonist, W-13 which did not attenuate
apoptosis in HL-60 cells. Collectively these findings, in conjuction with
the data presented in figure 4.2, may support the interpretation that
mobilisation of intracellular Ca2+ stores is particularly important in
regulation of the apoptotic programme in myeloid cells.
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Abundant evidence has emerged supporting the involvement of Ca2+ in
apoptosis, with documented findings particularly focussing on the role of
Ca2+ in the regulation of thymocyte apoptosis. One such report from
Wyllie et al., (1984) has demonstrated that Ca2+ ionophores cause
endonuclease activation as well as many of the morphological changes
typically associated with apoptosis in thymocytes. Our results are
particularly intriguing in that elevation of [Ca2+]j differentially affects
granulocyte apoptosis; again indicating that these cells are regulated
differently. Moreover, it has been suggested that the existence of
endonucleases with different requirements of Ca2+ for their activation
may be responsible for the heterogeneous action of Ca2+ in the regulation
of apoptosis in various cell types (Zhu & Loh, 1995). We have also
investigated the role of Ca2+ in dexamethasone-mediated granulocyte
apoptosis. Interpretation of experiments in which the Ca2+ elevating
agents A23187 and thapsigargin were co-cultured in the presence of
dexamethasone with either eosinophils or neutrophils has proven to be
difficult, given that these agents individually modulate the rate of
granulocyte apoptosis in vitro (figure 4.3). However, these experiments
may suggest that elevation of [Ca2+]j modulates dexamethasone-mediated
granulocyte apoptosis. Significantly, further studies investigating the role
!' Z. i ' .
of Ca2+ in dexamethasone-mediated inhibition of neutrophil apoptosis
argue against a role for Ca2+, since the anti-apoptotic effect of
dexamethasone was unaffected by chelation of intracellular Ca2+ (figure
4.4). Furthermore, preliminary studies involving the direct
measurement of cytosolic Ca2+ levels in freshly isolated neutrophils, did
not identify any changes in the [Ca2+]i above resting values of 100 nM,
upon dexamethasone addition. Although our findings argue against
a role for Ca2+ in dexamethasone-mediated inhibition of
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neutrophil apoptosis, more intensive experiments are necessary to make
any firm conclusions. Interestingly, contradictory results have been
reported on the question of the role of Ca2+ in glucocorticoid-induced
apoptosis in thymocytes. Early studies on the biochemical mechanism of
glucocorticoid-induced apoptosis in rat thymocytes have highlighted the
dependence of this induction of apoptosis on a sustained increase in
[Ca2+]j (Kaiser & Edelman, 1977, McConkey et al., 1989a), being inhibited
by the depletion of intracellular Ca2+ with EGTA (Kaiser & Edelman, 1977,
McConkey et al., 1989a) and buffering of intracellular Ca2+ with quin-
2/AM (McConkey et al., 1989a). On the other hand, Iseki et al., (1993)
have reported that glucocorticoid-induced apoptosis in murine and rat
thymocytes is not dependent on an increase in [Ca2+]j. Moreover, this
latter report suggests that the discrepancy between these results may be
accounted for by the different methods used for measurement of [Ca2+]i
levels. McConkey and colleagues measured [Ca2+]i using a fluorescence
spectrophotometer and a cell suspension in a curvette (McConkey et al.,
1989a). This classical method would give a false increase in [Ca2+]j if the
fluorescent Ca2+ indicator, fura-2, leaked from the cells by for example,
cytolysis during the measurement. However, Iseki et al., (1993) assessed
dexamethasone-induced [Ca2+]j elevations in murine thymocytes, by
microscopic fluorimetry with constant perfusion to remove leaked
indicator. Nevertheless, this differing methodology in the measurement
of [Ca2+]j does not account for their findings that depletion of extracellular
Ca2+ with EGTA or buffering intracellular Ca2+ with quin-2/AM did not
inhibit glucocorticoid-induced thymocyte apoptosis in contrast to findings
by McConkey and colleagues. In other systems, such as human CEM
lymphocytes (a human lymphoid line of T cell derivation) glucocorticoid-
induced apoptosis is induced by a Ca2+-independent mechanism
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(Alnemri & Litwack, 1990, Bansal et al., 1990). The involvement of Ca2+
in glucocorticoid-mediated thymocyte apoptosis therefore remains a
complex and controversial issue.
With increasing evidence implicating a role for Ca2+ in the regulation of
apoptosis, an important aspect of ongoing research involves defining the
targets of Ca2+ in apoptotic cells. Elevation of [Ca2+]i may regulate
apoptosis by direct effects on the enzymatic activities of proteases and/or
endonucleases responsible for mediating cellular demise in apoptosis.
Squier and colleagues have recently demonstrated that activation of the
Ca2+-dependent neutral protease calpain is involved in glucocorticoid-
and irradiation-induced thymocyte apoptosis (Squier et al., 1994, Squier &
Cohen, 1997). Moreover, other Ca2+-sensitive proteases may also
participate in the apoptotic process. Previous work has demonstrated that
a family of nuclear matrix proteins, the lamins are degraded in cells
undergoing apoptosis (Neamati et al., 1995, Oberhammer et al., 1994) and
in thymocytes lamin cleavage occurs via a Ca2+-dependent mechanism
(Neamati et al., 1995). Alternatively, Ca2+ may regulate apoptosis via
mechanisms involving activation of Ca2+-dependent protein kinases
and/or phosphatases leading to alterations in gene transcription. Studies
with the immunosuppressive drugs cyclosporin A (CsA) and FK506
support this model for how Ca2+ elevation may be coupled to
downstream events in apoptosis. CsA and FK506 bind to a family of
cytosolic receptors promoting direct binding to and inhibition of the
Ca2+/calmodulin-dependent protein serine/threonine phosphatase,
calcineurin (PP2B) (Liu et al., 1991). Evidence has now been presented
from several laboratories illustrating that CsA can block Ca2+-dependent
apoptosis in lymphoid model systems (Shi et al., 1989, Amendola et al.,
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1994, Bonnefoy-Berard et al., 1994, Makrigiannis et al., 1994), indicating
that calcineurin activation may be required for these responses and
thereby suggesting that calcineurin is one target for Ca2+ in apoptosis.
However, not all pathways of apoptosis are affected by these
immunosuppressive agents. Recent work confirms that CsA and FK506
block Ca2+-stimulated apoptosis in T cell hybridomas but are without
effect on Ca2+-dependent apoptosis in immature rodent thymocytes
(McConkey & Orrenius, 1996). Collectively, these findings suggest that
while calcineurin may represent a target for Ca2+ in apoptosis, it is not a
universal target. Recently, Dolmetsch et al., (1997) have shown that the
amplitude and duration of Ca2+ signals in B lymphocytes controls
differential activation of the pro-inflammatory transcriptional regulators
NF-fcB, JNK and NFAT. They report that NF-kB and JNK are selectively
activated by a large transient [Ca2+]j rise, whereas NFAT is activated by a
low, sustained Ca2+ plateau. These results show how downstream
effectors can decode information in relation to the amplitude and
duration of Ca2+ signals, revealing a mechanism by which Ca2+ can
achieve specificity in signalling to the nucleus. These recent observations
may therefore also prove to be relevant in the mechanism by which Ca2+
regulates apoptosis and mediates differential cell signalling.
We have also demonstrated that treatment of both eosinophils and
neutrophils with inhibitors of PKC induces apoptosis (figures 4.6 and 4.7).
Moreover, the pro-apoptotic effect upon neutrophils was noted in
response to both a relatively specific PKC inhibitor, Ro-31-8220 (Keller &
Niggli, 1993), as well as by the relatively nonspecific inhibitor,
staurosporine (Schachtele et al., 1988, Nakadate et al., 1988). Collectively,
these data implicate a role for PKC in the suppression of granulocyte
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apoptosis. Based upon our findings and those of several other
laboratories, the role of PKC in apoptotic events appears to vary with cell
type. In certain cells, phorbol ester-stimulated activation of PKC inhibits
apoptosis while in other cells a death programme is initiated by activation
of PKC (McConkey et al., 1989d, Araki et al., 1990, Forbes et al., 1992, Sun et
al., 1992, Ishii & Gobe, 1993). Activation of the PKC signal transduction
pathway appears to modulate apoptosis in a cell-specific fashion.
However, apart from describing the ability of PKC to modulate apoptosis,
very little is known with regards to the mechanisms responsible for
producing these divergent, cell-specific responses. It has now been
established that PKC is not a single molecular entity but infact exists as
many closely related PKC isotypes. The existence of at least twelve
members of the PKC gene family, indicated by the Greek symbols a, (31,
(311, y, 8, e, I;, r\, 0, i, k and p, may serve as a mechanism responsible for
the differential regulation by PKC of apoptosis (Dekker & Parker, 1994). It
is likely that a full range of PKC isotypes has not yet been identified and
that even more members of the PKC family will be discovered in the
future. Differences in the expression patterns, substrate specificity,
subcellular location and sensitivity to agonists among the individual PKC
isoforms may serve as possible mechanisms by which apoptosis is
modulated by PKC in a cell-specific manner. The expression pattern of
PKC isoenzymes in different tissues and cell lines is now emerging with
isotypes (31, (311, 5, 4 and r[ being ubiquitously expressed in myeloid cell
lines (Hug & Sarre, 1993).
The existence of different types of PKC with distinct properties may
explain the apparent contradiction of results between the role of PKC
activation in inducing thymocyte apoptosis as reported by both Kizaki et
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al., (1989a) and Ojeda et al., (1992), with that of McConkey et al., (1989d),
who reported inhibition of DNA fragmentation with agents that
stimulate PKC.
We have also demonstrated that staurosporine and Ro-31-8220, at a
concentration (0.1 (iM) that did not modulate the rate of constitutive
neutrophil apoptosis, partially abrogated dexamethasone-mediated
inhibition of neutrophil apoptosis. These data suggest that the
mechanism underlying dexamethasone-mediated inhibition of
neutrophil apoptosis may involve activation of PKC. The documented
effects of PKC in the regulation of glucocorticoid-mediated apoptosis, in
other cells, again appears to be cell-type specific. Ojeda and colleagues
have demonstrated that inhibition of PKC by exposure to H7 prevents
glucocorticoid-induced apoptosis in murine thymocytes, suggesting that
activation of PKC promotes this process (Ojeda et al., 1990). Whereas,
McConkey et al., (1989d) have shown that activation of PKC using PMA
opposes steroid-induced apoptosis in thymic lymphocytes, consistent with
an antagonistic influence of PKC. Moreover, Iwata et al., (1994) have
reported that glucocorticoid-induced apoptosis in immature thymocytes
involves glucocorticoid receptor-mediated and selective activation of
PKC-e, through de novo synthesis of macromolecules. We have
previously demonstrated that granulocyte apoptosis is dependent on
protein synthesis (Chapter 3), and as such glucocorticoids may activate
unknown genes involved in the production of a protein which induces
activation of one or more PKC isoenzymes. However, at present the role
of PKC in the regulation of glucocorticoid-mediated granulocyte apoptosis
and the mechanism of action of PKC remain unclear.
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With the advent of isotype-specific PKC stimulators and inhibitors, it is
now becoming possible to assess the specific role of PKC isoenzymes in
the regulation of apoptosis. Recent reports have indicated that PKC
isoenzymes are differentially involved in the regulation of apoptosis.
The potential importance of changes in PKC-P expression during
apoptosis has been suggested by several laboratories. Knox and colleagues
have demonstrated that the level of bcl-2, a protein known to prevent
apoptosis in many cell types, was inversely related to the expression of
PKC-P and -a in tonsil epithelial cells (Knox et al., 1993). Moreover, a
phorbol ester capable of selectively activating PKC-pi in vitro has been
shown to accelerate apoptosis in U937 cells (Pongracz et al., 1994) and
HL60 cells (Macfarlane & Manzel, 1994). It has therefore been suggested
that these findings may collectively indicate that PKC-P is an important
element regulating myeloid cell apoptosis. Furthermore, Pongracz et al.,
(1995) have more recently reported that the level of certain PKC
isoenzymes changed during spontaneous apoptosis of U937 promonocytic
cells; with an increase in PKC-P and a decrease in PKC-£. Moreover, the
intracellular location of PKC-a appeared to be altered in apoptotic U937
cells, being associated more with the nucleus than the cytosol. These data
suggest that the levels and disposition of the PKC isoenzymes are
modulated during apoptosis. Finally, Emoto et al., (1995) have reported
that apoptosis in irradiated U937 cells is associated with proteolytic
activation of PKC-^ by an ICE-like protease since the specific tetrapeptide
ICE inhibitor (YZAD) blocked both proteolytic activation of PKC-2, and
internucleosomal DNA fragmentation. These findings indicate that PKC-
^ is a downstream target of the ICE-like protease and may provide clues to
the potential targets of PKC-mediated myeloid cell apoptosis.
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The connection between PKC activation and modulation of apoptosis is
presumably mediated by proteins, which become phosphorylated by PKC
(Azzi et al., 1992). One such PKC substrate is IkB, a 35 kDa protein which
is able to bind to and inhibit the transcription factor NF-H3. The inactive
complex IfcB/NF-fcB is phosphorylated by PKC on the inhibitor protein
(Ghosh & Baltimore, 1990), allowing NF-kB to move to the nucleus
where it exerts specific DNA binding ability and is involved in the
activation of target genes (Finco & Baldwin, 1995). Moreover, it has been
recently reported that glucocorticoids inhibit NF-kB activity, specifically
by increasing synthesis of IA:B (Didonato et al., 1996, Barnes & Adcock,
1997). Thus the mechanism underlying PKC directed constitutive and
glucocorticoid-mediated apoptosis, may involve target proteins such as
IkB.
In summary, our present studies provide evidence that elevation of
[Ca2+]i differentially affects the rate of granulocyte apoptosis; promoting
eosinophil apoptosis and inhibiting neutrophil apoptosis. Moreover,
exposure of these granulocytes to PKC inhibitors of varying specificities
triggers apoptosis, which indirectly suggests that the basal activity of one
or more isoforms of PKC protects these cells from apoptosis. Thus our
findings implicate both Ca2+ and PKC signal transduction pathways in the
regulation of granulocyte apoptosis. However, further studies are
necessary to fully elucidate the mechanisms by which Ca2+ and PKC
either independently or synergistically modulate granulocyte apoptosis.
120
Chapter 5
The role of MAPK/ERK and protein phosphatases in basal and
glucocorticoid-mediated granulocyte apoptosis
5.1 Introduction
The level of protein phosphorylation in any cell ultimately depends upon
the integrated activities of both protein kinases and protein phosphatases.
The resulting phosphorylation and dephosphorylation of various
substrate proteins is a principle mechanism of signal transduction in
eukaryotic cells and is becoming recognised as being essential in the
control of cellular survival.
Mitogen-activated protein kinases (MAPKs) are important mediators of
signal transduction from the cell surface to the nucleus. Regulation by
MAPKs has been implicated in the mediation of a wide array of
physiological processes including cell shape, osmotic integrity and
pheromone responses in yeasts (Ammerer, 1994, Herskowitz, 1995), stress
responses in mammalian cells (Galcheva-Gargova et al., 1994, Han et al.,
1994, Rouse et al., 1994), cytokine signalling (Freshney et al., 1994) and cell
growth and proliferation (Davis, 1993). However, the involvement of
MAP kinases in the regulation of apoptosis has not been studied in any
depth.
There is good evidence that MAP kinase plays a key role in the
transduction of signals through both protein kinases and protein
phosphatases. The specific regulation of protein phosphatases indicates
their central role in cellular regulation and the discovery of many cell
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permeable phosphatase inhibitors, such as okadaic acid and calyculin A,
has assisted the study of the function of protein phosphatases in cellular
regulation (Holmes & Boland, 1993).
Although their precise functions are not yet known, several biological
roles of protein phophatases have been revealed in a number of recent
studies (Axton et al., 1990, Kinoshita et al., 1990, Nitschke et al., 1992). PP1
(and PP2A) have been implicated in many different cellular processes, as
diverse as glycogen metabolism, calcium transport, muscle contraction,
protein synthesis and intracellular transport (Cohen, 1989, Shenolikar &
Nairn, 1991, Bollen & Stalmans, 1992). Moreover, the protein
phosphatase inhibitors, okadaic acid and calyculin A, have been shown to
modify several neutrophil responses such as altered shape change and F-
actin distribution, suggesting that dephosphorylation has a regulatory role
in myeloid cells (Kreienbuhl et al., 1992). Phosphatase type 1 appears to be
a major regulator of the cAMP-response element binding protein (CREB)
(Hagiwara et al., 1992) and it has been suggested that these phosphatases
may regulate the activity of multiple transcription factors (Park et al.,
1992). Other studies have provided evidence that dephosphorylation of
proteins may play a role in both the positive and negative regulation of
apoptosis. Both okadaic acid and calyculin A have been shown to protect
cells against apoptotic cell death induced by heat and ionizing radiation in
tumour cell lines (Baxter & Lavin, 1992), Burkitt's lymphoma cell line
BM13674 cells (Song & Lavin, 1993) and from apoptosis induced by a
number of cytotoxic compounds (Song et al., 1992). Conversely, okadaic
acid has been shown to induce apoptosis in leukemic cells (Boe et al.,
1991, Ishida et al., 1992).
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In this study we have used PD 098059, an inhibitor of the MAPK/ERK
cascade and both okadaic acid and calyculin A, protein phosphatase
inhibitors, to investigate the potential involvement of MAP kinase and




5.2.1 Involvement of MAP kinase in eosinophil and neutrophil
apoptosis
Eosinophils (2x106/ml) cultured in serum-supplemented Iscove's DMEM
showed an inhibition in the light microscopic features of apoptosis in the
presence of the MAP kinase cascade inhibitor, PD 098059 (50 pM) (Figure
5.1A). In contrast to the effects observed on eosinophils, PD 098059 (50
|iM) had no significant effect upon the rate of apoptosis in neutrophils
(2xl06/ml), cultured in serum-supplemented Iscove's DMEM (Figure
5.IB). Treatment of both cell types with PD 098059 did not significantly
alter either cell viability or recovery. These results illustrate that the basal
rates of eosinophil and neutrophil apoptosis are regulated differently.
Inhibition of the MAP kinase signalling cascade appears to inhibit
eosinophil apoptosis, while having no effect on the rate of neutrophil
apoptosis.
5.2.2 Involvement of MAP kinase in glucocorticoid-mediated eosinophil
and neutrophil apoptosis
We subsequently investigated the effect of PD 098059 on the rate of
glucocorticoid-mediated granulocyte apoptosis. Figure 5.2 illustrates that
eosinophils pre-incubated for 30 min with PD 098059 (50 (iM), before
addition of dexamethasone (1 |iM), showed a slight inhibition of the pro-
apoptotic effect observed in the presence of dexamethasone alone.
Moreover, the extent of this inhibition was comparable to the inhibitory
effect of PD 098059 on the basal rate of eosinophil apoptosis. Thus, it
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Figure 5.1 Effect of PD 098059 on the rate of eosinophil (A) and
neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were cultured for 20 and 40 h, in serum-
supplemented Iscove's DMEM either alone (control) or in the presence of
PD 098059 (50 pM). At the time periods indicated, cells were harvested
and assessed for morphological features of apoptosis. Data represent
mean ± SEM of 6 separate experiments, each performed in duplicate (*
p<0.05 compared with control values). B, Neutrophils (2xl06/ml) were
cultured for 8 and 20 h, in serum-supplemented Iscove's DMEM either
alone (control) or in the presence of PD 098059 (50 pM). At the time
periods indicated, cells were harvested and assessed for morphological
features of apoptosis. Data represent mean ± SEM of 3 separate
experiments, each performed in duplicate (* p<0.05 compared with
control values).
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given that PD 098059 per se modulates the rate of basal eosinophil
apoptosis in culture. We were also interested in the effect of this MAP
kinase cascade inhibitor on other inflammatory mediators known to
inhibit eosinophil apoptosis. Figure 5.2 illustrates that PD 098059 (50 (iM)
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Figure 5.2 Effect of PD 098059 on dexamethasone-, IL-5- and GM-CSF-
mediated eosinophil apoptosis.
Eosinophils (2xl06/ml) were incubated in serum-supplemented Iscove's
DMEM either alone (control) or with dexamethasone (1 (iM), IL-5 (1
ng/ml) or GM-CSF (5 U/ml), in the presence and absence of PD 098059 (50
pM). Eosinophils were pre-incubated with PD 098059 for 30 min at 37°C
in each case. Cells were harvested following 40 h in culture and assessed
for morphological features of apoptosis. Data represent mean ± SEM of 3-
5 separate experiments, each performed in duplicate (* p<0.05 compared
with control values).
The effect of PD 098059 on dexamethasone-, LPS-, dibutyryl-cAMP, and
GM-CSF-mediated neutrophil apoptosis is illustrated in figure 5.3.
Interestingly, PD 098059 while having no effect on the basal rate of
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neutrophil apoptosis, or dexamethasone-, dibutyryl-cAMP- and GM-CSF-
mediated apoptosis, completely attenuated LPS-mediated inhibition of
neutrophil apoptosis. These data suggest that glucocorticoid-induced
inhibition of neutrophil apoptosis is not mediated by the MAPK/ERK
cascade. However, LPS-induced inhibition of neutrophil apoptosis may
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Figure 5.3 Effect of PD 098059 on dexamethasone-, LPS-, dibutyryl-cAMP-,
and GM-CSF-mediated neutrophil apoptosis.
Neutrophils (2xl06/ml) were incubated in serum-supplemented Iscove's
DMEM either alone (control) or with dexamethasone (1 |iM), LPS (1
(ig/ml), dibutyryl-cAMP (0.2 mM) or GM-CSF (5 U/ml), in the presence
and absence of PD 098059 (50 |iM). Neutrophils were pre-incubated with
PD 098059 for 30 min at 37°C in each case. Cells were harvested following
20 h in culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 5-8 separate experiments, each performed in
duplicate (* p<0.05 compared with control values).
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5.2.3 Involvement of protein phosphatases in basal and glucocorticoid-
mediated granulocyte apoptosis
In order to gain a better understanding of the role of protein
phosphorylation in the regulation of basal and glucocorticoid-mediated
granulocyte apoptosis, we investigated the effects of the protein
phosphatase inhibitors, okadaic acid and calyculin A. Figure 5.4A
illustrates the effect of okadaic acid (0.5-100 nM) on the rate of eosinophil
apoptosis, after 20 and 40 h in culture. At the time periods studied, the
lower concentrations of okadaic acid (< 5 nM) caused a decrease in the rate
of eosinophil apoptosis, while the higher concentrations (> 50 nM)
promoted apoptosis, as compared to the control population of cells.
Figure 5.4B illustrates the effect of okadaic acid (0.5-500 nM) on the rate of
neutrophil apoptosis, after 8 and 20 h in culture. At the time periods
studied, the lower concentrations of okadaic acid (< 50 nM) caused a
decrease in the rate of neutrophil apoptosis, while the higher
concentrations (> 100 nM) promoted apoptosis, as compared to the control
population of cells. These results indicate that okadaic acid has a bi-phasic
effect on the rate of both eosinophil and neutrophil apoptosis, with the
lower concentrations inhibiting and the higher concentrations promoting
apoptosis, without inducing cellular necrosis at the concentrations
shown. The range of concentrations of okadaic acid used, however,
varied between the two cell types. A high proportion of eosinophils
(>80%) admitted trypan blue when cultured with concentrations of
okadaic acid >100 nM, suggesting that this concentration of okadaic acid
was toxic to the cell and therefore induced cell necrosis. In contrast,
okadaic acid (0.5-500 nM) did not induce cellular necrosis in neutrophils
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Figure 5.4 Effect of okadaic acid on the rate of eosinophil (A) and
neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were cultured for 20 and 40 h, in serum-
supplemented Iscove's DMEM either alone (control) or in the presence of
okadaic acid (0.5-100 nM). At the time periods indicated, cells were
harvested and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 4 separate experiments, each performed in
duplicate (* p<0.05 compared with control values). B, Neutrophils
(2xl06/ml) were cultured for 8 and 20 h, in serum-supplemented Iscove's
DMEM either alone (control) or in the presence of okadaic acid (0.5-500
nM). At the time periods indicated, cells were harvested and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 3-4
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Figure 5.5 Effect of okadaic acid on dexamethasone-mediated eosinophil
(A) and neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with dexamethasone (1 |iM), in the
presence and absence of okadaic acid (0.5 nM). Eosinophils were
harvested following 20 and 40 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 3
separate experiments, each performed in duplicate (* p<0.05 compared
with control values). B, Neutrophils (2x106/ml) were cultured in serum-
supplemented Iscove's DMEM either alone (control) or with
dexamethasone (1 (iM), in the presence and absence of okadaic acid (100
nM). Neutrophils were harvested following 20 h in culture and assessed
for morphological features of apoptosis. Data represent mean ± SEM of 4
separate experiments, each performed in duplicate (* p<0.05 compared
with control values). Data obtained for okadaic acid plus dexamethasone
varied significantly from dexamethasone alone (" p<0.05).
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in figure 5.4B. Eosinophils therefore appear to be more sensitive to the
cytotoxic effects of okadaic acid than neutrophils.
Figure 5.5 illustrates the effect of okadaic acid on glucocorticoid-mediated
granulocyte apoptosis. Okadaic acid (0.5 nM) had no significant effect
upon the control rate of eosinophil apoptosis while partially attenuating
the pro-apoptotic effect of dexamethasone (Figure 5.5A). This okadaic
acid-induced partial attenuation of dexamethasone-mediated eosinophil
apoptosis was consistently observed in each individual experiment.
However, further experiments are required since the significance of these
results is masked by donor variation between the basal levels of
eosinophil apoptosis. Nevertheless, dexamethasone-mediated
promotion of eosinophil apoptosis is significantly different from the
control population of cells and co-culture of okadaic acid (0.5 nM) and
dexamethasone (1 pM) renders the dexamethasone effect to be no longer
significant. Figure 5.5B illustrates that okadaic acid (100 nM) had no
significant effect upon the control rate of neutrophil apoptosis while
completely attenuating dexamethasone-mediated inhibition of
neutrophil apoptosis. These data suggest that modulation of cellular
phosphatases may be an important factor in the regulation of
glucocorticoid-mediated granulocyte apoptosis.
An alternative protein phosphatase inhibitor, calyculin A, was therefore
used to assess the reproducibility of these results on neutrophils. Figure
5.6A illustrates that calyculin A (1-100 nM) has no significant effect on the
basal rate of neutrophil apoptosis after 20 h in culture. Moreover,
calyculin A (1-100 nM) induced a partial attenuation of dexamethasone-
mediated inhibition of neutrophil apoptosis (figure 5.6B). As illustrated
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in figure 5.6B, dexamethasone-mediated inhibition of neutrophil
apoptosis is significantly different from the control population of cells
and co-culture of calyculin A (1-100 nM) and dexamethasone (1 pM)
renders the dexamethasone effect to be no longer significant. These data
strengthen the hypothesis that modulation of protein phosphatases may
play a role in the regulation of glucocorticoid-mediated neutrophil
apoptosis.
Finally, to investigate the specificity of these results, we compared the
effect of calyculin A on dexamethasone-, LPS-, dibutyryl-cAMP-, and GM-
CSF-mediated neutrophil apoptosis (figure 5.7). Interestingly, calyculin A
while having no effect on the basal rate of neutrophil apoptosis, also
failed to modulate LPS-, dibutyryl-cAMP-, and GM-CSF-mediated
inhibition of neutrophil apoptosis. These data suggest that the partial
attenuation of dexamethasone-mediated inhibition of neutrophil
apoptosis by calyculin A, is specific to dexamethasone, since calyculin A
does not modulate the inhibition of neutrophil apoptosis mediated by





















Figure 5.6 Effect of calyculin on basal and dexamethasone-mediated
inhibition of neutrophil apoptosis.
A, Neutrophils (2xl06/ml) were cultured in serum-supplemented
Iscove's DMEM either alone (control) or in the presence of calyculin (1-
100 nM). Cells were harvested following 20 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 4
separate experiments, each performed in duplicate (* p<0.05 compared
with control values). B, Neutrophils (2xl06/ml) were cultured in serum-
supplemented Iscove's DMEM either alone (control) or with
dexamethasone (1 |iM), in the presence and absence of calyculin (1-100
nM). Cells were harvested following 20 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 3
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Figure 5.7 Effect of calyculin on dexamethasone-, LPS-, dibutyryl-cAMP,
and GM-CSF-mediated neutrophil apoptosis.
Neutrophils (2x106/ml) were incubated in serum-supplemented Iscove's
DMEM either alone (control) or with dexamethasone (1 |iM), LPS (1
(ig/ml), dibutyryl-cAMP (0.2 mM) or GM-CSF (5 U/ml), in the presence
and absence of calyculin (1 nM). Neutrophils were harvested following
20 h in culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3 separate experiments, each performed in
duplicate (* p<0.05 compared with control values). Data obtained for




We have demonstrated that PD 098059, a synthetic inhibitor of the
MAPK/ERK pathway (Alessi et al., 1995, Dudley et al., 1995), down-
regulates the basal rate of eosinophil apoptosis as compared to the control
population of cells (figure 5.1A), while having no effect on the basal rate
of neutrophil apoptosis (figure 5.IB). These data indicate that activation
of the MAPK/ERK signalling cascade may be an important factor in
driving eosinophils through the apoptotic process and may offer a
potential mechanism underlying the promotion of eosinophil apoptosis,
thereby contributing to the resolution of inflammation. PD 098059 is
reportedly a selective inhibitor of the MAPK-activating enzyme MEK, and
moreover appears to be relatively specific towards inhibition of MEK 1 as
opposed to MEK 2 activation (Alessi et al., 1995). Our data may therefore
implicate the specific involvement of p44MAPK (jjrk 1) in the regulation
of eosinophil apoptosis. In view of these findings, we investigated the
effect of PD 098059 on dexamethasone-mediated promotion of eosinophil
apoptosis. Moreover, inflammatory mediators such as IL-5 and GM-CSF,
known to inhibit eosinophil apoptosis (Stern et al., 1992), were also
studied. PD 098059 was shown to marginally inhibit dexamethasone-
mediated eosinophil apoptosis in a manner comparable to the inhibitory
effect of PD 098059 observed upon the basal rate of eosinophil apoptosis.
Moreover, PD 098059 did not significantly modulate IL-5- or GM-CSF-
mediated inhibition of eosinophil apoptosis. However, although these
data highlight a difference between the effect of PD 098059 on
dexamethasone-mediated compared with IL-5- and GM-CSF-mediated
eosinophil apoptosis, it is difficult to draw mechanistic conclusions from
such experiments, given that PD 098059 alone modulates the rate of basal
eosinophil apoptosis in culture. Clearly, further investigations are
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needed, particularly in light of reports that the MAPK cascade is activated
in response to a variety of cytokines (Feig, 1993), although the
mechanisms involved have not been fully elucidated. Interest has
particularly focussed around a possible link between the [5-subunit of IL-
3/IL-5/GM-CSF receptors, which is the subunit that has been shown to be
the common signal transducer for these cytokines, and activation of the
Ras pathway (Sato et al., 1993). Moreover, Yousefi et al., (1997) have
highlighted that in the absence of an intrinsic tyrosine kinase domain in
the (3-subunit, activation of the Ras pathway may involve receptor-
associated tyrosine kinases such as Lyn or Syk, which are src-type tyrosine
kinases. This hypothesis is strengthened by the finding that these
tyrosine kinases have been shown to be essential for IL-3/IL-5/GM-CSF-
mediated inhibition of eosinophil apoptosis (Yousefi et al., 1996).
Furthermore, these authors have also reported that since Jak2
constitutively associates with the IL-3/IL-5/GM-CSF receptor (3-subunit in
human eosinophils, Jaks may also be involved in the activation of the
Ras pathway (Yousefi et al., 1997). Thus, this report speculates that these
kinases either collectively or individually may activate the Ras pathway
to transcribe anti-apoptotic genes in eosinophils, thereby inferring that
activation of the MAP kinase signalling cascade in eosinophils suppresses
apoptosis. However, our results presented in figure 5.1A suggest that
activation of the MAP kinase pathway promotes eosinophil apoptosis.
Clearly, further experiments are required to determine conclusively, the
role of MAPK in the regulation of eosinophil apoptosis and to fully
elucidate the mechanism by which inflammatory cytokines such as IL-5
inhibit eosinophil apoptosis.
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In contrast to the results observed in eosinophils, PD 098059 while having
no effect on the basal rate of neutrophil apoptosis or dexamethasone-,
dibutyryl-cAMP- and GM-CSF-mediated apoptosis, completely attenuated
LPS-mediated inhibition of neutrophil apoptosis (figure 5.3). Moreover,
Paul and colleagues have also demonstrated that in human neutrophils,
where LPS delays the constitutive rate of apoptosis, PD 098059 (a
MAPK/ERK cascade inhibitor) completely suppressed and SB 203580 (a
p38 MAP kinase inhibitor) partially suppressed the effect of LPS (Paul et
al., 1997). In agreement with our findings, these results implicate
MAPKs/ERKs and to a lesser extent, p38 MAP kinase, in LPS-induced
cellular protection of neutrophils. Previous reports demonstrate that LPS
has been shown to stimulate both the 'classical' Ras-dependent
MAPK/ERK pathway and the cytokine-activated p38 MAP kinase. For
example, in certain murine cell lines LPS has been reported to result in
MAPK/ERK phosphorylation and activation (Weinstein et al., 1992, Dong
et al., 1993). However, in neutrophils (Nahas et al., 1996, Nick et al., 1996),
a murine pre-B cell line, 70Z/3, transfected with human CD14 (Han et al.,
1994) and PC-12 cells (Rouse et al., 1994), LPS induces phosphorylation
and activation of p38 MAP kinase, whose in vivo substrates include heat
shock protein (hsp) 27 (Cuenda et al., 1995) and the transcription factor,
CREB (Tan et al., 1996). Interestingly, the p90 ribosomal S6 kinase, a
downstream target of MAPKs/ERKs, is also able to phosphorylate CREB at
Ser-133, enabling stimulation of gene transcription (Ginty et al., 1994). It
is therefore possible that phosphorylation of CREB by p90 ribosomal S6
kinase may be an important factor regulating LPS-induced inhibition of
neutrophil apoptosis in our system.
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The importance of the classical MAP kinases in protection against
apoptosis is consistent with recent findings in PC-12 cells, where apoptosis
is suppressed by NGF, which activates the MAPKs/ERKs (Xia et al., 1995).
In these studies, withdrawal of NGF from the culture medium led to the
sustained activation of JNK and p38 MAP kinases and inhibition of ERKs,
which was accompanied by a stimulation of apoptosis. These results are
particularly interesting as they indicate that apoptosis in NGF-
differentiated PC-12 cells is regulated by the opposing actions of ERK and
JNK-p38 MAP kinase pathways. As suggested by Xia and colleagues, the
dynamic balance between growth factor-activated ERK and stress-
activated JNK-p38 pathways may be an important factor determining
whether a cell survives or undergoes apoptosis.
We have also demonstrated that PD 098059 did not modulate
dexamethasone-, dibutyryl-cAMP- or GM-CSF-mediated inhibition of
neutrophil apoptosis (figure 5.3). Moreover, these are the first results to
our knowledge, indicating that MAPKs/ERKs are not involved in the
cellular protection of neutrophils mediated by these agents. However,
GM-CSF has recently been shown to increase the kinase activity of both
p44 and p42 MAP kinases (Waterman & Sha'afi, 1995) and to a lesser
extent the p38 MAP kinase, in human neutrophils (Nahas et al., 1996). It
therefore seems likely that inflammatory mediators such as LPS and GM-
CSF, regulate cell activation and apoptosis differently through activation
of various MAP kinase cascades. Both agents have been shown to
stimulate MAPK/ERK and p38 MAP kinase to some degree. However, in
the control of the apoptotic process, the regulation of MAP kinases by
these agents appears to be mediated differently, with LPS utilizing both
MAPK/ERK and p38 MAP kinase again to some degree, while GM-CSF
138
does not appear to modulate neutrophil apoptosis with the involvement
of any MAP kinase.
Furthermore, although the MAPK/ERK cascade was not implicated in
dibutyryl-cAMP-mediated inhibition of neutrophil apoptosis (figure 5.3),
the cAMP/PKA pathway has been shown to both positively and
negatively regulate MAP kinase pathways. Previous studies have
demonstrated cross-talk between the Ras/Raf/MEK/MAP kinase cascade
and the cAMP second messenger system at the level of Raf-1. Cyclic-AMP
has been shown to inhibit the activation of Raf-1, resulting in inhibition
of MAP kinase activation in a variety of cell types including Rat-1 and
NIH 3T3 fibroblasts, rat adipocytes and human arterial smooth muscle
cells (Burgering et al., 1993, Cook & McCormick, 1993, Graves et al., 1993,
Sevetson et al., 1993, Wu et al., 1993). It has further been shown that Raf-1
is phosphorylated by PKA at a consensus site within the Raf-1 regulatory
domain (Wu et al., 1993). This phosphorylation reduces the affinity with
which Raf-1 binds to Ras, suggesting that it is responsible for cAMP-
mediated inhibition of Raf-1. However, the phenomenon of PKA-
mediated inhibition of MAP kinase activity is not universal. In the EAhy
926 endothelial cell line no acute inhibition of growth-factor stimulated
MAP kinase is observed (McLees et al., 1995). Moreover, positive
regulation of MAP kinases by cAMP has been shown to occur in neuronal
cells, such as PC-12 cells (Frodin et al., 1994, Young et al., 1994) and in B-16
melanoma cells (Englaro et al., 1995). These findings suggest the presence
of multiple Raf isoforms, which are differentially regulated by PKA or
alternatively, the presence of different PKA isoenzymes with differing
affinities for Raf. Erhardt et al., (1995) have exploited a major difference
between the Ras/Raf/MEK/MAP kinase cascades in PC-12 cells and Rat-1
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fibroblasts, which is likely to account for the differential regulation of this
pathway by cAMP/PKA. These cells reportedly contain two different
isotypes of Raf, Raf-1 and B-Raf, which are differentially sensitive to
inhibition by cAMP. B-Raf expression can contribute to cell type-specific
differences in the regulation of the MAP kinase signalling pathway, most
probably due to the fact that the PKA consensus site found in the
regulatory domain of Raf-1 is not present in B-Raf (Sithanandam et al.,
1990). Erhardt et al., (1995) confirmed that Raf-1 was effectively inhibited
by cAMP in both PC-12 and Rat-1 cells independent of growth conditions.
Conversely, B-Raf was refractory to inhibition by cAMP in PC-12 cells
maintained in normal growth medium, although it was inhibited by
cAMP in serum-starved cells as previously reported (Peraldi et al., 1995,
Vaillancourt et al., 1994). These findings illustrate that the expression of
B-Raf is an important determinant of the differential responses of PC-12
and Rat-1 cells to cAMP. Moreover, this report also pointed out that
while expression of B-Raf in Rat-1 cells was sufficient to make the MAP
kinase pathway resistant to inhibition by cAMP, it did not make MAP
kinase inducible by cAMP alone. Interestingly, stimulation of C5a, FMLP
and IL-8 receptors by their respective ligands has been shown to trigger
the MAPK pathway in neutrophils through Ras/Raf-mediated events
(Knall et al., 1996). Knall and colleagues have therefore suggested that
these observations implicating the involvement of the MAP kinase
cascade may also provide a mechanism whereby host defence
mechanisms are co-ordinately regulated in the neutrophil, since these
chemoattractants are able to activate both neutrophil respiratory burst and
degranulation responses. Moreover, cell-permeable analogs of cAMP
potently but transiently inhibited Raf activation by FMLP in neutrophils
(Worthen et al., 1994). These results, when considered in conjunction
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with the many studies linking cAMP to inhibition of neutrophil function
(Chapter 6), might suggest that activation of Raf may be involved in those
functional responses.
Protein phosphatases have previously been shown to regulate apoptosis
in a variety of cell types. It has been demonstrated that okadaic acid and
calyculin A exert differential effects on apoptosis, for example inducing
cell death in leukemic cells (Boe et al., 1991, Ishida et al., 1992) and
inhibiting apoptosis in tumour cell lines (Baxter & Lavin, 1992). Our data
illustrate that okadaic acid has a bi-phasic effect upon the rate of
eosinophil and neutrophil apoptosis; with lower concentrations
inhibiting and higher concentrations promoting granulocyte apoptosis
(figure 5.4). In view of reports that okadaic acid inhibits PP2A at lower
concentrations and also, PP1 at higher concentrations (Berndt et al., 1987),
these data may suggest that the specific inhibition of PP2A regulates
inhibition of apoptosis whereas the collective inhibition of both PP2A
and PP1, is responsible for inducing the pro-apoptotic effect in these
granulocytes. Further experiments investigating the effect of calyculin A
(1-100 nM) upon the constitutive rate of neutrophil apoptosis
demonstrated that at the concentrations used, this protein phosphatase
inhibitor did not modulate apoptosis (figure 5.6). Further experiments
are necessary to determine whether lower concentrations of calyculin A
will mirror the effect of okadaic acid on neutrophil apoptosis.
Furthermore, although these results appear to contradict the bi-phasic
effect of okadaic acid on neutrophil apoptosis discussed previously,
several differences between these two protein phosphatase inhibitors may
account for these discrepancies. Calyculin A has been shown to be a more
effective inhibitor than okadaic acid of the catalytic subunit of protein
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phosphatase type-1, with reported IC50 values for calyculin A of about 2
nM compared with 60-500 nM for okadaic acid (Ishihara et al., 1989).
Consequently, calyculin A will collectively inhibit both PP1 and PP2A at a
much lower concentration than okadaic acid. It is therefore possible that
the concentrations of calyculin A (1-100 nM) used, equate to the
concentration of okadaic acid shown to have no effect upon the basal rate
of neutrophil apoptosis. Moreover, calyculin A has a similar potency for
type 1 and type 2A protein phosphatases (Ishihara et al., 1989), therefore
inhibition data with this compound do not discriminate between the
enzymes. In support of this hypothesis, the concentration of calyculin A
required to inhibit apoptosis (20 nM) in Burkitt's lymphoma cell line
BM13674 cells was considerably less than that reported previously for
okadaic acid (500 nM) (Song & Lavin, 1993).
We have also presented results illustrating that the protein phosphatase
inhibitor, okadaic acid, modulates glucocorticoid-mediated granulocyte
apoptosis, with a partial attenuation of the pro-apoptotic effect of
dexamethasone in eosinophils (figure 5.5A) and a complete attenuation
of dexamethasone-mediated inhibition of apoptosis in neutrophils (figure
5.5B). In addition, calyculin A (1-100 nM) was also shown to partially
attenuate dexamethasone-mediated inhibition of neutrophil apoptosis
(figure 5.6B). These results obtained using two inhibitors with a different
structure and potency, indicate that glucocorticoid-mediated inhibition of
neutrophil apoptosis requires the activity of a phosphatase sensitive to
both okadaic acid and calyculin A. Collectively these observations are
particularly exciting as they suggest that protein dephosphorylation may
be an important factor regulating glucocorticoid-induced apoptosis in
eosinophils and the down-regulation, by glucocorticoids, of neutrophil
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apoptosis. In support of the observed partial attenuation of the pro-
apoptotic effect of dexamethasone on eosinophil apoptosis by okadaic acid
(0.5 nM), Ohoka et al., (1993) have also demonstrated that okadaic acid
inhibits glucocorticoid-induced apoptosis in T cell hybridomas, indicating
that protein dephosphorylation is an essential step for glucocorticoid-
induced apoptosis in this cell system. While the okadaic acid-sensitive
step essential for apoptosis was not biochemically identified, Ohoka and
colleagues reported that this step is at the late stage of the apoptotic
process since the inhibitory effect of okadaic acid was shown not to be due
to either the interference of the translocation of GR or interference of GR
binding to GRE or transcription or translation of GRE-regulated genes.
Although the mechanism of glucocorticoid-mediated apoptosis is largely
unknown, phosphorylation and dephosphorylation has been suggested to
influence GR function (Schmidt & Litwack, 1982, Orti et al., 1989).
Moreover, GRs are themselves phosphoproteins whose phosphorylation
state is quantitatively altered by hormone treatment (Hoeck et al., 1989,
Orti et al., 1989) and may therefore be regulated by the protein
phosphatases type-1 and type-2A. Furthermore, in the rat GR, there is
evidence to suggest that PP2A and/or PP1 may act on a specific subset of
phosphorylation sites (DeFranco et al., 1991).
Finally by investigating the effect of calyculin A upon dexamethasone-,
LPS-, dibutyryl-cAMP- and GM-CSF-mediated inhibition of neutrophil
apoptosis in the same experiment, we have demonstrated that the partial
attenuation of dexamethasone-mediated inhibition of neutrophil
apoptosis by calyculin A appears to be specific to dexamethasone (figure
5.7). The absence of any modulation by calyculin A of dibutyryl-cAMP-
mediated inhibition of neutrophil apoptosis may seem surprising in view
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of the abundance of literature regarding the regulation of protein
phosphatases by cAMP (Cohen & Cohen, 1989). In the PKA pathway, the
balance between PKA activity and opposing protein phosphatases is
critical in determining the extent and duration of the response. PKA
helps its own cause by phosphorylating 1-1, thereby converting it into an
inhibitor of PP-1, which is the major protein phosphatase that acts on
PKA substrates. In the nucleus, there is a second PP1 inhibitor, NIPP-1,
which is in part associated with the catalytic subunit of PP1 (PP1C) and in
contrast with PP1, is active in the unphosphorylated state (Beullens et al.,
1992). Moreover, unlike 1-1, PKA-mediated phosphorylation of NIPP-1
decreases its activity as a PP1 inhibitor and causes dissociation of the PP1C
subunit leading to the dephosphorylation of nuclear proteins (figure 5.8).
PP2A can reverse this activation and hence specific inhibition of nuclear
PP2A with okadaic acid is expected to activate PP1 (Wera & Hemmings,
1995). It has been suggested that the ability of PP2A to reverse PP1C
activation may account for why inhibition of PP2A (through okadaic acid
treatment) leads to phosphorylation of certain nuclear phosphoproteins
(Paulson et al., 1994), although an indirect effect of okadaic acid on protein
kinases has not been excluded (Wera & Hemmings, 1995).
One of the major nuclear PKA substrates is the transcription factor CREB
(Lalli & Sassone-Corsi, 1994); the phosphorylation of which is discussed in
Chapter 6. PP1 and PP2A have been implicated in the dephosphorylation
of CREB (figure 5.9), which is accompanied by decreased transcription of
cAMP-responsive genes (Hagiwara et al., 1992). In some cells, such as PC-
12 cells, PP1 is the major protein phosphatase that dephosphorylates
CREB on pSer-133 (Hagiwara et al., 1992), whereas in other cells such as
HepG2 hepatoma cells CREB dephosphorylation in nuclear extracts has
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been shown to be catalysed by a specific holoenzyme of PP2A (Wadzinski
et al., 1993).
It has been suggested that the protein phosphatases responsible for CREB
dephosphorylation differ in different cell types, depending on the
abundance of PP1 inhibitors and on relative levels of PP1 and PP2A in the
nucleus (Hunter, 1995). In addition, PP5, a newly identified member of
the PP1/PP2A family, is localised in the nucleus and this protein
phosphatase could also play a role in phospho-CREB dephosphorylation









Figure 5.8. A possible mechanism for the control of nuclear PP1
The catalytic subunit (PP1C) of the latent nuclear PP1 enzyme is
complexed with the inhibitor NIPP-1. Phosphorylation of NIPP-1 by PKA
relieves the inhibition of PP1C, and leads to dephosphorylation of nuclear
proteins (X). PP2A reverses the effect. (Diagram modified from Wera &
Hemmings, 1995.)
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Figure 5.9. A schematic illustration of the protein kinases and protein
phosphatases that regulate activation of the CREB transcription factor.
Abbreviations: AC, adenylyl cyclase; G, G-proteins; CREB, cyclic AMP
-response element binding protein; CRE, cyclic AMP-response element; I-
1, protein phosphatase-1 inhibitor; NIPP-1, nuclear protein phosphatase-1
inhibitor. (Modified diagram from Hunter, 1995)
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phosphorylation is complicated by the fact that other protein kinases can
phosphorylate CREB at Ser-133 and provide cAMP-independent
regulation. The Ca2+-calmodulin-stimulated protein kinases, CaMKII
and CaMKIV (Dash et al., 1991, Sheng et al., 1991) provide one such
example and in principle phosphorylation of these Ca2+-calmodulin-
directed kinases could explain how elevated intracellular Ca2+ induces
CREB Ser-133 phosphorylation and activates CRE-regulated genes such as
c-fos. Moreover, CaMKII phosphorylates not only the activating Ser-133
but also Ser-142, which inhibits CREB activity (Sun & Tonks, 1994). It has
been suggested that this phosphorylation could therefore be responsible
for down-regulating CRE-mediated transcription upon elevation of Ca2+
in conjuction with PP2B (or calcineurin) which is activated by Ca2+-
calmodulin and can dephosphorylate pSer-133 (Hunter, 1995). In contrast
to this marked association between cAMP and PP1/PP2A, Gjertsen and
colleagues have reported that in IPC-81 cells, a leukemia cell line, okadaic
acid and activation of PKA, both of which independently induce
apoptosis in this cell line, appear to work through different pathways.
They have shown that a mutant IPC subclone, defunct of cAMP response,
was as sensitive to okadaic acid as the wild-type IPC cells (Gjertsen et al.,
1994). Moreover, the PKA inhibitor H-8 protected against cAMP-induced
cell death while enhancing okadaic acid induced death, suggesting
synergism. Furthermore, different proteins were induced and
phosphorylated in IPC cells exposed to calyculin A, okadaic acid and
increased cAMP. These findings are particularly germane when
comparing the protein phosphatase inhibitor-mediated attenuation of
dexamethasone-induced inhibition of neutrophil apoptosis with the
results presented in Chapter 6. It is therefore possible in our system that
okadaic acid and calyculin A phosphorylate different substrate proteins to
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those phosphorylated by PKA and hence may explain why both protein
phosphorylation and dephosphorylation can result in modulation of
dexamethasone-mediated inhibition of neutrophil apoptosis.
Finally, the results regarding the involvement of protein phosphatases
presented in this chapter should be interpreted with caution. While there
is no doubt that increasing evidence suggests a role for phosphatase
activity in the regulation of apoptosis, it is possible that the protein
phosphatase inhibitors, okadaic acid and calyculin A at higher
concentrations (100-1000 nM), in intact cells, may have actions on other
protein phosphatases or other as yet unidentified targets. Furthermore,
the broad substrate specificity of PP2A and PP1 (Cohen & Cohen, 1989)
means that the phosphoprotein(s) presumably mediating the apoptotic
process cannot yet be identified using these pharmacological reagents.
However some interesting proteins, whose activity state or
phosphorylation state are known to be increased by okadaic acid, are the
p34crfc2/Hl kinase (Yamashita et al., 1990) and the nucleolin fragment, N-
60 (Issinger et al., 1988).
In this chapter we have referenced several parallel pathways leading to
activation of different subsets of MAPKs, although the extent to which
there is cross-talk between these pathways is unknown (Denhardt, 1996).
It is however likely that additional signalling cascades remain to be
defined in mammalian cells in light of the emerging pathways in yeast,
such as MEK5 (English et al., 1995). It is clear, however, that cellular
control cannot be achieved by collections of linear signal transduction
pathways alone; mechanisms for integrating pathways and generating
interactions between pathways are required. The complexity of the
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protein phosphorylation and dephosphorylation networks is growing and
elucidating the outputs becomes an increasingly daunting task, especially
given the cell-type specificities, some of which have been discussed in this
chapter. However, the data presented do suggest the involvement of the
MAPK/ERK cascade and protein phosphatases in the regulation of some
aspects of granulocyte apoptosis.
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Chapter 6
The role of PKA (cAMP-dependent protein kinase) in basal and
glucocorticoid-mediated granulocyte apoptosis
6.1 Introduction
The ubiquitous role of cAMP as an intracellular 'second messenger' is
now well established. This cyclic nucleotide mediates many physiological
responses, including growth and differentiation, and has a modulatory
effect on many immune mechanisms (Parker, 1979, Kammer, 1988,
Haraguchi et al., 1995). Historically, cAMP has been viewed primarily as a
negative regulator of immune responses (Kammer, 1988). This has been
based on a variety of studies which have demonstrated that cAMP
analogs, employed in the high micromolar and low millimolar
concentration range, inhibit both B- and T-cell function. More recently,
however, cAMP has been shown to enhance a number of immune
responses including IL-2 production (Chakkalath & Jung, 1992) and
receptor expression (Scholz & Altman, 1989), lymphocyte proliferation
(Vazquez et al., 1991, Chakkalath & Jung, 1992, Whisler et al., 1992),
antibody production (Gilbert & Hoffmann, 1985) and NF-A:B activation
(Shirakawa & Mizel, 1989). Moreover, several reports suggest that
different cell-type subsets, such as in the case of T-cells, possess differential
sensitivity to cAMP (Novak & Rothenberg, 1990, Gajewski et al., 1990,
Phipps et al., 1991). These observations are indicative of cAMP as both a
positive and negative regulatory molecule and it is now generally
accepted that in immune responses, cAMP exhibits positive regulatory
influences at low concentrations and inhibitory influences at high
concentrations (Feuerstein et al., 1996, Koh et al., 1995).
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Previous work has established a correlation between an increase in the
cAMP level and apoptosis in mammalian epithelial cells and certain
plant cells (Pratt & Martin, 1975, Basile et al., 1973). More recent reports
have now emerged, also illustrating that elevation of cAMP promotes
apoptosis in a variety of cell types including thymocytes (McConkey et al.,
1990b, Suzuki et al., 1991, Mastino et al., 1992, Mentz et al., 1995), myeloid
cell lines such as IPC-81 (Lanotte et al., 1991), WEH17.2 murine
lymphocytes (Dowd & Miesfeld, 1992), ovarian surface epithelial cells
(Ackerman & Murdoch, 1993), primary granulosa cells (Aharoni et al.,
1995), rat IPC-81 promyelocytic leukemia cells (Vintermyr et al., 1993), and
B lymphocytes (Lomo et al., 1995, Brown et al., 1992). However the
mechanisms by which cAMP influences granulocyte apoptosis and the
effect of cAMP-elevating agents or activation of PKA on these cells,
remain ill defined.
Elevation of intracellular cAMP is known to inhibit the activation of
many pro-inflammatory immune effector cells (Elwood et al., 1995),
including neutrophils, resulting in the suppressed release of eicosanoids
and other inflammatory mediators, and the inhibition of neutrophil
functions such as agonist-stimulated superoxide release (Kuehl et al.,
1987, Schudt et al., 1991a; 1991b) and enzyme release (Rossi & O'Flaherty,
1989). Moreover cAMP can regulate certain eosinophilic functions such
as the inhibition of degranulation (Kita et al., 1991b), leukotriene C4
production (Munoz et al., 1994), thromboxane generation (Souness et al.,
1994) and suppress the respiratory burst response of human eosinophils
(Dent et al., 1994) and of both guinea pig peritoneal eosinophils (Dent et
al., 1991, Souness et al., 1991) and macrophages (Turner et al., 1993). In
view of this inhibitory action upon inflammatory cells, it has been
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suggested that agents capable of elevating cAMP levels in such cells (e.g.,
phosphodiesterase (PDE) inhibitors) may have therapeutic potential in
inflammatory diseases such as bronchial asthma (Torphy & Undem, 1991,
Giembycz, 1992, Giembycz & Dent, 1992). It is now recognised that cyclic
nucleotide PDE is not a single enzyme but constitutes a diverse group of
structurally distinct proteins, that have been broadly categorised into at
least seven isoenzyme families. The involvement of cAMP in the
intracellular actions of (3 adrenoceptor agonists has been well established.
PDE inhibition provides an alternative approach to elevating cAMP
levels with the aim of combining the bronchodilator actions of P2-
adrenoceptor agonists with anti-inflammatory attributes (Dent &
Giembycz, 1996).
We have previously highlighted the importance of apoptosis in the
resolution of the inflammatory response (Savill et al., 1989a, Stern et al.,
1992), in particular limiting tissue injury and promoting wound repair.
In light of the current literature, we investigated the direct effects of
cAMP-elevating agents and the role of PKA in basal and glucocorticoid-
modulated eosinophil and neutrophil apoptosis.
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6.2 Results
6.2.1 Effect of cAMP-elevating agents on the rate of eosinophil and
neutrophil apoptosis
Eosinophils (2x106/ml) cultured in serum-supplemented Iscove's DMEM
showed an inhibition in the light microscopic features of apoptosis in the
presence of 0.2 mM dibutyryl-cAMP (Figure 6.1A). Similarly, treatment of
neutrophils (2x106/ml) with cAMP-elevating agents also inhibited the
rate of apoptosis (Figure 6.1B). These results indicate that cell permeable
cAMP analogs (2 mM dibutyryl-cAMP and 2 mM 8-Br-cAMP) and PG
mimetics, specifically the PGD2 mimetic, ZK 118.182 (30 pM) and the PGE2
mimetic, 11-deoxy PGEi (30 |J.M), all result in down-regulation of
neutrophil apoptosis. Assessment of cell viability and recovery, in both
cell types, demonstrated that treatment with these reagents did not
significantly alter either of these parameters. Figure 6.2 illustrates the
time-course of dibutyryl-cAMP (0.2 mM) and ZK 118.182 (30 |iM) induced
inhibition of neutrophil apoptosis. After 30 h, the proportion of cells
admitting trypan blue in the control population of neutrophils increased
rapidly, indicating the onset of secondary cellular necrosis in the 'post-
apoptotic' population of cells. However, in the presence of dibutyryl-
cAMP and ZK 118.182, cells displayed a high viability (>90%) and the
onset of significant necrosis was delayed until the 40 h time period. These
results illustrate that agents elevating the intracellular levels of cAMP,

































Figure 6.1 Effect of cAMP-elevating agents on the rate of eosinophil (A)
and neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were cultured for 20 and 40 h, in serum-
supplemented Iscove's DMEM either alone (control) or in the presence of
dibutyryl-cAMP (0.2 mM). At the time periods indicated, cells were
harvested and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3 separate experiments, each performed in
triplicate (* p<0.05 compared with control values). B, Neutrophils
(2xl06/ml) were cultured in serum-supplemented Iscove's DMEM either
alone (control) or in the presence of the PG mimetics, ZK 118.182 (30 pM)
and 11-deoxy PGEi (30 pM) or the cAMP analogs, dibutyryl-cAMP (2 mM)
and 8-Br-cAMP (2 mM). Neutrophils were harvested following 20 h in
culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3-6 separate experiments, each performed in
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Figure 6.2 Time course for the effect of cAMP-elevating agents on the rate
of neutrophil apoptosis.
Neutrophils (2xl06/ml) were incubated in serum-supplemented Iscove's
DMEM either alone (control) or in the presence of dibutyryl-cAMP (0.2
mM) or ZK 118.182 (30 (iM). At the time periods indicated, cells were
harvested and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 4 separate experiments, each performed in
triplicate (* p<0.05 compared with control values).
6.2.2 Involvement of PKA in eosinophil and neutrophil apoptosis
In light of the findings that cAMP-elevating agents delay apoptosis in
both eosinophilic and neutrophilic granulocytes, we were interested in
investigating the role of PKA in basal (constitutive) and dibutyryl-cAMP-
delayed granulocyte apoptosis. Figure 6.3 illustrates the effect of the PKA
inhibitor, H-89, on the rate of eosinophil (A) and neutrophil (B)
apoptosis. H-89 per se did not alter the rate of apoptosis in either
granulocyte type as compared to the control cell population, suggesting
that the basal turnover of cAMP and subsequent activation of PKA may
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not be an important factor in regulating the constitutive rate of apoptosis.
However, the range of concentrations of H-89 used varied between the
two cell types. A high proportion of eosinophils admitted trypan blue
when cultured with concentrations of H-89 >10 pM, suggesting that this
concentration of the PKA inhibitor was toxic to the cell and therefore
induced cell necrosis. In contrast, H-89 (0.01-100 pM) did not induce
cellular necrosis in neutrophils with the viability reproducibly being
>90% at the time periods indicated in figure 6.4B.
The effect of H-89 on dibutyryl-cAMP-mediated inhibition of eosinophil
(A) and neutrophil (B) apoptosis is illustrated in figure 6.4. Initial
experiments were carried out, to compare the results obtained from pre-
incubating cells with H-89 for 30 min at 37°C before addition of dibutyryl-
cAMP, with simultaneous addition or co-culture of these reagents. No
significant difference between the results was detected (data not shown).
For convenience, all experiments involving H-89 were subsequently
carried out by co-culture. H-89 (1-10 |iM) was shown to have no effect on
dibutyryl-cAMP-induced inhibition of eosinophil apoptosis (figure 6.4A),
suggesting that cAMP-mediated inhibition of eosinophil apoptosis may
not be modulated by PKA activation. In contrast to the effects observed
on eosinophils, H-89 (10-100 pM) was shown to attenuate dibutyryl-
cAMP-induced inhibition of neutrophil apoptosis in a concentration-
dependent manner, with a partial reversal of the inhibitory effect seen at
a concentration of 10 pM H-89, followed by a complete reversal of the
inhibitory effect at a concentration of 100 pM H-89 (figure 6.4B). H-89
(0.01-100 pM) alone was shown to have no effect on the basal rate of


















































Figure 6.3 Effect of H-89 on the rate of eosinophil (A) and neutrophil (B)
apoptosis.
A, Eosinophils (2x106/ml) were cultured for 20 and 40 h, in serum-
supplemented Iscove's DMEM either alone (control) or in the presence of
H-89 (1-10 |iM). At the time periods indicated, cells were harvested and
assessed for morphological features of apoptosis. Data represent mean ±
SEM of 4 separate experiments, each performed in duplicate. B,
Neutrophils (2xl06/ml) were cultured for 8 and 20 h, in serum-
supplemented Iscove's DMEM either alone (control) or in the presence of
H-89 (0.01-100 jiM). At the time periods indicated, cells were harvested
and assessed for morphological features of apoptosis. Data represent
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Figure 6.4 Effect of H-89 on dibutyryl-cAMP-mediated inhibition of
eosinophil (A) and neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were incubated in serum-supplemented
Iscove's DMEM either alone (control) or with dibutyryl-cAMP (0.2 mM),
in the presence and absence of H-89 (1-10 (iM). Eosinophils were
harvested following 20 and 40 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 3-4
separate experiments, each performed in duplicate (* p<0.05 compared
with control values). B, Neutrophils (2xl06/ml) were incubated for 20 h,
in serum-supplemented Iscove's DMEM either alone (control) or with
dibutyryl-cAMP (0.2 mM), in the presence and absence of H-89 (0.01-100
|iM). At the time periods indicated, cells were harvested and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 3
separate experiments, each performed in duplicate (* p<0.05 compared
with control values).
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For this reason only one concentration of H-89 (100 pM) alone is
illustrated in figure 6.4B. These results suggest that cAMP-mediated
inhibition of neutrophil apoptosis is signalled by PKA activation. These
data are particularly exciting because although cAMP-elevating agents
inhibit apoptosis in both eosinophils and neutrophils, the intracellular
regulatory mechanisms appear to be different. In eosinophils, our results
suggest that elevation of intracellular cAMP levels inhibit apoptosis by a
PKA-independent mechanism. However, in contrast cAMP-induced
inhibition of neutrophil apoptosis is mediated by a PKA-dependent
mechanism.
6.2.3 Involvement of PKA in dexamethasone-mediated eosinophil and
neutrophil apoptosis
The intriguing nature of the results illustrated in section 6.2.2 created
interest into the possible involvement of PKA as an intracellular
regulatory signalling pathway mediating dexamethasone-modulated
granulocyte apoptosis. To investigate whether dexamethasone modulates
apoptosis via PKA activation, dexamethasone (1 pM) was co-cultured
with various concentrations of H-89. Figure 6.5A illustrates that H-89 (1-
10 pM) does not modulate the pro-apoptotic effect of dexamethasone
upon eosinophil apoptosis at the time periods indicated. These results
suggest that dexamethasone mediates eosinophil apoptosis via a PKA-
independent mechanism. However, in contrast to the effects observed on
eosinophils, H-89 (10-100 pM) was shown to attenuate dexamethasone-
mediated inhibition of neutrophil apoptosis in a concentration-
dependent manner, with a partial reversal of the inhibitory effect seen at
a concentration of 10 pM H-89, followed by a complete reversal of the
inhibitory effect at a concentration of 100 pM H-89 (figure 6.5B). H-89
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(0.01-100 pM) alone was shown to have no effect on the basal rate of
neutrophil apoptosis, as previously demonstrated in figure 6.3B. For this
reason only one concentration of H-89 (100 pM) is illustrated in figure
6.5B. This pattern of attenuation by H-89 on dexamethasone-mediated
inhibition of neutrophil apoptosis mirrors precisely the results illustrated
in figure 6.4B. Interestingly, at the same concentration that H-89
attenuates dibutyryl-cAMP-induced inhibition of neutrophil apoptosis,
this PKA inhibitor also attenuates dexamethasone-mediated inhibition of
neutrophil apoptosis. These results suggest that dexamethasone-
mediated inhibition of neutrophil apoptosis may be mediated by PKA
activation.
6.2.4 Involvement of PKA in LPS-induced inhibition of neutrophil
apoptosis
We have demonstrated that both dexamethasone and dibutyryl-cAMP
inhibit neutrophil apoptosis and that this inhibitory effect is attenuated by
co-culture of these agents with the PKA inhibitior, H-89. To investigate
the specificity of these results, LPS (1 pg/ml), another agent known to
inhibit the rate of neutrophil apoptosis (Lee et al., 1993) was co-cultured
for 20 h in the presence of H-89 (10 pM). The concentration of H-89 (10
pM) that was chosen for use in these experiments was sufficient to
observe a partial but significant attenuation of the inhibitory effect
mediated by both dexamethasone and dibutyryl-cAMP. Figure 6.6
illustrates that H-89 (10 pM) had no effect on the basal rate of neutrophil
apoptosis and did not modulate LPS-induced inhibition of neutrophil
apoptosis. However, in the same experiments, H-89 (10 pM) significantly
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Figure 6.5 Effect of H-89 on dexamethasone-mediated eosinophil (A) and
neutrophil (B) apoptosis.
A, Eosinophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with dexamethasone (1 fiM), in the
presence and absence of H-89 (1-10 pM). Eosinophils were harvested
following 20 and 40 h in culture and assessed for morphological features
of apoptosis. Data represent mean ± SEM of 4 separate experiments, each
performed in duplicate (* p<0.05 compared with control values). B,
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with dexamethasone (1 pM), in the
presence and absence of H-89 (0.01-100 pM). Neutrophils were harvested
following 20 h in culture and assessed for morphological features of
apoptosis. Data represent mean ± SEM of 3-6 separate experiments, each
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Figure 6.6 Effect of H-89 on LPS-induced inhibition of neutrophil
apoptosis.
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with LPS (1 pg/ml), in the presence and
absence of H-89 (10 pM). Neutrophils were harvested following 20 h in
culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 3 separate experiments, each performed in
duplicate (* p<0.05 compared with control values).
These data argue against the possibility that H-89 has non-specific effects
leading to attenuation of all agents that inhibit the rate of neutrophil
apoptosis.
6.2.5 Cross-talk between Ca2+ and PKA signalling pathways
Given that cAMP-induced thymocyte apoptosis may be a Ca2+-dependent
process (McConkey et al., 1990b) and in light of the results presented in
Chapter 4, in which the calcium ionophore, A23187 (0.1 pM) was shown
to inhibit the rate of neutrophil apoptosis, we investigated whether H-89
would modulate this inhibitory effect, suggesting the possibility of 'cross¬
talk' between calcium and PKA intracellular signalling pathways. Figure
6.7 illustrates that co-culture of neutrophils with A23187 (0.1 pM) and H-
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89 (10 pM) did not modulate the inhibition observed in the presence of
A23187 alone. H-89 (10 pM) was again shown to attenuate
dexamethasone- and dibutyryl-cAMP-mediated inhibition of neutrophil







Figure 6.7 Effect of H-89 on A23187-induced inhibition of neutrophil
apoptosis.
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with A23187 (0.1 pM), in the presence
and absence of H-89 (10 pM). Neutrophils were harvested following 8 h
in culture and assessed for morphological features of apoptosis. Data
represent mean ± SEM of 4 separate experiments, each performed in
duplicate (* p<0.05 compared with control values).
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Figure 6.8 illustrates the effect of the intracellular Ca2+ chelator,
BAPTA/AM (2.5 pM), on dibutyryl-cAMP (0.2 mM)-mediated inhibition
of neutrophil apoptosis. The results demonstrate that BAPTA/AM (2.5
pM) did not modulate the inhibition observed in the presence of
dibutyryl-cAMP (0.2 mM) alone. An earlier time point of 8 h was chosen
for the experiments illustrated in figures 6.7 and 6.8, given that they were
carried out as one experiment using the same blood donors, involving
use of the reagent BAPTA/AM, which exerts a pro-apoptotic effect upon
the rate of neutrophil apoptosis. An earlier time period therefore
facilitates easy detection of changes in apoptotic morphology, as explained
in Chapter 4 (section 4.2.3). Collectively, these data argue against the
possibility of direct 'cross-talk' between calcium and PKA signalling
pathways and suggest that these signalling cascades may act
independently to regulate neutrophil apoptosis.
Figure 6.8 Effect of BAPTA/AM on dibutyryl-cAMP-mediated inhibition
of neutrophil apoptosis.
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with A23187 (0.1 pM) and dibutyryl-
cAMP (0.2 mM), in the presence and absence of BAPTA/AM (2.5 pM).
Neutrophils were harvested following 8 h in culture and assessed for
morphological features of apoptosis. Data represent mean ± SEM of 4
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6.2.6 Effect of dibutyryl-cAMP on dexamethasone-mediated inhibition of
neutrophil apoptosis
We have reported the dramatic inhibitory effects that both
dexamethasone and dibutyryl-cAMP individually induce on the rate of
neutrophil apoptosis. To investigate whether a common inhibitory
mechanism is used by these agents, we studied the effect of co-culturing
dibutyryl-cAMP and dexamethasone on the rate of neutrophil apoptosis.
Figure 6.9 shows that when neutrophils are cultured in the presence of
both dexamethasone and dibutyryl-cAMP their individual inhibitory
effects are less than additive, suggesting that these reagents inhibit
neutrophil apoptosis possibly by the same pathway. However, further
experiments involving much wider concentration ranges of both agents
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Figure 6.9 Effect of dibutyryl-cAMP on dexamethasone-mediated
inhibition of neutrophil apoptosis.
Neutrophils (2xl06/ml) were cultured for 8 and 20 h, in serum-
supplemented Iscove's DMEM either alone (control) or with
dexamethasone (1 pM), in the presence and absence of dibutyryl-cAMP
(0.2 mM). At the time periods indicated, cells were harvested and
assessed for morphological features of apoptosis. Data represent mean ±
SEM of 3 separate experiments, each performed in duplicate (* p<0.05
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6.2.7 Measurement of PKA activity in neutrophils
Using the pharmacological PKA inhibitor, H-89, we have presented
results suggesting that dexamethasone-mediates the inhibition of
neutrophil apoptosis by a PKA-dependent mechanism. We therefore
investigated the A-kinase isoenzyme profile present within neutrophils
and measured PKA activity directly in response to dexamethasone
treatment. A-kinase isoenzymes present in the soluble fraction of freshly
isolated neutrophils were separated by anion-exchange chromatography
over Q-sepharose and the relative proportions of each class were
determined using kemptide as a substrate (Giembycz & Diamond, 1990).
The specific eicosa-peptide A-kinase inhibitor (IP20) was used to ensure
that kemptide was phosphorylated specifically by soluble PKA (Cheng et
al., 1986), as indicated by the ability of IP20 to abolish cAMP-stimulated
phosphokemptide formation (figure 6.10). Thus, figure 6.10 illustrates
that analysis of cAMP-stimulated, IP20-sensitive phosphotransferase
activity revealed two main peaks eluting at 128 mM (type I) and 216 mM
NaCl (type II), with the approximate type I:type II isoenzyme percentage
ratio being 73:27 respectively. The observation that human neutrophils
contain a mixture of both type I and type II A-kinase isoenzymes,
suggested that in the PKA assay method, buffers with an intermediary
ionic strength of 100 mM would be optimal for the dissociation and
reassociation kinetics of A-kinase (see Discussion). The subcellular
distribution of cAMP-dependent protein kinase in neutrophils is shown
in table 6.1 and these results illustrate that the intracellular distribution of
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Figure 6.10 A-kinase isoenzyme elution profile of the cytosol fraction of
neutrophils.
Lysates of freshly isolated neutrophils (200x106) were applied to a column
of Q-sepharose and A-kinase enzymes were eluted with a linear NaCl
gradient, running from 0 to 320 mM. IP20-sensitive (o) A-kinase activity
was then estimated in the absence (0) and presence (□) of cyclic AMP (10
jj,M) using kemptide as the substrate, as described in Materials and
Methods (Chapter 2). Values denoted by the symbols refer to pmol of [y-
32P]ATP transferred to kemptide per minute per ml. The results




Soluble 76.3 ± 28.0
Particulate 48.6 ± 26.0
Table 6.1 Subcellular distribution of cAMP-dependent protein kinase in
neutrophils.
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM alone. After 20 h, cells were harvested and divided into 2
samples. Sample (1) was lysed for 30 min in buffer A containing 1%
Triton X-100, to form the soluble fraction and sample (2) was lysed for 30
min in buffer A in the absence of Triton X-100. Sample (2) was then
centrifuged (31000 g, 30 min) at 4°C, to form the particulate fraction. A-
kinase activity was then estimated for the soluble and particulate
untreated fractions, as described in Materials and Methods (Chapter 2).
Data represent mean ± SEM of 3 separate experiments, each performed in
triplicate.
Figure 6.11 illustrates the effect of dexamethasone on the activation state
of PKA. Treatment of neutrophils with dexamethasone (1 pM for 20 h)
increased the basal PKA activity ratio from 0.33 ± 0.05 to 0.41 ± 0.06,
(p<0.05, n=4). Similarly, neutrophils co-cultured in the presence of PGE2
(1 pM) and IBMX (100 pM), as a positive control, for 1 h, after 19 h in
culture previously untreated (from 19 to 20 h), increased the basal PKA
activity ratio from 0.33 ± 0.05 to 0.69 ± 0.03, (p<0.05, n=4). The percentages
of apoptosis in identical cultures were assessed morphologically as:











Figure 6.11 Effect of dexamethasone on the PKA activity ratio of
neutrophils.
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone (control) or with dexamethasone (1 pM) for 20 h, or
alternatively in the presence of both PGE2 (1 pM) and IBMX (100 pM) for
Ih (from 19 to 20 n). Neutrophils were harvested following 20 h in
culture and the PKA activity ratio was subsequently estimated as
described in Materials and Methods. Data represent mean ± SEM of 4
separate experiments, each performed in triplicate (* p<0.05 compared
with control values).
These results illustrate that dexamethasone may inhibit neutrophil
apoptosis by a mechanism involving an increase in PKA activity.
Moreover the results expressed in table 6.2 show that the increase in the
PKA activity ratio is specifically mediated via the glucocorticoid receptor,
since RU38486 (10 pM) attenuated the increase in PKA activity induced by
dexamethasone.
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Treatment PKA Activity Ratio
(pmol/min/106 cells)
Control 0.28 ± 0.01
Dexamethasone (1 pM) 0.33 ± 0.04
PGE2 (1 pM) + IBMX (100 pM) 0.73 ± 0.37
RU38486 (10 pM) 0.29 ± 0.01
RU38486 (10 pM) + Dexamethasone (1 pM) 0.25 ± 0.04
Table 6.2 Effect of co-culturing neutrophils with RU38486 and
dexamethasone on the PKA activity ratio.
Neutrophils (2xl06/ml) were cultured in serum-supplemented Iscove's
DMEM either alone or in the presence of dexamethasone (1 pM for 20 h),
PGE2 (1 pM) and IBMX (100 pM) (for 1 h, after 19 h in culture previously
untreated), RU38486 (10 pM for 20 h) or co-cultured with RU38486 and
dexamethasone (10 pM and 1 pM respectively for 20 h). After 20 h, cells
were harvested and the PKA activity ratio was subsequently estimated as
described in Materials and Methods (Chapter 2). Data represent mean of
an individual experiment, performed in triplicate.
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6.3 Discussion
We have demonstrated that cAMP-elevating agents inhibit granulocyte
apoptosis (figure 6.1), whereas in a number of other cell types increases in
the intracellular levels of cAMP have been associated with the induction
of apoptosis (McConkey et al., 1990b, Lanotte et al., 1991). In the case of the
neutrophil, we have illustrated that elevation of cAMP, through
independent mechanisms, using cell permeable cAMP analogs (dibutyryl-
cAMP and 8-Br-cAMP), receptor agonists (ZK 118.182 and 11-deoxy PGEi)
and direct activation of adenylyl cyclase (forskolin), all result in the down-
regulation of neutrophil apoptosis (Results and Rossi et al., 1995).
Dibutyryl-cAMP-induced inhibition of eosinophil apoptosis was found to
be mediated by a mechanism that was insensitive to H-89 and therefore
PKA-independent (figure 6.4A). H-89 alone had no significant effect upon
the rate of eosinophil apoptosis at concentrations up to 10 pM, suggesting
that basal turnover of cAMP may not be an important factor in regulating
eosinophil apoptosis. However, since we have not identified a positive
control showing that H-89 is accessing and functioning in eosinophils,
these data should be interpreted with caution. Nevertheless, these
observations are consistent with the recent findings by Hallsworth and
colleagues, who have reported that cholera toxin, which elevates cAMP
by interacting with Gs and dibutyryl-cAMP, a cell permeable analog of
cAMP, prolonged eosinophil survival in the absence of GM-CSF by a
PKA-independent mechanism (Hallsworth et al., 1996). Moreover, they
demonstrated that these cAMP-elevating agents have the ability to
overcome the protective effect of GM-CSF on eosinophil apoptosis,
suggesting that cAMP is able to interfere with the anti-apoptotic signals
induced by GM-CSF. The mechanism of inhibition of GM-CSF-induced
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cell survival by cAMP, was shown to be PKA-dependent since addition of
H-89 to eosinophils cultured with GM-CSF and cholera toxin attenuated
the effect of cholera toxin on eosinophil survival. However, the
mechanism by which GM-CSF prolongs eosinophil survival was shown
not to be related to detectable reductions in cAMP levels within the cell.
Although PKA is known to mediate many of the biological responses of
cells to cAMP, PKA-independent events have been reported involving
the direct binding of cAMP (Piper et al., 1993, DiFrancesco & Tortora, 1991)
and there is also evidence that cAMP can activate PKG (Lincoln et al.,
1990). However, Hallsworth and colleagues have shown in their study,
that dibutyryl-cGMP, a cell permeable cGMP analog, did not affect
eosinophil survival under any condition, indicating that cAMP does not
mediate its effects by activation of PKG in human eosinophils
(Hallsworth et al., 1996). Similarly in neutrophils, dibutyryl-cGMP (0.2
mM) does not affect the control rate of apoptosis or indeed modulate
dexamethasone-mediated neutrophil apoptosis (n=3): control, 52.7 ±
17.5%; dibutyryl-cGMP (0.2 mM), 52.3 ± 18.3%; dexamethasone (1 (J.M), 22.6
± 11.1%; co-culture of dibutyryl-cGMP (0.2 mM) and dexamethasone (1
pM), 21.1 ± 7.0%. The mechanism underlying cAMP-mediated inhibition
of eosinophil apoptosis is therefore unknown and is an exciting finding
requiring further work.
In contrast, dibutyryl-cAMP-induced inhibition of neutrophil apoptosis
was found to mediated by a mechanism that was sensitive to H-89 and
therefore probably PKA-dependent (figure 6.4B). H-89 alone had no
significant effect upon the rate of neutrophil apoptosis suggesting that the
basal turnover of cAMP may not be important in the regulation of
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neutrophil apoptosis. In summary, we have shown that cAMP-elevating
agents inhibit eosinophil apoptosis by a PKA-independent mechanism
and inhibit neutrophil apoptosis by a PKA-dependent mechanism. These
results illustrate yet again that eosinophils and neutrophils are regulated
differently.
We were therefore interested in investigating the effect of H-89 on
glucocorticoid-mediated granulocyte apoptosis (figure 6.5). Interestingly,
the same pattern of PKA-independency in eosinophils and dependency in
neutrophils was observed. In eosinophils, the pro-apoptotic effect of
dexamethasone was shown to be insensitive to H-89, therefore suggesting
that dexamethasone up-regulates eosinophil apoptosis by a PKA-
independent mechanism. However, this mechanism could still involve
dexamethasone-induced alterations in cAMP levels within the cell, since
dibutyryl-cAMP-modulated eosinophil apoptosis was also shown to be
PKA-independent. In neutrophils, the anti-apoptotic effect of
dexamethasone was shown to be sensitive to H-89 and was attenuated at
concentrations of H-89 >10 |iM. This result is particularly exciting and
suggests that the mechanism of dexamethasone-mediated inhibition of
neutrophil apoptosis may be PKA-dependent. The PKA-dependency of
glucocorticoid-mediated inhibition of neutrophil apoptosis was shown to
be specific to dexamethasone since other agents known to inhibit
neutrophil apoptosis such as LPS (figure 6.6) and the calcium ionophore,
A23187 (figure 6.7) were not sensitive to H-89. Moreover, we have
illustrated that in the neutrophil there is no evidence of direct cross-talk
between Ca2+ and cAMP-dependent intracellular signalling pathways
governing apoptosis (figures 6.7 and 6.8). This is in contrast to cAMP-
induced thymocyte apoptosis, which although does not involve an
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increase in intracellular Ca2+ levels, is a Ca2+-dependent process, as the
presence of intracellular Ca2+ chelators inhibits the cAMP effect
(McConkey et al., 1990b). Moreover, reported synergistic chloride
secretory responses as a result of combined treatment with agents that
increase either cAMP or cytosolic Ca2+, in Ts4 human colonic epithelial
cells and rat pancreatic acinar cells, suggest cross-talk between Ca2+ and
cAMP-dependent signalling pathways at the level of second messenger
generation (Vajanaphanich et al., 1995). Furthermore, less than additive
inhibition of neutrophil apoptosis observed in the presence of both
dibutyryl-cAMP and dexamethasone (figure 6.9), suggests that these
reagents inhibit neutrophil apoptosis by the same mechanism. Although
we have not directly monitored cAMP levels, these data may suggest that
dexamethasone-mediates neutrophil apoptosis by PKA activation. In
support of this hypothesis, cAMP elevation by PGE2 or forskolin, and the
glucocorticoid, methylprednisolone have been reported to enhance each
others effects on DNA fragmentation and viability in mouse thymocytes
(McConkey et al., 1993).
The formation of cAMP within a cell results from the complex
interaction of receptors, G-proteins and adenylyl cyclase (Levitzki, 1988).
Interactions among the components of this signalling cascade dictate the
magnitude of the intracellular formation of cAMP, and thereby provide
several loci where glucocorticoids may exert their regulatory influence.
For example, the gene for the human ^-adrenoceptor which is expressed
in all types of lymphocytes to stimulate cAMP formation (Brodde et al.,
1987, Maisel et al., 1989) contains a glucocorticoid response element
(Hadcock et al., 1989) and is therefore a potential loci where
glucocorticoids may exert their regulatory influence. Glucocorticoids can
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enhance expression of the a-subunit of the adenylyl cyclase-stimulating
G-protein, Gs, in various non-lymphoid cell lines including ROS 17/2.8
osteosarcoma cells (Rodan & Rodan, 1986), opossum kidney (OK) cells
(Rizzoli & Bonjour, 1987) and rat pituitary (GH3) cells (Chang & Bourne,
1987). Based on these observations, it has been hypothesised that cAMP
may play a role in the immunosuppressant effects of glucocorticoids
(Gruol et al., 1989, Michel & Brodde, 1989). Interestingly, Michel and
colleagues demonstrated that dexamethasone sensitizes cAMP formation
in resting lymphocytes by altering adenylyl cyclase, resulting in an
enhanced capability of cAMP generating agonists to inhibit early steps of
lymphocyte activation (Michel et al., 1994). Dexamethasone reportedly
enhanced the maximal adenylyl cyclase responses to a similar extent for a
range of agonists tested. However since forskolin (a direct adenylyl
cyclase catalyst activator which also has some G-protein effects) and
MnCl2 (a direct adenylyl cyclase activator) stimulate adenylyl cyclase distal
to receptors (as assessed using the receptor agonist, PGE2) and G-proteins
(as assessed using GTP as a direct G-protein activator), these authors
concluded that dexamethasone treatment might primarily affect adenylyl
cyclase. This study also directly investigated the effect of dexamethasone
treatment on lymphocyte [^-adrenoceptor and G-protein a-subunit
expression, producing results that did not significantly alter the
expression of [^-adrenoceptors or G-protein a-subunits, namely Gs and
Gi. Michel and colleagues also reported that PGEi-, GTP- and forskolin-
stimulated adenylyl cyclase activity is also enhanced in lymphocytes
obtained from patients treated with glucocorticoids thus providing
evidence that the mechanisms discussed above may also operate in a
clinical situation. These findings are of particular interest in light of our
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results and may provide possible clues to the loci where dexamethasone
exerts its regulatory effect upon neutrophil apoptosis.
Further evidence substantiating our hypothesis that dexamethasone
mediates inhibition of neutrophil apoptosis by a PKA-dependent
mechanism was obtained by A-kinase isoenzyme elution (figure 6.10) and
from the direct measurement of PKA activity in dexamethasone treated
neutrophils, aged for 20 h in culture (figure 6.11). Performing the A-
kinase isoenzyme elution profile was particularly important to determine
which PKA isoenzymes are present in human neutrophils; a parameter
that has not been fully determined to our knowledge, thereby allowing
efficient measurement of PKA activity. Human neutrophils were shown
to contain a mixture of both type I and type II A-kinase isoenzymes as
assessed by Q-sepharose column chromatography, where A-kinase
isoenzymes were eluted with a linear NaCl gradient. Cyclic AMP
activates PKA through the formation of a regulatory subunit
(R).cAMP.catalytic subunit (C) complex (Palmer et al., 1980) and the
subsequent dissociation of this ternary complex produces active catalytic
subunits.
Equation (1)
R2C2 + 4cAMP = R2.4cAMP.C2 = R2-4cAMP + 2C
Direct measurement of PKA activity is expressed as an 'activity ratio' and
is derived from assessment of the cAMP-dependency of the protein
kinase (i.e., activity minus cAMP/activity plus cAMP) (Corbin et al., 1973).
Validity of the protein kinase activity ratio depends upon total inhibition
of both the forward (i.e., dissociation) and backward (i.e., reassociation)
reactions, illustrated in Equation 1, being maintained during the PKA
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assay. Various procedures have therefore been employed to ensure that
this inhibition is maintained (Palmer et al., 1980).
(1) Reassociation of type II protein kinase isoenzyme is blocked by use of a
high NaCl concentration
(2) Reassociation of type I isoenzyme is blocked by addition of the
phosphodiesterase inhibitior IBMX and a low NaCl concentration is used
and
(3) Cells shown to contain both type I and type II isoenzymes require the
use of an intermediary NaCl concentration in addition to the presence of
IBMX.
The A-kinase isoenzyme elution profile (figure 6.10) demonstrating the
presence of both type I and type II isoenzymes in neutrophils, was
therefore suggestive of an intermediary NaCl concentration used in the
presence of IBMX; providing optimum conditions for the direct
measurement of PKA activity, by inhibiting the breakdown of cAMP and
thereby maintaining the position of the equilibrium of the reaction
shown in Equation (1). The subcellular distribution of cAMP-dependent
protein kinase in neutrophils (table 6.1) was shown to be most enriched
in the cytosol. These data indicate that the cellular distribution of PKA is
not random. Moreover, a major group of anchoring proteins (AKAPs)
that target the RH-containing protein kinase to specific subcellular
locations has now been identified (Carr et al., 1991, Coghlan et al., 1993,
Scott & McCartney, 1994).
Direct measurement of the effect of glucocorticoids on the activation state
of PKA in neutrophils demonstrated a significant increase in the PKA
activity ratio as compared to that of control cells (figure 6.11). Moreover,
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dexamethasone was shown to both increase the PKA activity ratio and
inhibit apoptosis, as assessed morphologically, in identical cultures of
neutrophils. These data are extremely interesting and support the
pharmacological data discussed previously. However, the observed
increase in the PKA activity ratio may simply reflect the lower rate of
apoptosis in dexamethasone-treated neutrophils as compared to the
control population of cells. Further experiments performed at earlier
time periods (e.g., 8 h), when the dexamethasone-induced alteration in
the rate of neutrophil apoptosis is far less marked, may help to validate
these findings.
Neutrophils were cultured in the presence of dexamethasone for the
usual 20 h time period, before direct measurements of PKA activity were
carried out (figure 6.11). However, cells co-cultured with PGE2 and IBMX,
as a positive control for the experiment, were incubated for 20 h in total,
with the addition of PGE2 and IBMX for only 1 h, from the time period 19
h to 20 h. This precaution was taken in light of recent reports
demonstrating that prolonged elevation of intracellular cAMP leads to
up-regulation of phosphodiesterases, thereby resulting in an increased
degradation of cAMP and an actual decline in intracellular cAMP levels.
This has been shown to be the case in human monocytic cell lines, with
prolonged elevation of cAMP leading to the up-regulation of PDE IV
(Dent & Giembycz, 1996) and also in LRM55 glial cells which have been
shown to produce a rapid increase followed by a slow decline in
intracellular cAMP levels in response to continuous stimulation with (3-
adrenoceptor agonists (Madelian et al., 1985). The presence of PDE
inhibitors during treatment abolished this decline in cAMP contents,
suggesting that the apparent 'desensitization' observed in these cells
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might reflect an increase in the degradation of cAMP rather than a decline
in its synthesis (Madelian & Shain, 1987).
Recently, there has been an intense interest in the potential usefulness of
PDE inhibitors for the treatment of inflammatory diseases (Torphy &
Undem, 1991, Giembycz, 1992, Nicholson & Shahid, 1994). The
distribution of PDE isoenzymes in inflammatory cells has now been
extensively studied and the prominant PDEs expressed are the type III and
IV isoenzymes (Nicholson & Shahid, 1994). Interestingly, eosinophils
and neutrophils have been reported to contain only PDE IV (Dent &
Giembycz, 1996). In vitro studies have established that inhibition of these
isoenzymes by selective PDE inhibitors, suppresses a variety of
inflammatory cell functions including oxygen radical generation and
secretion of granule proteins and cytokines (Dent & Giembycz, 1996).
Moreover, Elwood and colleagues have demonstrated that PDE
isoenzyme inhibitors possess inhibitory activity in vivo (Elwood et al.,
1995). Rolipram (a type IV PDE isoenzyme inhibitor) and Org 20241 (a
combined type III and IV inhibitor) were shown to inhibit allergen-
induced eosinophil and neutrophil accumulation into the lungs of
ovalbumin-sensitized Brown-Norway rats. This in vivo model was
chosen as it mimics several of the features of asthma in man.
Interestingly, these data support a potential anti-inflammatory role of
PDE IV inhibitors in this species. Furthermore, glucocorticoids have also
been shown to inhibit eosinophil accumulation in this model (Elwood et
al., 1992). In addition, rolipram has been shown to inhibit neutrophil
apoptosis (Rossi et al., personal communication) which may offer another
possible mechanism by which glucocorticoids regulate apoptosis and co¬
ordinate their anti-inflammatory actions.
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Although the mechanisms by which cAMP influences neutrophil
apoptosis and PKA (or cAMP-dependent protein kinase) influences
glucocorticoid-mediated neutrophil apoptosis are unknown, the
expression of key regulatory genes may be involved. Downstream effects
of cAMP on gene expression are thought to be mediated through PKA
phosphorylation of the transcription factor, CREB, at Ser-133 (Gonzalez &
Montminy, 1989) (figure 6.12). CREB is a member of a diverse family of
DNA-binding proteins, whose phosphorylation results in the
transcriptional activation of various genes that contain cAMP response
elements (CREs) in their promoter or enhancer regions (Hoeffler et al.,
1988, Gonzalez & Montminy, 1989, Sheng et al., 1991). Glucocorticoid
receptors offer yet another mechanism by which an external signal may be
transduced into the nucleus. The binding of these hormones to their
receptors causes a conformational change of the proteins which allows
them to recognise hormone response elements (HREs) in the DNA
sequence of inducible genes (Yamamoto, 1985, Beato, 1989). The
mechanisms underlying dexamethasone-mediated inhibition of
neutrophil apoptosis may therefore also involve a synergistic interaction
between the glucocorticoid receptor (GR) and CREB hormone-responsive
transcription factors, acting in concert to regulate gene transcription.
Studies investigating the effects of PKA inhibitors on glucocorticoid
receptor numbers and glucocorticoid receptor translocation and binding
to GREs by electrophoretic mobility shift assays (EMSA), may elucidate
further the specific mechanisms governing dexamethasone-mediated
inhibition of neutrophil apoptosis.
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Figure 6.12 Schematic diagram illustrating the cAMP/PKA signal
transduction pathway.
Ligands interacting with transmembrane receptors (R) stimulate the
enzyme adenylyl cyclase (AC) via interactions with G proteins (G). The
subsequent rise in intracellular cAMP concentrations results in the
dissociation of the regulatory and catalytic subunits of PKA, and the
translocation of active catalytic subunits of PKA into the nucleus. PKA
phosphorylates and thereby stimulates transcriptional activators, such as
CREB, binding to CREs which induce transcription from the promoters of
cAMP-responsive genes.
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Although the precise mechanisms underlying cAMP-mediated regulation
of granulocyte apoptosis are unknown, we have demonstrated clearly that
(a) elevation of cAMP, either by cell permeable analogs or by PG receptor-
directed agonists, inhibits neutrophil and eosinophil apoptosis, (b) cAMP-
induced inhibition of neutrophil apoptosis, but not eosinophil apoptosis,
is mediated by a PKA-dependent mechanism, (c) dexamethasone-
mediated effects on neutrophil apoptosis, but not eosinophil apoptosis,
may also be regulated by a PKA-dependent mechanism, (d) LPS and
elevated [Ca2+]j-induced suppression of neutrophil apoptosis is not
mediated by PKA activation, and importantly (e) glucocorticoids, via a
steroid receptor-dependent mechanism, up-regulate the activity of a
predominantly cytosolic PKA, which we have shown exists in two
isoforms in human neutrophils. Therefore, I believe that this work has
shed some light on the mechanisms regulating cAMP- and steroid-
mediated effects on granulocyte apoptosis and lays the foundation for




Effect of glucocorticoids on macrophage recognition of aged
granulocytes
7.1 Introduction
The inflammatory macrophage plays a central role in the inflammatory
process, being able to secrete and respond to a range of pro-inflammatory
cytokines that mediate the initiation, progression and resolution of
inflammation. Apoptosis is now emerging as an efficient mechanism for
clearance of unwanted cells during the resolution of inflammation,
without inciting any further inflammatory response (Savill & Haslett,
1995). Eosinophils (Stern et al., 1992) and neutrophils (Haslett et al., 1987)
are constitutively programmed to undergo apoptosis which limits their
pro-inflammatory potential and leads to rapid recognition by
macrophages. Similar mechanisms have also been implicated in the
clearance of lymphocytes (Pender et al., 1991) and monocytes (Mangan et
al., 1991). It is thought that in mammals tissue macrophages are the key
cells that remove apoptotic cells. However, cells of other lineages, such as
glomerular mesangial cells (Savill et al., 1992a) and fibroblasts (Hall et al.,
1994), may also act as 'semi-professional' phagocytes and assist in the
clearance mechanism. Inflammatory infiltrates of eosinophils and
neutrophils have been associated with the pathogenesis of a variety of
diseases (Malech & Gallin, 1987), since these effector cells contain an array
of agents, including cytotoxic and degradative enzymes, cationic proteins
and inflammatory mediators, with the capacity to injure tissues and
further exacerbate the inflammatory response (Henson & Johnston, 1987).
Resolution of inflammation therefore requires rapid recognition of effete
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cells to ensure against the detrimental consequences to the surrounding
tissue, that would follow if cell disintegration or necrosis occurred.
Neutrophil-mediated tissue damage, for example, has been implicated in
the pathology of rheumatoid arthritis and adult respiratory distress
syndrome (Weiss, 1989), whereas eosinophils have been specifically
implicated in the pathogenesis of a number of diseases associated with a
peripheral blood eosinophilia, including both allergy and asthma (Gleich
et al., 1993). Nevertheless, most inflammatory reactions, including those
associated with a massive granulocyte recruitment, resolve with return of
normal tissue structure and organ function.
Initial studies providing direct support for an efficient mechanism of
resolution, that might protect the host from incidental tissue injury,
involved a series of in vitro experiments showing that senescent
neutrophils can be engulfed by macrophages (Newman et al., 1982).
These experiments were the first to highlight that neutrophils meet their
fate in situ, where intact senescent neutrophils are removed by
macrophages, providing an important injury-limiting neutrophil
disposal route. It was subsequently clearly demonstrated that neutrophils
had to be apoptotic before phagocytosis occurred since aged non-apoptotic
neutrophils, as well as fresh neutrophils, are not recognised (Savill et al.,
1989a). Further compelling evidence emphasizing the injury-limiting
potential of neutrophil clearance by apoptosis, was provided by Meagher
and colleagues, who have demonstrated that macrophages do not secrete
pro-inflammatory thromboxane B2 during phagocytosis of aged
neutrophils, by contrast with the marked release of thromboxane B2
which occurs in response to ingestion of opsonized erythrocytes or
zymosan, which are standard 'control' particles (Meagher et al., 1992).
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More recently, Bellingan et al., (1996) have investigated the in vivo fate of
inflammatory macrophages during the resolution of inflammation and
have demonstrated that these cells, in contrast to eosinophils and
neutrophils, do not meet their fate locally by apoptosis and phagocytosis,
but emigrate from the peritoneum specifically to draining lymph nodes.
Clearance of senescent or effete cells has been shown to play a vital role in
many fundamental biological processes, including normal tissue
turnover (Han et al., 1993) and remodelling of embryological tissues
(Hopkinson-Woolley et al., 1994). Moreover, phagocytic clearance of
apoptotic neutrophils by macrophages has been illustrated in vivo in
inflammation of the joint (Savill et al., 1989a), lung (Grigg et al., 1991), gut
(Savill, 1992) and kidney (Savill et al., 1992a). These observations strongly
imply that cellular apoptosis and engulfment by macrophages provides a
potential mechanism for the efficient clearance of redundant, intact
inflammatory effector cells from inflamed tissue sites.
Given that glucocorticoids have been shown to influence macrophage
function (Russo-Marie, 1992) and as we have shown in Chapter 3, that
glucocorticoids profoundly and differentially regulate granulocyte
apoptosis, we investigated the effect of dexamethasone on granulocyte
clearance by macrophages in vitro.
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7.2 Results
7.2.1 Effect of dexamethasone on macrophage phagocytosis of aged
neutrophils
We have demonstrated that incubation of monocyte-derived
macrophages with dexamethasone (1 fiM) for 20 h, promoted macrophage
recognition and phagocytosis of aged, apoptotic neutrophils (figure 7.1).
In all experiments undertaken, neutrophils were aged in culture for 20 h,
to ensure that the constitutive rate of apoptosis was sufficient (between
60-80% apoptosis) to allow a significant rate of phagocytosis by the control
population of macrophages. Figure 7.2 illustrates photomicrographs of
tissue culture plates bearing a monolayer of human monocyte-derived
macrophages which have been interacted with aged, apoptotic
neutrophils, before non-ingested neutrophils were washed away and the
monolayer was fixed and stained for myeloperoxidase (MPO). Aged
neutrophils are therefore identified as darkly stained circles within the
MPO-negative macrophages. The interaction performed using
dexamethasone (1 (iM)-treated macrophages (figure 7.2B), demonstrates
the dramatic increase in the proportion of macrophages ingesting aged,
apoptotic neutrophils compared with the untreated population of
macrophages in the control interaction (figure 7.2A). As illustrated in
figure 7.2, the total number of macrophages per field was found to be
consistent between control and dexamethasone-treated macrophages.
These findings suggest that dexamethasone directly up-regulates
phagocytosis of apoptotic cells, and is not due to a direct effect of
dexamethasone inducing an increase in either the number of
macrophages adhered to the tissue culture plate or the number of


















Figure 7.1 Effect of dexamethasone on macrophage recognition of aged
neutrophils.
Monocyte-derived macrophages were either incubated alone or pre-
incubated with dexamethasone (1 pM for 20 h), before washing and 30
min interaction with aged neutrophils. Data represent mean % of control
± SEM of 18 separate experiments, each performed in duplicate (* p<0.05
compared with control values), in which under control conditions 37.2 ±
3.5% and in dexamethasone-treated macrophages, 61.7 ± 2.9% of
macrophages ingested apoptotic neutrophils.
this in vitro method which is based on direct counting by light
microscopy of macrophages which have ingested apoptotic cells, is that it
is difficult to distinguish between binding and ingestion of the apoptotic
cell by the phagocyte, although sufficient washing is performed to ensure
that simply bound neutrophils are removed. However, attempts have
been made to dissect the relative prevalence of these two processes by
detaching the macrophages, following their interaction with aged
neutrophils, from the plastic wells of the tissue culture plates and
cytocentrifuging the cells onto a glass slide before staining. These studies
(data not shown) have revealed that dexamethasone-mediated up-
regulation of phagocytosis, promotes ingestion rather that binding of
apoptotic neutrophils.
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Figure 7.2 Effect of dexamethasone on macrophage recognition of aged
neutrophils.
Photomicrographs (xl250 magnification) of the vitro interaction between
macrophages and apoptotic neutrophils. Monocyte-derived macrophages
were incubated in the absence (A) and presence of dexamethasone (1 |iM for
20 h) (B) before being overlaid with a suspension of apoptotic neutrophils
for 30 min. Ingested neutrophils were stained for MPO. Note that
macrophages are MPO-negative.
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Moreover, we have also demonstrated that the endogenous
glucocorticoid, Cortisol, mirrors the effect of dexamethasone in
potentiating macrophage recognition of apoptotic neutrophils. However,
in contrast, progesterone, which has little glucocorticoid activity, does not





S3 Dex (lpM)-treated macrophages
EU Cortisol (lOpM)-treated macrophages
E3 Progesterone (10 pM)-treated macrophages
Figure 7.3 Effect of different corticosteroids on macrophage recognition of
aged neutrophils.
Monocyte-derived macrophages were incubated in the absence and
presence of dexamethasone (1 pM), Cortisol (10 pM) and progesterone (10
pM) for 20 h, before being overlaid with a suspension of aged neutrophils.
Data represent mean ± SEM of 3 separate experiments, each performed in
duplicate (* p<0.05 compared with control values).
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7.2.2 Effect of RU38486 on dexamethasone-mediated up-regulation of
macrophage recognition of apoptotic neutrophils
Figure 7.4 illustrates that the glucocorticoid receptor antagonist, RU38486
(10 (J.M), while having no significant effect upon the control rate of
macrophage recognition and ingestion, completely attenuated
dexamethasone augmentation of macrophage recognition of apoptotic
neutrophils. These data suggest that potentiation of macrophage
recognition by dexamethasone is mediated via the glucocorticoid receptor.
Figure 7.4 Effect of RU38486 on macrophage recognition of aged
neutrophils.
Monocyte-derived macrophages were incubated either alone or with
dexamethasone (1 pM for 20 h), in the absence and presence of RU38486
(10 pM for 20 h), before being overlaid with a suspension of aged
neutrophils. Data represent mean ± SEM of 8 separate experiments, each
performed in duplicate (* p<0.05 compared with control values).
100 1 ■ Control macrophages
@ Dex (lgM)-treated macrophages
H Control macrophages + RU38486 (10(iM)





7.2.3 Time-course for the effect of dexamethasone on macrophage
recognition of apoptotic neutrophils
Initial studies investigating the effect of dexamethasone on macrophage
recognition of apoptotic neutrophils were performed using a pre¬
incubation time of 20 h, for the treatment of macrophages with
dexamethasone (1 pM). We subsequently investigated the time-course of
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Figure 7.5 Time-course of the effect of dexamethasone on macrophage
recognition of aged neutrophils.
Monocyte-derived macrophages were incubated in the absence and
presence of dexamethasone (1 pM), for the time periods indicated, before
being overlaid with a suspension of aged neutrophils. Data represent
mean % of control ± SEM of 3 separate experiments, each performed in
duplicate (* p<0.05 compared with control values), in which under
control conditions 10.9 ± 0.2% macrophages ingested apoptotic
neutrophils.
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Dexamethasone does not augment recognition of apoptotic neutrophils
until macrophages have been pre-incubated for at least 12 h with
dexamethasone before interaction with apoptotic neutrophils (figure 7.5).
The potentiating effect of dexamethasone appears likely to be exerted on
the macrophage and not the apoptotic neutrophil, since macrophages
were washed prior to the interaction with apoptotic neutrophils and the
degree of enhancement by dexamethasone (1 pM) depended on the time
of incubation of macrophages with dexamethasone before interaction
with apoptotic neutrophils. Thus potentiation was clearly apparent by 12
h, and maximal by 20 h (figure 7.5).
7.2.4 Concentration-dependency of the effect of dexamethasone on
macrophage recognition of apoptotic neutrophils
We were interested to investigate the effect of increasing concentrations
of dexamethasone (0.01-1 pM) on macrophage recognition of apoptotic
neutrophils. Figure 7.6 illustrates that dexamethasone promotes
recognition in a concentration-dependent manner, with an approximate
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Figure 7.6 Concentration-response for the effect of dexamethasone on
macrophage recognition of aged neutrophils.
Monocyte-derived macrophages were incubated in the absence and
presence of dexamethasone (0.01-1 jiM for 20 h), before being overlaid
with a suspension of aged neutrophils. Data represent mean ± SEM of 7
separate experiments, each performed in duplicate (* p<0.05 compared
with control values).
7.2.5 Specificity of dexamethasone-mediated up-regulation of
macrophage recognition
It has previously been demonstrated that macrophages selectively
recognise and ingest intact neutrophils that have been aged in culture,
however fresh neutrophils are not recognised (Newman et al., 1982,
Savill et al., 1989a). These findings suggest that in the phagocytosis of
apoptotic cells, the macrophage recruits a specific recognition mechanism.
We were therefore interested to investigate whether dexamethasone-












I Control macrophages + apoptotic neutrophils
B Control macrophages + fresh neutrophils
H Dex (IpM)-treated macrophages + apoptotic neutrophils
E3 Dex (lpM)-treated macrophages + fresh neutrophils
Figure 7.7 Comparison of the effect of dexamethasone on macrophage
recognition of aged and fresh neutrophils.
Monocyte-derived macrophages were incubated in the absence and
presence of dexamethasone (1 pM for 20 h) before being overlaid with a
suspension of either apoptotic neutrophils, previously aged for 20 h in
culture, or freshly isolated (non-apoptotic) neutrophils, for 30 min. Data
represent mean ± SEM of 5 separate experiments, each performed in
duplicate (* p<0.05 compared with control values).
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B Control macrophages + apoptotic neutrophils
E22 Dex(l(iM)-treated macrophages + apoptotic neutrophils
H Control macrophages + opsonised erythrocytes
E2 Dex (lpM)-treated macrophages + opsonised erythrocytes
20 hours
Treatment
Figure 7.8 Comparison of the effect of dexamethasone on macrophage
recognition of aged neutrophils and IgG-opsonised erythrocytes.
Monocyte-derived macrophages were incubated in the absence and
presence of dexamethasone (1 pM for 20) before being overlaid with a
suspension of either apoptotic neutrophils, previously aged for 20 h in
culture, or IgG-opsonised erythrocytes, for 30 min. Data represent mean ±
SEM of 3 separate experiments, each performed in duplicate (* p<0.05
compared with control values).
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phagocytosis mechanism employed for recognition of apoptotic cells or
whether dexamethasone up-regulated an altogether non-specific
stimulation of the phagocytic potential of macrophages. Figure 7.7
illustrates the effect of dexamethasone on macrophage recognition and
ingestion of freshly isolated neutrophils (non-apoptotic) compared with
aged, apoptotic neutrophils. These data demonstrate that both control
and dexamethasone-treated macrophages did not phagocytose fresh
neutrophils, whereas in the same experiment, apoptotic neutrophils were
ingested. Moreover, dexamethasone did not augment macrophage
recognition of immunoglobulin-opsonised erythrocytes (the standard
'control' particle) as compared to control macrophages (figure 7.8),
whereas in the same experiment, aged, apoptotic neutrophils were
ingested by control macrophages and this phagocytic capacity was shown
to be increased in dexamethasone-treated macrophages. Collectively,
these data exclude the possibility that dexamethasone up-regulates non¬
specific phagocytosis by macrophages and suggest that dexamethasone
may have an important role in promoting the efficient clearance of
apoptotic cells, thereby promoting the resolution of inflammation.
7.2.6 Effect of dexamethasone on macrophage phagocytosis of aged
eosinophils
Interestingly, we also demonstrated that incubation of monocyte-derived
macrophages with dexamethasone (1 pM) for 20 h, promoted macrophage
recognition and phagocytosis of aged, apoptotic eosinophils (figure 7.9).
In the preliminary experiments undertaken, eosinophils were aged for 40
h in culture, to ensure that the constitutive rate of apoptosis, which is
slower in eosinophils compared to neutrophils, was sufficient to allow a















Figure 7.9 Effect of dexamethasone on macrophage recognition of aged
eosinophils.
Monocyte-derived macrophages were either incubated alone or pre-
incubated with dexamethasone (1 pM for 20 h), before washing and 30
min interaction with aged eosinophils. Data represent mean % of control
± SEM of 3 separate experiments, each performed in duplicate (* p<0.05
compared with control values), in which under control conditions 71.5 ±
13.3% and in dexamethasone-treated macrophages, 94.0 ± 1.1% of
macrophages ingested apoptotic eosinophils.
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7.3 Discussion
In this study, we have examined whether glucocorticoids modulate
human macrophage phagocytosis of senescent eosinophils and
neutrophils undergoing apoptosis. We have demonstrated that
macrophages pre-treated with dexamethasone (1 |iM) for 20 h prior to
interaction with aged, apoptotic granulocytes, showed an augmentation
in their phagocytic capacity as compared to control, untreated
macrophages (figures 7.1 & 7.9). This is a novel and particularly
interesting finding in view of the common use of glucocorticoids as
potent anti-inflammatory agents. These results suggest that in addition to
modulating granulocyte apoptosis (Chapter 3), dexamethasone may also
regulate the clearance of aged, apoptotic cells, an event which may
promote more efficient resolution of the inflammatory response.
Dexamethasone-mediated regulation of granulocyte clearance is
particularly exciting in view of the differential effect of
i
glucocorticoids upon granulocyte apoptosis, discussed in Chapter 3. It
is therefore interesting to speculate about the in vivo significance of
why dexamethasone should augment eosinophil apoptosis and inhibit
neutrophil apoptosis, yet promote the clearance of both cell types.
This observation may be related to the kinetics of effector cell arrival
at an inflammatory site. Neutrophils are the first cells to arrive at
the scene of tissue perturbation and as such it may be desirable that
the effective life of the extravasated neutrophil is prolonged in order
' ■
i
to fight invading microbes, thereby promoting host defence.
Moreover, this may allow time for recruited monocytes, which
are unable to ingest apoptotic neutrophils, to differentiate into
phagocytically competent macrophages (Savill et al., 1990).
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However, when these granulocytes eventually succumb to apoptosis,
glucocorticoids enhance their removal by macrophages. The eosinophil,
however, in allergic reactions and diseases is largely an unwanted cell,
t'.
therefore glucocorticoids may induce their apoptosis and subsequent
removal accordingly. The differential effect of dexamethasone on
granulocyte apoptosis in vitro, may therefore co-operate with the
temporal recruitment of granulocytes at an inflammatory site. By
promoting apoptotic clearance, dexamethasone facilitates ingestion of
intact granulocytes without disgorgement of their toxic contents, further
ensuring an alternative fate to necrosis and thereby promoting the
I ; J.I.! j
normal resolution process of inflammation. Collectively these findings
may give rise to new anti-inflammatory treatments, as evidenced by
clearance of eosinophils from a model of allergic lung inflammation
(Tsuyuki et al., 1995) by intratracheal instillation of agents ligating Fas on
murine lung eosinophils and thereby inducing apoptosis and phagocytic
clearance. Tsuyuki and colleagues have demonstrated that macrophage-
mediated phagocytosis of eosinophils, as revealed by an increase in the
number of peroxidase positive macrophages, occurred in vivo, after
t v. : • .
treatment with the anti-Fas mAb and was temporarily associated with the
resolution of eosinophilic inflammation. Interestingly, this report shows
that the increase in the number of peroxidase positive macrophages was
transient; a finding supported by in vitro observations, demonstrating
that when neutrophils are ingested by macrophages, they are degraded
within 30 min and are no longer recognisable (Savill et al., 1989a).
Moreover, Tsuyuki et al., (1995) also demonstrated that 24-48 h after mAb
treatment, the number of peroxidase positive macrophages increased
compared to time 0 (i.e., 72 h after antigen challenge), and suggest that
under control condition^, eosinophils undergo apoptosis and are
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engulfed by macrophages as the 'normal surveillance' mechanism to
; i '
remove unwanted apoptotic cells.
Similar findings have also been reported in neutrophilic inflammatory
models, in vivo. Cox and colleagues used a rat model of acute pulmonary
inflammation induced by intratracheal administration of LPS, which
induces a prompt marked neutrophilic response in the lung that peaks at
18 h and resolves after 72 h (Cox et al., 1995). This study showed that the
neutrophilic response was accompanied by the presence of a gradually
increasing number of apoptotic neutrophils and of macrophages
containing apoptotic neutrophils, peaking at 24 h, and declining with
resolution of the neutrophilic response. These observations demonstrate
that macrophage-mediated engulfment of apoptotic neutrophils after an
acute inflammatory response is both temporally correlated with and
i it '!
required for the resolution of acute neutrophilic inflammation.
Moreover, there have been two reports, particularly germane to our in
i!r'.
vitro findings, of the potentiation of macrophage clearance of apoptotic
granulocytes by dexamethasone. It has been shown in vivo that
i A v. .1 .
macrophages engulf eosinophils with apoptotic morphology in the
jejunal mucosa of parasitized rats treated with dexamethasone (Kawabori
et al., 1991) and more recently Woolley and colleagues have provided the
first report of eosinophil apoptosis in vivo in human asthma (Woolley et
al., 1996). The latter report showed that eosinophil apoptosis increased
after corticosteroid treatment for an exacerbation of asthma and that
•j i j
eosinophil products were apparent within macrophages. The increase in
eosinophil apoptosis occurred in association with clinical improvement
and the resolution of eosinophilic inflammation. Taken together with
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our in vitro findings, these results suggest that apoptosis is a mechanism
for the reduction of eosinophilic airway inflammation in asthma.
Interestingly, eosinophil and neutrophil apoptosis can be slowed down by
a number of factors, including activating agents such as LPS and the
cytokine GM-CSF (Squier et al., 1995, Lopez et al., 1986, Takanaski et al.,
1994). Moreover, it has previously been reported that GM-CSF and other
pro-inflammatory cytokines increased phagocytosis of apoptotic
neutrophils by a rapid and selective effect on the macrophage (Ren &
Savill, 1995). This report suggested that GM-CSF may act in a coordinate
fashion on neutrophils and monocyte-derived macrophages to ensure
that apoptosis in the former is carefully timed to match acquisition of
phagocytic capacity by the latter. These suggestions mirror the temporal
explanations offered to account for the differential effect of
dexamethasone on granulocyte apoptosis and promotion of macrophage
clearance of both cell types in our system.
We have demonstrated that dexamethasone-induced up-regulation of
phagocytosis is limited to glucocorticoids (figure 7.3) and is time- (figure
7.5) and concentration-dependent (figure 7.6). Moreover, dexamethasone
appears to selectively up-regulate the phagocytic mechanism employed
for recognition of apoptotic cells, rather than a wholly non-specific
stimulation of the phagocytic capacity of macrophages (figures 7.7 and 7.8).
These findings suggest that dexamethasone-treated macrophages, like
untreated (control) phagocytes, can recognise changes on the surface of
cells as they undergo apoptosis which identifies them as 'senescent self'.
Furthermore, the glucocorticoid receptor antagonist, RU38486, was shown
to inhibit potentiation of macrophage recognition by dexamethasone,
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while having no effect on the control rate of macrophage phagocytosis
(figure 7.4). These results suggest the involvement of macrophage
glucocorticoid receptors, which have been previously identified as high
affinity receptors (Werb et al., 1978), as having an important role in
mediating the effect of dexamethasone on phagocytosis. Further
experiments are required to determine the precise mechanism(s)
underlying dexamethasone-mediated potentiation of phagocytic clearance
of apoptotic granulocytes. However, over recent years there has been
intense interest in the mechanisms by which phagocytes recognise cells
undergoing apoptosis in vitro, and some of these now elucidated
mechanisms may also be implicated in dexamethasone-mediated up-
regulation of granulocyte clearance. The known molecular mechanisms
underlying the recognition of apoptotic cells are summarised in table 7.1
(Savill et al., 1993, Hart et al., 1996, Savill, 1997). Significantly, eosinophil
(Stern et al., 1996) and neutrophil (Savill et al., 1992b) data indicate that
phagocytosis depends upon two macrophage receptors for TSP, the avp3
vitronectin receptor integrin and CD36 (see figure 7.10). Antibody
inhibition experiments have now shown that this avp3/TSP/CD36
recognition mechanism is also employed by macrophage uptake of
apoptotic lymphocytes (Akbar et al., 1994). It is therefore possible that
since monocyte-derived macrophages ingest both apoptotic eosinophils
and neutrophils by deploying the ocvp3/TSP/CD36 recognition
mechanism, that dexamethasone-mediates potentiation of phagocytosis
by increasing the expression of these macrophage surface receptors and
also macrophage secretion of TSP. However, further experiments are
necessary to determine the precise mechanism by which dexamethasone
augments phagocytosis of apoptotic granulocytes.
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Molecular mechanisms of




Specific carbohydrates on the surface
of apoptotic cells are recognised by
phagocytic cells containing lectin-
like receptors such as the
asialoglycoprotein, mannose or
mannose/fructose receptor.
Duvall et al., 1985, Hall et al., 1994.,
Dini et al., 1992, Dini et al., 1995.
ocvp3/TSP/CD36
It is hypothesized that a TSP binding
moiety expressed on the surface of
apoptotic cells binds to nearby TSP
which in turn acts as a bridging
molecule between the apoptotic cell
and the ingesting phagocyte. The
phagocyte expresses two receptors
on its surface; the avp3 integrm or
'vitronectin receptor' and CD36,
which co-operate to bind TSP.
Savill et al., 1989b, Savill et al., 1990,
Savill et al., 1992b, Ren et al., 1995,
Ren & Savill, 1995.
Phosphatidylserine (PS) and PS
receptors
Exposure of phosphatidylserine on
the surface of apoptotic cells is
believed to be recognised by putative
phosphatidylserine receptors located
on the surface of the ingesting
phagocyte. Recently, it has been
suggested that members of the
scavenger receptor family may act as
PS receptors.
Fadok et al., 1992a, Fadok et al.,
1992b, Fadok et al., 1993, Martin et
al., 1995, Verhoven et al., 1995, Piatt
et al., 1996, Fukasawa et al., 1996,
Sambrano & Steinberg, 1995.
61D3 antigen
The mAb 61D3 can specifically
attenuate the recognition of
apoptotic cells by human monocyte-
derived macrophages. The 61D3
antigen has not been fully
characterised.
Flora & Gregory, 1994.
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Figure 7.10 Diagram illustrating avP3/TSP/CD36 phagocytic recognition
mechanism of apoptotic neutrophils. Abbreviations: Vn, vitronectin; Fn,
fibronectin; VnR, avP3/ vitronectin receptor integrin; TSP,
thrombospondin. (Diagram from Savill, 1992).
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In summary, we have demonstrated that dexamethasone promotes
macrophage recognition and ingestion of aged, apoptotic granulocytes in
vitro. This finding is particularly exciting in view of the recent in vivo
reports discussed, and may potentially underlie some of the anti¬
inflammatory mechanisms employed by glucocorticoids, in mediating the
temporal correlation of granulocyte clearance with the resolution of acute
eosinophilic and neutrophilic inflammation. Recent findings by Stern
and colleagues demonstrating that uptake of post-apoptotic eosinophil
fragments increases macrophage release of pro-inflammatory mediators
(Stern et al., 1996), accentuates the significance of our findings with
regards to the resolution of inflammation.
The mechanism by which dexamethasone selectively potentiates
.4 ' ; j
recognition and phagocytosis of apoptotic cells has not been determined.
However, we have highlighted several recognition mechanisms that are
i'.ci V | ,
known to be deployed by macrophages in the clearance of apoptotic
• i i jj , .
granulocytes and other cells. Dexamethasone may therefore increase the
I II j... .
expression of selective macrophage surface receptors such as CD36 or
alternatively may recruit its own novel and specific mechanism
).' I- » .. !•
mediating the clearance of apoptotic cells. Further experiments are
• i : 4 ;
essential to establish any firm conclusions regarding the phagocytic
mechanism of dexamethasone-mediated up-regulation of apoptotic
granulocytes.
Interestingly, our laboratory has recently reported that ligation of the cell
surface glycoprotein CD44 on macrophages, causes a specific
augmentation of the phagocytosis of apoptotic neutrophils, but not of
apoptotic lymphocytes. However, as with dexamethasone-mediated
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upregulation of phagocytosis, the precise mechanism underlying CD44-
augmentation of phagocytosis, has not been clearly defined (Hart et al.,
1997).
In conclusion, our findings may result in conferring an anti¬
inflammatory advantage upon tissues, providing the possibility of
therapeutic gain, by modulating the inflammatory response such that
resolution is favoured rather than tissue destruction and fibrosis.
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Chapter 8
Summary and General Discussion
We have demonstrated that glucocorticoids differentially affect the rate of
granulocyte apoptosis in vitro; promoting eosinophil apoptosis and
inhibiting neutrophil apoptosis. Dexamethasone-induced modulation of
granulocyte apoptosis is limited to glucocorticoids and is specifically
modulated via the glucocorticoid receptor. Moreover, the diametrically
opposed effects of dexamethasone on granulocyte apoptosis does not
appear to result from the differential elaboration of GM-CSF by
eosinophils and neutrophils. Therefore, these results are particularly
intriguing since they suggest that the apoptotic programme is under
different controls in these two closely related myeloid cells. Hence
interest has been focussed on dissecting the intracellular signalling
processes whereby this discrepancy occurs.
We have presented data implicating both Ca2+ and PKC in the regulation
of granulocyte apoptosis. Elevation of [Ca2+]i using A23187, up-regulates
eosinophil apoptosis. In contrast, elevation of [Ca2 + ]i through
independent mechanisms, by using either A23187 or thapsigargin, down-
regulates neutrophil apoptosis. Thus, the effect of Ca2+ elevation on
granulocyte apoptosis appears to mirror the effects of dexamethasone;
promoting eosinophil apoptosis and inhibiting neutrophil apoptosis.
However, experiments designed to investigate the role of Ca2+ in
dexamethasone-mediated inhibition of neutrophil apoptosis have
indicated that Ca2+ may not be the intracellular second messenger
involved. Direct measurements of cytosolic Ca2+ levels in freshly isolated
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neutrophils did not identify any changes in the [Ca2+]i above resting
values upon addition of dexamethasone. Moreover, BAPTA/AM, an
intracellular Ca2+ chelator, did not modulate dexamethasone-mediated
inhibition of neutrophil apoptosis. Thus, preliminary studies argue
against a role for calcium in dexamethasone-mediated neutrophil
apoptosis. We have also demonstrated that treatment of both eosinophils
and neutrophils with agents that inhibit PKC induces apoptosis, thereby
indirectly implicating a role for PKC in the suppression of granulocyte
apoptosis. Moreover, at a concentration found to have no significant
effect upon the rate of constitutive apoptosis, the PKC inhibitors,
staurosporine and Ro-31-8220, partially abrogated dexamethasone-
mediated inhibition of neutrophil apoptosis. Thus, activation of PKC
may, in part, underlie the anti-inflammatory action of glucocorticoids.
With the advent of PD 098059, which is a selective inhibitor of the MAP
kinase-activating enzyme MEK and hence the MAPK/ERK cascade, we
have been able to study the involvement of MAPK/ERK in the
regulation of granulocyte apoptosis. We have demonstrated that
inhibition of the MAPK/ERK pathway down-regulates the basal rate of
eosinophil apoptosis, while having no effect on the basal rate of
neutrophil apoptosis. Thus, these data may suggest that activation of this
signalling cascade may be an important component promoting eosinophil
apoptosis and thereby facilitate the resolution of inflammation.
Moreover, PD 098059 reversed LPS-mediated inhibition of neutrophil
apoptosis while having no effect on glucocorticoid-induced suppression
of neutrophil apoptosis. Thus, the effect of glucocorticoids on the rate of
neutrophil apoptosis does not appear to involve MAPKs/ERKs.
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Since the level of protein phosphorylation in any cell ultimately depends
upon the combined activities of both protein kinases and protein
phosphatases we were interested to investigate the effect of protein
phosphatase inhibitors on the rate of granulocyte apoptosis. We have
demonstrated that okadaic acid has a bi-phasic effect upon the rate of
granulocyte apoptosis; with lower concentrations inhibiting apoptosis and
higher concentrations promoting apoptosis. These results may reflect the
ability of okadaic acid to differentiate between PP2A and PP1, promoting
selective inhibition depending on the concentration used. Thus, at lower
concentrations okadaic acid preferentially inhibits PP2A, whereas at
higher concentrations okadaic acid inhibits both PP2A and PP1 in concert.
These data may therefore suggest that the specific inhibition of PP2A
regulates inhibition of granulocyte apoptosis, whereas the collective
inhibition of both PP2A and PP1 is responsible for the promotion of
apoptosis in these granulocytes. Moreover, at a concentration found to
have no significant effect on the rate of granulocyte apoptosis, okadaic
acid partially attenuated the pro-apoptotic effect of dexamethasone on
eosinophils and completely attenuated dexamethasone-mediated
inhibition of neutrophil apoptosis. Thus, these results suggest that
glucocorticoid-mediated granulocyte apoptosis requires the activity of
protein phosphatases.
We have observed that agents that elevate intracellular levels of cAMP
inhibit granulocyte apoptosis. Interestingly, H-89, a selective inhibitor of
PKA, does not modulate the rate of constitutive granulocyte apoptosis
suggesting that PKA may not be important in the regulation of basal
granulocyte apoptosis. However, cAMP-induced inhibition of neutrophil
apoptosis, in contrast to eosinophil apoptosis, does appear to be mediated
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by a PKA-dependent mechanism. Similarly, dexamethasone-mediated
effects on neutrophil apoptosis, but not eosinophil apoptosis, also appear
to be regulated by a PKA-dependent mechanism. Significantly, direct
measurement of PKA activity after dexamethasone treatment in
neutrophils revealed increased activity compared to the control
population of cells, of a predominantly cytosolic localised PKA, which we
have shown exists in two isoforms.
As discussed in Chapter 5, the finding that protein phosphatase inhibition
and PKA inhibition both individually attenuate dexamethasone-
mediated inhibition of neutrophil apoptosis appears confusing.
However, these results may suggest that the protein phosphatase
inhibitors, okadaic acid and calyculin A, phosphorylate different substrate
proteins to those phosphorylated by PKA, hence providing an
explanation as to why both protein phosphorylation and
dephosphorylation result in modulation of dexamethasone-mediated
inhibition of neutrophil apoptosis.
Finally, we have demonstrated that dexamethasone promotes
macrophage-mediated phagocytosis of aged, apoptotic granulocytes in
vitro. More detailed studies on the recognition and ingestion of aged
neutrophils by macrophages, have revealed that dexamethasone induced
up-regulation of phagocytosis is limited to glucocorticoids and is
specifically mediated via the glucocorticoid receptor. Moreover,
dexamethasone appears to selectively up-regulate the phagocytic
mechanism employed for recognition of apoptotic cells rather than a
wholly non-specific stimulation of the phagocytic capacity of
macrophages. These findings are particularly exciting and may
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potentially underlie the anti-inflammatory mechanisms used by
glucocorticoids, in facilitating the clearance of unwanted inflammatory
cells. These data are particularly germane in light of recent in vivo
reports demonstrating the temporal correlation of granulocyte clearance
with the resolution of acute eosinophilic and neutrophilic inflammation
after glucocorticoid administration (Cox et al., 1995, Woolley et al., 1996).
Thus, using a pharmacological approach, many insights have been made
into the intracellular signalling pathways regulating constitutive and
glucocorticoid-mediated granulocyte apoptosis. Our observations do have
limitations, however, in view of the unknown precise specificity of the
agents used in our cellular system. New and more specific
pharmacological tools may be useful to probe our findings further in the
future. Since peripheral blood eosinophils are relatively low and
comparatively more difficult to isolate, the majority of the investigations
featured in this thesis have been undertaken on the neutrophil.
However, preliminary and comparative studies on the eosinophil, have
highlighted some important differences between the regulation of
apoptosis in these two closely related myeloid cells. Thus, there seems to
be a fundamental inter-relationship between the regulation of
granulocyte apoptosis and signal transduction. While we have focussed
on investigating the individual influences, upon granulocyte apoptosis,
of modulating specific intracellular pathways, it is important to
remember that there is a multitude of diverse interactions between single
i I t« V
signalling pathways. These interactions include potentiation, co¬
operation, synergism and antagonism; many examples of which have
been addressed during the course of this thesis (figure 8.1). Thus, at this
stage of our understanding it is difficult to tie all of these apparently
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disparate pieces of data into one comprehensive picture. However,
despite these alternative signalling pathways, at some point it is likely
that the signals converge into a common step or steps that allow
progression of the apoptotic programme.
Given that in chronic inflammation there is a persistent accumulation of
inflammatory cells which are likely to liberate their armamentarium of
noxious intracellular products leading to tissue injury and scarring, it
seems likely that effective removal of these potentially tissue damaging
inflammatory cells would be desirable. Apoptosis therefore provides a
mechanism for the safe disposal of extravasated granulocytes as the
inflammatory response evolves. Significantly, differences between the
intracellular regulation of inflammatory cells provide a special
opportunity to selectively induce apoptosis in discrete populations of
inflammatory cells, for which it may be possible to extrapolate these
findings for therapeutic gain. The anti-inflammatory action of
glucocorticoids is thought to be a crucial component of their efficacy in
allergic diseases. However, this is tempered by the side-effects of these
drugs, which has fuelled the desire to create compounds that have
steroid-like actions but fewer side-effects. In combination with an
effective therapeutic strategy to selectively induce apoptosis, development
of mechanisms to specifically enhance apoptotic cell clearance by
phagocytes, such as the macrophage, may be equally desirable in
promoting the resolution of inflammation.
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AZUROPHIL SPEC3HC GELATINASE SECRETORY
GRANULES GRANULES GRANULES GRANULES
Defensins Lactoferrin Gelatinase Alkaline
phosphatases
Myeloperoxidase Cytochrome bsss
CDllb
Lysozyme fMLP-R
fMLP-R
Acid hydrolases CDllb
Cytochrome bsss
Lysozyme
Collagenase
Vitamin
Bi2-binding
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